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ABSTRACT
Advances in recent treatments for HIV/AIDS patients have shown dramatic outcomes in 
extending the incubation period and AIDS survival time, whilst also providing significant 
improvements in the quality of patients’ lives.
This thesis establishes a model of the HIV/AIDS epidemic that incorporates the effects of 
treatments, in particular, the introduction of highly active antiretroviral therapy 
(HAART), which became widely available during 1996.
The technique of compartmental modelling is employed in an attempt to reproduce 
observed AIDS incidence/prevalence, HIV incidence/prevalence, and deaths from AIDS 
data. There are movements between compartments (sub-populations affected by the 
HIV/AIDS epidemic) each with an associated parameter. Each sub-population has a 
differential-difference equation associated with it. Once these equations have been 
solved numerically they give a set of steady-state solutions, from which it is possible to 
estimate HIV/AIDS incidence and prevalence.
Some parameter values within the model are obtained from surveys, census results, etc., 
but others are derived using a maximum likelihood estimation (MLE) procedure. The use 
of realistic values gives impressive results, creating a remarkable fit with routinely 
collected data relating to levels of HIV/AIDS incidence and prevalence in the UK 
homosexual population.
Finally, the model is used to project levels of incidence and prevalence over the next few 
years, and to investigate several possible ‘what-if scenarios, with a brief investigation 
into the consequent cost implications.
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CHAPTER 1
INTRODUCTION
The aim of this thesis is to produce an excellent fitting mathematical model of the 
HIV/AIDS epidemic, over the years 1979-2002, in order to create confidence in 
predicting future counts of HIV and AIDS incidence, HIV/AIDS prevalence and deaths 
from AIDS, and to investigate the effect of certain ‘what-if scenarios.
In order to achieve this goal, an appreciation of the history of HIV/AIDS needs to be 
obtained, including a biological comprehension of how HIV attacks the immune system 
and spreads between individuals. In particular, knowledge of the progression of 
treatment scenarios is crucial in understanding the shape of the epidemic and how it has 
changed over time. This first chapter of the thesis consists of a literature review which 
provides a background of the HIV/AIDS epidemic significant when building the 
mathematical model. Chapter 2 focuses on the creation of the model, comparing 
compartmental transmission modelling to other mathematical and statistical techniques, 
illustrating the Cardiff model for the first time within the thesis, defining all the 
parameters involved, and discussing the assumptions employed. Chapter 3 utilises the 
Cardiff model, estimating 5 parameters, using the maximum likelihood estimator (MLE) 
technique, to produce as good a fit as possible between observed and expected AIDS 
incidence. Within Chapter 3, the Entry Rate is investigated in order to decide which form 
it should take in order to allow the best fit possible, and the inclusion of HIV incidence 
data and/or deaths from AIDS data into the fitting process (via the minimisation of the 
chi-square) is explored to see if the overall fit of the model can be improved. It is not 
until Chapter 4 that the model in its final format is seen, introducing and estimating the 
parameter r (treatment effect), splitting time up into periods subject to the introduction of 
treatments and including HIV and deaths from AIDS data in the minimisation of the chi- 
square. The fit created by the model employed in Chapter 4 is outstanding and allows 
confidence in projecting the short-term future of the HIV/AIDS epidemic, hence 
extrapolations up until the year 2008 and drawn at this point. Chapter 5 uses the model 
produced in Chapter 4 to investigate possible future ‘what-if’ scenarios, including: a 
change in the number of male homosexuals living in the UK; a change in the number of
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These numbers are now significantly shy of the true amounts, due to the continuous and 
ongoing damage that the HIV/AIDS epidemic still inflicts on the world today.
Globally, HIV is continuing to spread, especially in areas with large population densities, 
such as India and China. WHO and UNAIDS reported in June 2002, that 40 million 
people worldwide were estimated to be living with HIV, of whom 28.5 million live in 
sub-Saharan Africa (CDSC 2002).
Table 1.1, on the previous page, provides a summary of the impact the HIV/AIDS 
epidemic has had on the world by December 2002 (UNAIDS and WHO 2002).
1.1.1 The Discovery of HIV/AIDS
An article in the Morbidity and Mortality Weekly Report (MMWR), on the 5th June 1981, 
states that a rare pneumonia, Pneumocystis Carinii Pneumonia (PCP), caused by a micro­
organism called Pneumocystis Carinii infecting the lungs, was reported in 5, previously 
healthy, homosexual men from Los Angeles (CDC 198 la). On the 4th July, of the same 
year, the MMWR reported that 26 cases of a rare type of skin cancer, Kaposi’s Sarcoma 
(KS), had been diagnosed (CDC 198lb). All 26 individuals (6 of whom lived in 
California and the remainder in New York) were young homosexual males suffering from 
a weakened immune system (Tavanyar 1992). The occurrence of these rare diseases, in 
such succession, among a well-defined group of people was considered very unusual. 
This, together with the fact that before 1980 there were only a few requests for the 
unlicensed drug pentamidine (used for treatment of PCP and available only through CDC 
in Atlanta) compared with increased demand from 1980 onwards, created support for the 
idea that these reported cases were indeed a new distinct clinical syndrome.
It was soon recognised that the reported patients had profound defects in their cell- 
mediated immune response, thus the new syndrome was named the Gay-Related Immune 
Deficiency Syndrome (GRIDS), until 1982, when it was re-named Acquired Immune 
Deficiency Syndrome, most commonly abbreviated to AIDS. The change of name took 
place when the same condition was found, not only in homosexual men, but also in 
haemophiliacs, intravenous drug users (IVDU’s) and heterosexuals (Brookmeyer & Gail 
1994). In retrospect, it appears that sporadic cases of AIDS in the US had already 
occurred since 1968 and probably earlier (Grmek 1990).
3
The similarity with the epidemiology of Hepatitus B with ADDS incurred the hypothesis 
that a transmissible agent was the most likely cause of ADDS. A new class of virus, 
called a retrovirus, was isolated from a homosexual man with generalised 
lymphadenopathy (which can precede ADDS) in 1983, by a group of French investigators, 
lead by Montagnier, from the Institut Pasteur. The retrovirus was thought to be the cause 
of this weakened immune system, thus the causative agent of AIDS (Gallo & Montagnier 
1988), and was named the lymphadenopathy associated virus. In 1984, a similar virus 
was isolated by Gallo and co-workers from the National Institute of Health in the US. 
This virus was named human T-lymphotropic virus type III (HTLV-III). Finally, in 
1986, the virus was officially named as Human Immunodeficiency Virus, or HIV 
(Tavanyar 1992). Also in 1986, HIV-2 was found in two people with AIDS in West 
Africa. HIV-2 is much less common than HIV-1 (usually just referred to as HIV), and is 
closely linked to Simian Immunodeficiency Virus (SIV) which infects monkeys. Both 
HIV-1 and HIV-2 are transmitted in the same way and both lead to AIDS.
When AIDS was first recognised, in 1981, it was not unusual for patients with the disease 
to live no longer than 1 or 2 years. The epidemic spread quickly and by the end of 2000 
there were more than 36.1 million people living with HIV worldwide (UNAIDS 2002). 
The infection introduces more than 15,000 new patients every day, of which the vast 
majority, over 95%, are in resource poor countries. KS is now one of the most common 
tumours in Africa and the most frequent tumour found in patients with HIV-1 infection 
(Smith et al. 2004). Today, AIDS is the leading cause of death in Africa and the 4th most 
common cause worldwide (UNAIDS 2002).
Dr. Angus Nicoll, Director of PHLS Communicable Disease Surveillance Centre, states: 
“HIV and AIDS are a huge global health problem and the challenge is at its most acute in 
developing countries, particularly in sub-Saharan Africa. There are also growing 
epidemics in China, Russia, Indonesia and West Africa... At the same time., we cannot 
afford to be complacent about HIV in Western Europe, including in the UK., worryingly, 
there is no sign that the problem is diminishing -  in fact, the truth is completely the 
opposite” (PHLS 2002a).
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1.1.2 The immune system and HIV/AIDS
Tavanyar (1992) provides a descriptive, easy to understand, explanation of how HIV 
reproduces within the body. Other publications of note are: Brookmeyer& Gail (1994); 
Kirschner (1996); and AIDS Knowledge Base (1999).
The immune system’s objective is to detect foreign agents, such as viruses and bacteria, 
recognise them, and attempt to eliminate them from the body. These foreign substances, 
known as antigens, do not only include viruses and bacteria, but also cancer cells or 
transplanted organs. The immune system, having recognised the antigen, destroys it 
fairly quickly; however, if the antigen is unfamiliar to the immune system the elimination 
process may take longer. If the process takes too long, infection occurs and the immune 
system produces antibodies, which attach themselves to the particular antigens and 
removes them, to get rid of the infection.
Types of Blood cells j
Phagocytes Lymphocytes
Macrophages Monocytes T-Lymphocytes B-tymphocytes
— T-Suppressor
-  ™
—  T-Helper
Figure 1.1 HIV within the immune system
To understand how HIV attacks the immune system it is important to know the types of 
blood cells within the immune system, and how they try to eliminate antigens (as 
illustrated in Figure 1.1). Firstly, there are two types of phagocytes (white blood cells): 
macrophages, consisting of large cells, and monocytes, smaller immature forms of 
macrophages which have the ability to transform into macrophages if necessary. 
Secondly, lymphocytes are white blood cells that control the way the body deals with 
infection. B-lymphocytes (B-cells) produce the antibodies which try to dispose of the 
antigens, either by directly killing the antigen or by making it easier for other cells in the 
blood to do so. T-lymphocytes (T-cells) can act as either: T-suppressor cells, which
5
suppress the response of the immune system to the invasion of antigens, i.e. halt the 
production of antibodies from the B-cells once the infection has been eradicated; T- 
cytotoxic (T ‘killer’) cells, which stop the organisms within the infected cells from 
reproducing and, hence, spreading the infection; or T-helper cells, which have a 
supervisory role over all T-lymphocytes, B-lymphocytes and macrophages. It is these T- 
helper cells, which detect the presence of an antigen and send monocytes/macrophages to 
eliminate it, that are targeted by HIV for depletion, hence weakening the immune system. 
The T-helper cells, B-cells and macrophages all carry a molecule called CD4. Once HIV 
has entered into the bloodstream, irrespective of mode of transmission, the virus most 
commonly attaches itself to the CD4 molecule. Note that other receptors do exist, as it 
has been possible to infect CD4-negative cells also (Lewin & Crowe 1994). Potential 
accessory receptors are galactosyl ceramide on brain and bowel cells and Fc and 
complement receptors in cells of the monocyte/macrophage lineage. Both T-helper cells 
and B-cells are attacked, and eventually destroyed, by HIV, but macrophages act as a 
carrier for the virus.
HIV is a retrovirus, which means its genetic material is in the form of RNA. This RNA is 
inserted into the invaded cell by means of an enzyme called reverse transcriptase (RT), 
which turns the RNA of the virus into DNA and then integrates the DNA of the virus into 
the host cell’s DNA so that the host cell has the genetic code of HIV for its lifetime.
Note that a virus is only able to reproduce by entering a host cell and injecting the genetic 
material DNA so that the cell reproduces the virus by making RNA. Houweling & 
Coutinho (1997) give a very detailed and informative explanation of different sub­
families of retroviruses, how they are made up of a variety of proteins and how, HIV in 
particular, uses those proteins to infect an individual. Prior to the discovery of HIV, only 
two retroviruses had ever been found in humans: human T-lymphotropic virus type I 
(HTLV-I), the cause of adult T-cell leukaemia and tropical spastic paraparesis (TSP), and 
human T-lymphotropic virus type II (HTLV-II), associated with a T-cell variant of hairy 
cell leukaemia.
After acquiring the HIV virus, the body starts to manufacture antibodies, which become 
detectable at about six weeks; at this stage a person is said to be HIV-positive. The viral 
DNA may stay within the host cell for a long time without reproducing; this period of
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time is known as the latent period. During the latent period the immune system responds 
to HIV as it would any other infection, by releasing antibodies, which generally takes 3-6 
months. This process of producing antibodies is known as seroconversion, and may be 
accompanied by mild symptoms such as fever, lethargy, and a sore throat (Tindall et al. 
1988). Quite early on in AIDS research, virologists were able to confirm that, around the 
time of seroconversion in the host, there was a substantial peak in viraemia (measure of 
viral load). This fell to almost negligible amounts as the immune system responded and 
the patient would then exhibit an asymptomatic period of, maybe, eight years or longer 
duration.
After the latent period, HIV begins full-scale reproduction. The cell DNA, containing the 
genetic material of HIV, is stimulated and HIV particles move to the surface of the 
invaded cell. The particles explode, taking sections of the cell’s membrane with them 
and using it to form the wrapping for new viruses. The infection process then restarts.
As the virus reproduces within an HIV positive individual, more and more CD4 cells are 
eradicated and so the CD4 cell count decreases over time. Eventually, the immune 
system is progressively overcome and the patient becomes quite ill, with levels of 
viraemia increasing towards another peak. More serious symptoms may develop 
including permanently swollen glands (Persistent Generalised Lymphadenopathy, or 
PGL) and more unpleasant symptoms such as oral thrush, chronic diarrhoea, fevers, night 
sweats, and severe weight loss. Also, the mental illness associated with HIV, HIV 
encephalopathy (AIDS dementia complex), and other psychiatric symptoms are 
facilitated by the ability of macrophages carrying the HIV virus to enter the brain, 
breaking the blood-brain barrier (Gallo & Montagnier 1988). Collectively, these 
symptoms are known as AIDS Related Complex or ARC and permit a diagnosis of AIDS 
itself. Two of the most common conditions associated with AIDS are pneumocystis 
carinii pneumonia (PCP), symptoms of which may be present but unalarming over a 
period of weeks to months (for instance, a dry cough, dyspnoea at exertion and fever), 
and Kaposi’s sarcoma (KS), a form of skin cancer where a malignant tumour of the blood 
vessels results in lesions which are usually multiple, purple to red, painless, firm nodules 
and plaques that may affect any part of the skin.
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In summary, the virus works by destroying the immune system, which is the body system 
concerned with fighting infections and cancers. HIV strikes the CD4 cells, which play an 
important role in immune function; as the CD4 cell count decreases, the body becomes 
increasingly susceptible to opportunistic infections and cancers which take advantage of 
the weakened immune system.
1.1.3 Definition of AIDS and the importance of markers
AIDS is officially diagnosed by the presence of one or more defining conditions. The 
system of case definitions for AIDS which is currently used worldwide, is the 1987 
classification system laid down by the Centres for Disease Control (CDC) in Atlanta, 
Georgia, CDC (1987). However, the CDC revised this classification scheme (CDC 
1992a) to integrate the CD4 cell count (CDR 1993). The European Non-Aggregate Data 
Set (ENAADS) is used throughout this thesis as the main source of data, and this 
employs the 1993 European AIDS surveillance case definition to classify AIDS cases 
(EuroHIV 2003). The definition includes 26 AIDS defining conditions, the latest of 
which was added in 1993 (Ancelle-Park 1993). The US definition for AIDS is identical 
to the European AIDS surveillance case definition with the exception of one criteria; 
within the US an HIV positive individual with a CD4 count <200 cells/pl is classified as 
an AIDS case (CDC 1992a). Ancelle-Park (1992) gives five reasons why this criterion 
was not adopted into the European Centre for the Epidemiological Monitoring of AIDS:
“1) The extensive but varied coverage for medical care and other social benefits in 
Europe makes the US and European issues of access to care very different.
2) Since all diseases included in the 1987 definition severely affect patients’ 
wellbeing, the vast majority of these patients will seek health care and will 
probably be diagnosed as AIDS cases, so completeness of reporting can be 
assessed quite easily... The completeness of reporting of the number in the total 
population of HIV-infected persons who have a CD4 count below 200/pl would 
be difficult to estimate.
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3) Those with ready access to lymphocyte phenotying would be over-represented if 
the CDC definition were applied ... interpretation of trends would be subject to 
bias, and linkage with data would be impossible.
4) ... symptom-free HIV-infected people would be labelled as “AIDS”, which would 
carry psychological and social consequences for them.
5) CD4 cell counting is not yet well standardised.”
Within the UK, the most common indicators of AIDS are PCP, candidiasis, KS, 
mycobacterium tuberculosis, wasting, encephalopathy, lymphoma, cytomegalovirus, 
toxoplasma and other forms of mycobacterium (CDR 1999b). Of these diseases, some 
occur more frequently in particular risk groups than others; for instance, in the 
homosexual category the risk of KS is five times greater than for any other risk sub­
population (McKie 1986).
In the pre-HAART (Highly Active Antiretroviral Therapy) era most deaths were 
associated with recent AIDS-defining events. Since then, the situation has become more 
complex; the current definition of AIDS is no longer a near complete marker for overall 
progression (The Antiretroviral Therapy (ART) Cohort Collaboration 2003). After the 
introduction of treatments such as HAART, the hazard ratio for death fell from an already 
reduced value of 0.47 in 1997 to 0.16 in 2001 (CASCADE Collaboration 2003). Clinical 
event rates are now so low that most studies concentrate on virological and 
immunological end-points (Mocroft et al. 2003).
Markers are a consequence of disease and are used to monitor the progress of disease 
within the body; the incubation period can be described as a progression through a 
marker path. In 1990, Goedert defined three classifications of markers: Immunological 
markers, viral markers and clinical markers. Brookmeyer & Gail (1994) provide three 
reasons for the importance of markers:
1) Markers characterise the natural history of HIV infection,
2) Markers are useful for surrogate endpoints in clinical trials (alternatives to 
traditional endpoints of AIDS diagnosis and death),
3) Markers make useful prognostic factors for predicting progression to AIDS and 
thus useful in the clinical management of patients.
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The most commonly used markers are CD4 count and viral load (HIV-RNA). In general, 
the lower the CD4 cell count, the worse the condition of the immune system and hence 
the severity of the illness. Viral load is the measurement of HIV-RNA blood levels and 
denotes the level of viral activity within the blood stream. Hence, increases in viral load 
correspond to a worsening of health, which is the opposite trend to the CD4 cell count. 
The monitoring of these two markers, with respect to (3) above, can provide information 
about whether an individual is a slow, medium or fast progressor to AIDS (CDC 1997a). 
Both markers have independent predictive value, yet CD4 seems to be the stronger 
individual predictor (HIV Paediatric Prognostic Markers Collaborative Study Group 
2003). In 2004, The PLATO Collaboration published results, based on 2488 people with 
three-class virological failure, which strongly indicate that the current CD4 cell count, but 
not the current viral load, determines the short term risk of death in this setting.
However, the viral load retains some independent prognostic significance in prediction of 
risk of new AIDS or death. Viral load appeared to be a major determinant of the CD4 
cell count slope. Van Sighem et al. (2003) discovered that a high baseline CD4+ T cell 
count; absence of CDC category-C event before the start of HAART; and no or limited 
prior treatment with antiretroviral drugs, were all clinical markers associated with higher 
survival probability and a slower progression to AIDS. In accordance with this, Deeks 
(2003) found that low pre-treatment counts of CD4-positive T cells and high pre­
treatment viral loads are associated with a greater risk of virological failure. The 
Antiretroviral Therapy (ART) Cohort Collaboration (2003) examined 9323 patients, who 
started HAART, survived and were followed up for longer than 6 months. Initial 
immunological and virological response, as reflected by CD4 cell count and viral load, 
were, again, found to be the two most important factors for prediction of progression to 
AIDS or death. They discovered that patients whose 6 month CD4 cell count was less 
than 25 cells/pL had the worst prognosis. Age 50+; transmission through IDU; and an 
AIDS diagnosis before or within 6 months of starting HAART were also found to be 
predictive.
Other studies on markers and their ability to predict the progression to AIDS or death 
show that sex or ethnicity do not have an affect on disease progression, despite reports 
that average viral load levels may be lower in girls than in boys (The HIV Paediatric
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Prognostic Markers Collaborative Study Group 2003); age and IVDU are significant 
predictors for progression to death but not for development of AIDS (Van Sighem et al.
2003); and maternal HIV disease and death are very strong predictors of child mortality 
(Dabis 2003).
More recently, markers have proved to be of great importance in monitoring the effect of 
therapy. Within both clinical trials and the general population, frequent measurements of 
CD4+ cells and viral load are in use so that the effect of treatment on HIV/AIDS can be 
supervised. This is of particular significance if HIV should become resistant to the 
current treatments available as measurements in CD4 count and viral load would indicate 
this.
1.1.4 Surveillance of HIV in the UK
In 1950, the use of the term surveillance, which was previously limited to following 
persons who had been in contact with patients in order to isolate them as soon as early 
symptoms were recognised, changed from a person-oriented to a population-oriented 
instrument and, consequently, achieved a more quantitative basis (Houweling 1997). In 
1963, disease surveillance was defined as ‘the continued watchfulness over the 
distribution and trends of incidence through the systematic collection, consolidation and 
evaluation of morbidity and mortality reports and other relevant data’ and the regular 
dissemination to ‘all who need to know’ (Langmuir 1963). Surveillance provides a 
stimulus to keep prevention and control activities moving rapidly and in the right 
direction, guiding the response to individual cases as well as public policy (Berkelman et 
al. 1997), however, in Langmuir’s definition programmes for prevention and control 
were not yet considered a fundamental part of the surveillance system. It has only been 
over the last 50 years that the concept, methods and applications of disease surveillance 
have developed in this way (Thacker & Berkelman 1988). Recent practiced definitions 
include WHO’s description of surveillance at the 21st World Health Assembly (1968), 
Last (1983) and Klaucke et al. (1988), the latter of which defined epidemiological 
surveillance as ‘the ongoing and systematic collection, analysis and interpretation of 
health data in the process of describing and monitoring a health event. This information 
is used for planning, implementing and evaluating public health interventions and
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programmes. Surveillance data are used both to determine the need for public health 
action and to assess the effectiveness of programs’. A thorough summary of the modem 
concept of public health surveillance is given by Berkelman et al. (1997). Despite the 
vast improvements in surveillance, over the past few years especially, there is still plenty 
of room for further development and advancement in the rate of diagnoses of HIV 
infection (DH 2002).
1.2 Transmission of HIV
In 1981, it was presumed that homosexuals were the only risk group for AIDS, due to the 
fact that the first AIDS cases reported were in gay men (CDC 1981a, 1981b). However, 
soon after, in 1982/1983, other risk groups were acknowledged, including heterosexuals, 
haemophiliacs and mother-to-child transmission exposure categories (Brookmeyer &
Gail 1994). Tavanyar (1992) states that HIV is detectable in the blood, breast milk, urine, 
faeces, semen, saliva, vaginal secretions, rectal secretions and the fluid that surrounds the 
brain. However, when determining the risk of transmission, the amount of vims that an 
HIV negative person is exposed to is a crucial factor. Therefore, HIV transmission via 
blood, semen, vaginal secretions and breast milk are the only realistic possibilities.
Today, the European Non-Aggregate AIDS Data Set (ENAADS), which is the principle 
dataset used throughout this thesis, classifies reported AIDS cases into a number of 
different exposure categories, the main four of which are detailed in the following 
sections of this chapter (they are, homosexual, heterosexual, IVDU’s and vertical 
transmission). The 8 distinct classifications defined by ENAADS are as follows:
• Homo/bisexual male
• Injecting drug user (IVDU)
• Homosexual/bisexual male & IVDU
• Haemophiliac/coagulation disorder
• Transfusion recipient
• Heterosexual contact
• Mother-to-child
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• Nosocomial infection1
• Other/undetermined2
[l including patients infected in health care setting]
[2 including cases of occupational exposure such as health care workers]
1.2.1 Homosexual Transmission (MSM)
In the UK, United States and Western Europe, male homosexuals have contributed the 
largest proportion of the cumulative reported cases of AIDS, although this is now falling 
as the epidemic in other groups begins to accelerate. Homosexual transmission has 
always been the main mode of spread of HIV/AIDS in the UK due to the increased risk of 
contraction during gay sexual activities and the average sizeable number of sexual 
partners. One particular study showed that HIV negative gay men had an average of 25 
partners per year whereas HIV positive homosexuals had an average of 60; some 
homosexual men were reported to have had several hundred partners in their lifetime 
(McKie 1986). Today, there is a continuing high rate of transmission among homosexual 
and bisexual men (DH 2002). Approximately 15,100 men who have sex with men 
(MSM) were living with diagnosed HIV at the end of 2001 in the UK and an estimated 
4200 remain undiagnosed, CDSC (2002). According to this same report (CDSC 2002: 
“HIV and AIDS in the UK in 2001”), 57% of MSM live in London. They remain the 
group at greatest risk in the UK with 1415 new diagnoses reported for 2001 by the end of 
June 2002. However, while prevalence of the virus is increasing, the proportion of MSM 
infected has fallen from 52% in 2000 to 50% in 2001. This does not mean that fewer 
homo/bisexual men are becoming infected year on year. In fact, in 2004, Murphy et al. 
collected specimens from 8,908 homo/bisexual men attending GUM clinics in England, 
Wales and Northern Ireland. 1,816 were HIV-1 positive, of which 332 were from 
individuals whose HIV infection had not previously been identified. The serological 
testing algorithm for recent HIV seroconversion (STARHS) was performed on 331 of the 
332 specimens. STARHS is a dual testing algorithm in which specimens that are 
confirmed HIV-positive following detection by a sensitive screening assay are tested on
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an assay which has been changed to make it less sensitive. Specimens that are unreactive 
on this less sensitive assay are deemed to be new infections while specimens that are 
reactive in both assays are deemed to be infections that have been established for some 
time. Subsequently, STARHS recognises primary infection if it arises within the region 
of 6 months before an HIV positive specimen is collected (Janssen et a l 1998). Of the 
331 specimens whom STARHS was performed on, 82 were identified as recent 
infections, giving a predicted annual incidence of 3.5% (earlier findings, commencing in 
1995, indicated a HIV incidence of approximately 2.5% per year). The data suggest an 
upward trend in the rate of HIV transmission and provide an early warning of a 
potentially significant rise in HIV incidence. This increasing incidence implies a failure 
in current prevention methods. Goldberg (2002) estimated HIV prevalence and found 
that a mean annual growth of 1020 cases in men who have sex with men (MSM) are 
anticipated over the years 2002-2005 (63% expected to be living in London).
1.2.2 Heterosexual Transmission
Since heterosexuals have fewer sexual partners than homosexual men (Johnson et al.
1992 and Williams & Anderson 1994), the AIDS epidemic within the heterosexual risk 
group has proven not to be as severe. Although the heterosexual community in Europe, 
for the most part, has not seen a serious epidemic develop, a subset of that population -  
migrants -  is facing its own more circumscribed threat. Two-thirds of all heterosexually 
acquired HIV infections during 1997-2000 in the UK were in migrants from high- 
prevalence countries and in 2002 three-quarters of heterosexually acquired HIV 
infections diagnosed in the UK are thought to have been acquired in Africa (EDITORIAL
2004). There is an increasing impact of the global situation on heterosexuals in the UK 
(DH 2002). Most of the heterosexually infected probably acquired their infection from 
outside the UK (the majority of which from sub-Saharan Africa).
The increasing number of reported heterosexual infections in the UK provides cause for 
concern with an over three-fold increase in the number of heterosexual cases diagnosed 
each year since 1999 (Carter 2003). In contrast to the proportion of individuals infected 
through homosexual sex decreasing, the proportion that contracts the virus through 
heterosexual sex has risen from 31% in 2000 to 36 % in 2001. In fact, annual numbers of
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new diagnoses of heterosexually acquired infection have outnumbered those in MSM 
each year since 1999 (CDSC 2002). In 2002, 3305 new cases of heterosexual 
transmission of HIV were recorded. That is almost twice the 1691 new diagnoses 
involving gay men made in the same year. Also in 2002, HIV prevalence was estimated 
by Goldberg who found that a mean annual 1150 cases in non-injecting heterosexuals are 
anticipated over the years 2002-2005 (63% expected to be living in London). It may also 
be worth noting that 66% of all instances of heterosexual transmission in 2002 were 
women (Carter 2003). This could be due to the fact that the risk of transmitting HIV 
during heterosexual exposure is higher for male-to-female than for female-to-male. In 
fact, studies by Padian et al. (1991); European Study Group (1992) and Haverkos & 
Battjes (1992) estimate the male-to-female infection risk to be at least twice as high as in 
the female-to-male case. Additionally of interest in the transmission of HIV 
heterosexually are the findings by Peters et al. (2004) that suggest that HLA antigens in 
seminal fluid and vaginal secretions might induce mucosal alloimmunisation (an immune 
system response) in women, and to a lesser extent in men, during unprotected sex. In 
HIV-1 infection, the viral coat contains HLA class I and II proteins. Ejaculates contain 
epithelial cells, which express HLA antigens, and cell-free HLA antigens. Stimulation of 
T cell proliferation (MLR -  mixed leucocyte reaction) was greatly increased in peripheral 
blood mononuclear cells (PBMC) for women practising unprotected intercourse in 
response to their partners’ PBMC compared to unrelated control cells. The MLR of male 
cells stimulated with cells from the female partners also showed a similar increase 
compared with controls but only with the highest percentage of stimulating cells. The 
evidence that mucosal alloimmunisation occurs naturally during sexual intercourse 
indicates a physiological function of enhancing genital immunity to sexually transmitted 
pathogens and supports the concept of alloimmunisation as a strategy for vaccination 
against HIV-1 infection.
1.2.3 IVDU’s
Intravenous drug users (IVDU’s) are the third largest risk group in the United Kingdom, 
after MSM and heterosexuals. When an HIV-positive individual injects drugs the virus 
enters the needle and syringe. After injecting, IVDU’s may draw blood back into the
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needle and syringe from the vein. This mixes with any of the remaining drug and then 
the IVDU injects again. This technique increases the risk of infection. If an HIV positive 
IVDU then shares a needle and syringe with an HIV negative IVDU, the virus is directly 
entered into the blood stream. Friedland (1989) identifies the following significant risk 
factors for IVDU’s:
1. Frequency of which IVDU’s inject drugs,
2. Frequency of needle sharing,
3. Proportion sharing needles (works) with more than two other IVDU’s.
Experimentally, a single flush of a syringe or needle with water leads to an approximate 
70% decrease in the proportion that contain sufficient HIV-1 to replicate in culture, while 
two flushes decrease that proportion by 95%. Furthermore, heating in water at 60-65°C 
will inactivate HIV-1 within seconds (Schmid et al. 2004). Despite the high risks 
involved, the numbers of new HIV diagnoses in IDU’s remain low (CDSC 2002). 
However, an increase in hepatitis C transmission in IDU’s (DH 2002) could suggest that 
the epidemic amongst this population group is set to expand.
It has been argued that unsafe injections are a major if not the main mode of HIV-1 
transmission in sub-Saharan Africa. However, a report by Schmid et al. (2004) indicates 
that there is no compelling evidence as such. In the 1980’s, WHO estimated that unsafe 
injections and the use of other inadequately sterilised skin-piercing instruments caused 
1.6% of HIV-1 infections in Africa. More recent estimates have put the proportion at 
2.5% of all infections in sub-Saharan Africa. Even with these modest estimates, there are 
worrying facts about this mode of transmission that can not be ignored. For instance, the 
numbers of injections administered for health reasons has been estimated at an average of
3.4 per person per year in low-income and middle-income countries. Of these, about 
39% are given with unsafe injection equipment. Injections given with re-used equipment 
are more common in the Middle East and South Asia than in sub-Saharan Africa where
2.1 injections are estimated per person per year, of which 18% are given with reused 
equipment resulting in a mean of 0.4 potentially unsafe injections per person per year 
(Schmid et al. 2004).
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1.2.4 Vertical Transmission
In the majority of vertical transmission cases, it is impossible to determine the route of 
infection from mother-to-baby. Perhaps the most common route of HIV infection takes 
place between mother and baby during pregnancy, when HIV can cross through the 
placenta and into the foetus. Another route is during birth, when the baby is exposed to 
the mother’s infected blood and vaginal secretions. Krivine et a l (1992) argue that 
transmission of HIV is most likely to occur this way, during delivery. Even if a child 
survives pregnancy and birth without infection, s/he can still contract HIV via the 
mother’s breast milk. A study by Dunn et al. (1992) estimated that breastfeeding 
increases the rate of vertical transmission by 14%. As a consequence of this high 
probability, European and American HIV-positive mothers are advised not to breast-feed 
(CDC 1998). However, where infectious diseases and malnutrition are the main cause of 
infant deaths, World Health Organisation (WHO) advise breast-feeding to be the best 
option, even for those women who are HIV-positive (Panos Institute 1992). The 
European Collaborative Study, in 1991, produced estimates of overall probability of 
transmission of HIV from mother-to-child by all routes discussed above. They ranged 
from 11.4% to 16% dependant on the adjustments for babies lost to follow up. Up to the 
age of 18 months a baby’s blood contains identical antibodies to the mother; 
consequently, all babies bom to HIV-positive mothers are seropositive initially. If a child 
is still seropositive at 18 months, if the virus was cultured, or if the HIV antigen was 
detected in two different samples, then that child is classified HIV-positive (European 
Collaborative Study 1991). By this time the child may already have been diagnosed with 
AIDS or died from HIV-related conditions. The natural history of HIV disease in 
children is described as bimodal; many children progress rapidly to AIDS or death during 
the first year of life, while others have a better prognosis, some now surviving into young 
adulthood (Abrams & Kuhn 2003). 20-25% of children infected with HIV-1 progress 
rapidly to AIDS or die during infancy, with slower disease progression in older children 
(HIV Paediatric Prognostic Markers Collaborative Study Group 2003).
Improvements of antenatal diagnoses of HIV have continued (CDSC 2002). Maybe as a 
consequence to this, the prevalence of HIV in pregnant women is increasing. More than 
3 million children are estimated to be living with HIV infection, and hundreds of
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thousands continue to become infected annually. In 2002, there were 800,000 newly 
infected children worldwide, most of them in sub-Saharan Africa. Fortunately, due to 
antiretroviral therapy during pregnancy, few babies are now bom with HIV infection in 
areas where access to these therapies is widespread (Abrams & Kuhn 2003). Even in 
resource poor settings, such as Africa, where mortality of those infected generally 
exceeds 40-50% in the first two years of life, prevention of mother-to-child transmission 
of HIV by antiretroviral is, vitally, now a feasible public health approach (Dabis 2003).
1.3 HIV as a global epidemic
Though we tend to call it ‘the global AIDS epidemic’, what we are facing is not one 
epidemic, but many. The introductory Editorial to the Lancet, volume 364, states that 
‘Each of these epidemics has a different dynamic and course, each varying from city to 
city, village to village, community to community’ (EDITORIAL 2004). How each of 
these epidemics, around the world, will develop and evolve depends on many variables, 
some known and some not yet discovered. Biology may play a part, with certain strains 
and sub-types spreading more easily than others; host genetics may make some 
populations more or less susceptible; and culture, economics and politics certainly shape 
each epidemic’s course, but perhaps the most important factor is the willingness of 
political leaders to acknowledge the crisis and implement needed interventions swiftly 
even in the face of political opposition.
1.3.1 Africa
The overwhelming burden of HIV/AIDS is still concentrated in this region, which 
accounts for only 3% of the global population yet some 50% of global HIV cases 
(Halperin & Epstein 2004); Africa is the hardest hit of the continents with some countries 
in the region witnessing the epidemic continuing to spread and others facing an 
increasing danger of, even greater, explosive growth. The virus now runs unbridled 
through the heterosexual populations of many sub-Saharan nations, while leaving more 
North African countries relatively untouched (UNAIDS 2002).
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Throughout the entire world, the HIV/AIDS epidemic is most relentless in Southern 
Africa; with HIV prevalence growing higher than deemed possible, exceeding 30% in 
some South African countries (UNAIDS 2002). In 2002, in sub-Saharan Africa, there 
were another 3.5 million new HIV infections diagnosed and an estimated 2.4 million 
Africans lost their lives to AIDS (UNAIDS 2002). In contrast, Uganda, in the east of the 
continent, has managed to maintain diminishing trends in prevalence rates. It is the first 
African country to have restrained a major HIV/AIDS epidemic, demonstrating that it is 
possible to reduce the epidemic using human intervention.
Epidemiological data suggests that sexual contact continues to be by far the main mode 
of transmission in sub-Saharan Africa and inadequate care and attention addresses 
specific needs of African HIV infected women of childbearing age who are informed of 
their serostatus (Schmid et al. 2004). Of growing interest to epidemiologists is the 
contemplation that, in Africa, men and women often have more than one -  classically two 
or three -  concurrent relationships that can coincide for months or years. This trend 
differs from that of the serial monogamy more frequent in the west, or the one-off casual 
and commercial sexual encounters that occur everywhere (Halperin & Epstein 2004). 
Morris and Kretzschmar (1997) used mathematical modelling to compare the growth of 
HIV in two populations, one in which serial monogamy was the standard and one in 
which long-term concurrency was customary. Although the total number of sexual 
interactions was alike in both populations, HIV transmission was much quicker with 
long-term concurrency and the resulting epidemic was 10 times larger.
Now that treatments are becoming available in low-income and middle-income countries, 
Africa will undoubtedly be hugely relieved. At the end of 2001, fewer than 30,000 
people were predicted to have been benefiting from antiretroviral drugs, a minute fraction 
of the millions of Africans who are in desperate need of them. The Barcelona Report 
(2002), produced by UNAIDS, gives a very informative look at the state of the 
HIV/AIDS epidemic in Africa and the political commitment present there to turn the tide 
against AIDS.
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1.3.2 Asia
In contrast to Africa, HIV has been present in Asia for nearly two decades, yet 
widespread coverage has yet to occur (Halperin & Epstein 2004). Today, 20% of new 
annual infections occur in this region. The Barcelona Report on the Global HIV/AIDS 
Epidemic states that, in 2002, nearly 1 million people became infected with HIV and
490,000 people are predicted to have died from AIDS. 7.2 million individuals are 
presently living with HIV and only 30,000 of those people are on antiretroviral treatment. 
China is home to a fifth of the world’s population; the growth of the epidemic is largely 
attributable to the developing epidemic in China alone. 1 million people are now living 
with HIV in China and official estimates propose a multiple upsurge in this figure in the 
near future.
1.3.3 High-income countries
Countries such as Australia, Canada and the USA have witnessed HIV/AIDS-related 
deaths significantly drop since 1995/1996, when antiretroviral therapy was first 
introduced. However, the last couple of years have seen this trend level off, with an 
estimated 15,000 people dying from AIDS in America last year. The response, in terms 
of prevention, to treatments becoming widely available has resulted in an increase in 
high-risk behaviour and, accordingly, some countries saw a rise in the rate of new 
infections. There is evidence that the epidemic is spreading into more deprived and 
poorer communities within some of these high-income countries. Consequently, there is 
a strong need to fight complacency and to reinvent prevention programmes. The main 
mode of transmission in the USA is that of sex between males; it accounted for the 
largest proportion (42%) of new infections in 2000. AIDS incidence rose during the 
1980’s, declined from the mid 1990’s through 2001 and increased 2% in 2002 compared 
with 2001. The number of deaths among persons with AIDS continued to drop (14% 
from 1998-2002) and AIDS prevalence sustained its growth (CDC 2002).
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1.3.4 Europe
Although more than 500,000 people are infected in Europe, with 30-40,000 new cases 
each year, the explosive growth of the epidemic, that was once feared, has not occurred. 
Instead, the disease has become established in high-risk populations. Even within these 
groups there are variations from country to country and even city to city (EDITORIAL 
2004). EuroHIV’s 2003 report on HIV/AIDS Surveillance in Europe is extremely 
valuable when summarising the progression of the epidemic in Europe to date and has 
been used as the main source of reference for the following synopsis of the epidemic 
within Europe, along with Hamers & Downs review published in the Lancet in 2004. 
Central Europe
A cumulative total of 20,300 HIV infections were reported by the end of June 2003. Of 
these, 8,191 (40%) were in Poland and 5,580 (27%) were in Romania. Newly diagnosed 
HIV infection and AIDS remain low and moderately unchanged in recent years. In 2002, 
HIV reporting rates were highest in: Poland (15.0 per million population); Romania 
(15.0); and Slovenia (11.1). All other countries reported no more than 10 new HIV 
diagnoses per million population. HIV prevalence levels are minimal (<0.1% in most 
years) and show no distinct pattern over time. However, there were prevalence levels of 
over 2 per 100 000 blood donations reported in all or most of the last 5 years from: 
Albania (between 5 and 7 per 100 000); Bulgaria (2-5); Poland (2-3 overall, but <1 
among repeat donors); Romania (5-10); Serbia and Montenegro (2-9); and Turkey (3-5). 
Elsewhere, levels remain small, generally <1 per 100 000.
Eastern Europe
A cumulative total of 324,913 HIV infections had been reported by mid 2003 by the 15 
countries of the former Soviet Union. After increasing sharply for some years, the 
number of new HIV diagnoses fell for the first time in 2002 -  from 100,580 (346.7 per 
million) in 2001 to 64,352 (222.5 per million) in 2002 (-36%). This decline appears to be 
continuing in 2003 due to a steep drop in cases reported among IDU (-53%). However, 
heterosexual contact (HC) cases continued to increase steadily (+31%).
Data for the East follow similar patterns in several countries (with some differences in 
timing). However, the data are disproportionately influenced by the Russian Federation 
(which accounts for 76% of all HIV infections ever reported in the East) where the
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epidemic is extremely heterogeneous (60% of cumulative HIV infections reported by 
only 10 of its 87 regions).
Western Europe
At the start of the 21st century, HIV/AIDS maintains its status as a major public health 
problem in Western Europe. More than half a million people are living with an HIV 
infection that remains incurable and necessitates costly permanent treatment. UNAIDS 
and WHO published country-specific estimates for 2001, and estimated that 520,000 -
680,000 individuals were living with HIV in Western Europe by the end of 2003.
The HIV/AIDS epidemic in the UK is akin to that of the rest of N. Europe, while SW. 
Europe has experienced a much larger epidemic, especially amongst IDU’s (CDSC
2002). In 2001, there was an additional increase in the total number of HIV infections in 
adults in the UK (DH 2002). The best estimate, at November 2002, of the total number 
of adults living with HIV in the UK at the end of 2001, undiagnosed or diagnosed, is 
41,200 (CDSC 2002). By 2003, almost 50,000 people had been diagnosed with HIV in 
the UK (Carter 2003); an increase of 20% on the previous year. McHenry et al. (2002), 
Communicable Disease and Public Health, used data from 1996-2000 to extrapolate 
trends in prevalent numbers of diagnosed HIV infections for the years 2001-2005 using 
the method of back-calculation; the prevalence in 1996 was 14,205, this increased by 
62% by the end of 2000 and 139% by the end of 2005. Possible drivers for this increase 
are a sustained rise in diagnosis and a continuing number of new diagnoses. Sexually 
Transmitted Infections (STI) are, in general, at their highest levels since records began. 
The country has the worst sexual health record in Western Europe.
It has been approximated that HIV incidence within Western Europe reached its peak in 
1983, or thereabouts, among homosexual men, and peaked in 1987-88 among IDU’s, 
with 120,000 homo/bisexual men and 144,000 IDU’s having contracted HIV by 1985 and 
1989, respectively. Heterosexually transmitted infections rose gradually during the late 
1980’s and early 1990’s. The scale of newly diagnosed HIV infections (among countries 
with data available for a minimum of the last 6 yrs) has increased by 46%, from 8,021 in 
1997 to 11,683 in 2002. The number of new HIV diagnoses among IDU’s fell steadily (- 
9% between 1997 and 2002); that among persons infected through heterosexual contact 
(HC) grew noticeably (+116% over the same period); and that among homo/bisexual men
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(HBM) rose in 2002 (+22% compared with 2001) after gradually decreasing between 
1997 and 2001. The increase in HC cases is mostly a consequence of a rise in cases 
diagnosed originating from a country with a generalised HIV epidemic.
Recent movements within the epidemic of newly diagnosed HIV infections in Western 
Europe are propelled by the UK, which accounted for 30% of the population and about 
40% of HIV diagnoses reported during 1997-2002, in a study by Hamers & Downs in 
2004. Between 1999 and 2002, HIV incidence rose by about 20% each year with about a 
third of HIV-positive people being unaware of their serostatus (Carter 2003). Within the 
UK, there has been a steady increase in diagnoses of persons infected with HIV (from 
147 in 1998 to 275 in 2002), the majority of these individuals most likely contracting 
HIV infection through partners infected from outside Europe. Note that 70% of HIV- 
positive immigrants were unaware of their serostatus on arrival into the UK, dispelling 
the myth that so-called treatment tourism is a problem (Power 2004).
Throughout Western Europe, following the introduction and widespread use of HAART, 
AIDS incidence and AIDS deaths declined sharply in the mid 1990’s; thus, the number of 
people living with AIDS increased. AIDS incidence in Western Europe increased again 
in 2002 by 3% (compared with 2001). The number of deaths among persons with AIDS 
has continued to decline (-8% between 2001 and 2002), a cumulative total of 147,065 by 
mid 2003 had been reported (152,000, according to Hamers & Downs 2004). This 
implies that the number of persons living with AIDS has continued to increase and was 
estimated at approximately 108,000 by mid 2003 (107,000, according to Hamers & 
Downs 2004). Also, a proportion of people with HIV today are unaware of their 
infection, hence have no opportunity to benefit from antiretroviral treatment. For those 
who are aware of their serostatus, since access to health care is almost universal in 
Western Europe they are eligible for free treatment. In the UK and in Spain more than 
three-quarters of the patients seen for care in 2002, and eligible for antiretroviral 
treatment, were receiving therapy.
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1.4 Treatments for HIV and AIDS
1.4.1 Mono-therapy
In section 1.1.2, details of how the HIV virus attacks and weakens the immune system 
were provided. That is, the insertion of HIV-RNA into the host cell, using an enzyme 
known as reverse transcriptase, converting the RNA into DNA and integrating the viral 
DNA with the host cells’ DNA, ensuring that the host has the genetic material of HIV for 
their lifetime. There are currently more than 20 antiretroviral drugs (so called because 
HIV is a retrovirus) that have been approved for treating HIV infection (AVERT 2005°). 
These antiretroviral drugs work by interfering with the virus’ ability to use enzymes in 
order to survive. They fall into two main types:
• Reverse transcriptase inhibitors (RT inhibitors) which interfere with an enzyme 
called reverse transcriptase (RT) that HIV relies on in order to reproduce.
• Protease inhibitors which interfere with the protease enzyme that HIV uses to 
produce infectious viral particles.
Treating an individual with just one of these drugs is called mono-therapy. This form of 
treatment was first introduced following the development of the premier anti-HIV drug 
zidovudine (AZT) in 1987. The early zidovudine therapy, despite initial optimism, was 
eventually shown not to be effective in delaying progression to AIDS. Primary 
prophylaxis for PCP, however, met with substantial achievement in reducing the extent of 
this particular condition as an AIDS-defining illness. Mono-therapy regimens result in 
significantly greater CD4 cell recovery compared with no therapy and suggest that 
continuous triple or quadruple therapy in acute HIV infection gives a high probability of 
short- to medium- term viral suppression, although the comparative potency of various 
therapies has not yet been clearly defined (Smith et a l 2004). In support of this, the 
Delta trial, Delta Co-ordinating Committee (1996), discovered that the two drugs 
zidovudine (AZT) and didanosine (ddl), in combination, are more effective than treating 
an individual with only the one drug zidovudine. Also, HIV can become resistant to any
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one drug, thus, treatment regimens now involve a combination of 2 or 3 different drugs, 
with an increasing number of individuals receiving quadruple therapy (Beck et al. 1999).
1.4.2 The introduction of dual-therapy and HAART
HAART is a combination (cocktail) of potent and effective antiretroviral drugs such as 
protease inhibitors and nucleoside-analogue reverse transcriptase inhibitors (NRTI’s). 
Since mid-1996, with the introduction of triple-combination antiretroviral therapy, a trio 
of retrovirals which the patient is required to take on a regular basis and indefinitely, 
there has been a well-documented reduction in mortality and risk of AIDS-defining 
illnesses (Van Sighem et al. 2003). Prior to the introduction of these new combination 
therapies, nearly 50% of young men who acquired HIV died from their infection within 
12 years (NIH 2002a). Provided the HAART regime is faithfully adhered to, it seems to 
virtually clear virions (infectious virus particles) from plasma; indeed, the reduction 
occurs within the two weeks following the initiation of therapy. The short-term benefits 
of HAART are that both life expectancy and quality of life for HIV-infected patients 
improve. Smith et al. (2004) demonstrate that, if not an absolute explanation for the 
speedy resolution of KS, immune responses to the initiation of HAART could contribute 
to its reduced incidence. In fact, progression to an ADDS-defining illness, in those who 
can tolerate treatment and do not develop drug resistance, has now been effectively 
stopped as long as HIV is diagnosed and treated properly early enough in the course of 
clinical progression (McHenry et al. 2002). Another benefit of HAART is brought to our 
attention by Dabis (2003), who showed that a single dose nevirapine regimen can reduce 
by 40% the natural transmission rate from mother-to-child. In addition, the most potent 
short-course combined regimens can achieve residual peripartum transmission rates (rates 
of transmission from mother-to-child) of around 5% in breastfeeding populations (Dabis 
2003).
The death rate across Europe dropped rapidly after the introduction of HAART; within 2 
years of the widespread availability of HAART the numbers of deaths were less than a 
fifth of those before HAART (Mocroft et al. 2003). The HIV Paediatric Prognostic 
Markers Collaborative Study Group (2003) confirm that the rates of both morbidity and 
mortality have declined over calendar time -  especially since 1996, coincident with the
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widespread use of dual, then triple, antiretroviral therapy. Part of the decline might be 
attributable to changes in the infected and treated population during the years 1996-2000 
and not just the initial impact of cocktail therapies. Over these years the population 
shifted towards one in a less advanced stage of HIV-1 infection at the start of HAART 
with a growing fraction of therapy-naive patients (Van Sighem et al. 2003).
The optimum time to initiate HAART in asymptomatic patients is an issue that is hard to 
resolve; universal treatment seems compelling but would expose many to a premature 
risk of toxic effects and resistance development. For children, early treatment may delay, 
rather than overcome, the factors that influence rapid progression of disease. Although 
higher CD4 percentage and lower viral load in older children helps to predict when to 
safely defer therapy, markers cannot be used to identify younger children at low risk for 
progression (Abrams & Kuhn 2003). A study by Chang-Heok Soh et al. (2003) showed 
that CD4 improved substantially in children and adolescents who started protease 
inhibitor-based (Pi-based) combination therapy for HIV-1 infection. There was an 
overall improvement in median CD4% between 1996 (first prescribed) and 2000 of 22% 
to 28%, with younger children showing a greater improvement than older children. 
However, for the majority of children, who were substantially immunosuppressed before 
they started Pi-based therapy, it was not adequate to recover normal CD4%. In this 
article by Chang-Heok Soh et al. it is suggested that if normal immune function is the 
goal of therapy then current guidelines, which advocate delaying the start of therapy until 
lower CD4% values are reached, may not achieve this ultimate aim. However, when 
considering toxic events and treatment failure due to viral resistance, time for which 
effective treatments are available for any individual patient is limited. Current guidelines 
are now suggesting initiating HAART at later stages of infection, which should allow 
physicians more time to assess the potential barriers to adherence before prescribing 
HAART (Kleeberger et al. 2004).
1.4.3 Adherence and Resistance Problems
Drug toxicity, medication adherence and resistance emergence are the main obstacles to 
long-term therapy for HIV infection (Moyle & Boffito 2004). High levels of treatment 
failure have been reported, which have been associated with serious adverse events,
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emergence of drug resistance, difficulties in maintenance of long-term adherence and the 
few types of drugs available (Mocroft et al. 2003).
Treatment Uptake and Adherence
The lack of availability of antiretroviral drugs is obviously damaging the potential for 
therapy in resource poor countries and, consequently, treatment uptake is poor. As an 
example of this, Dabis (2003) reports that only about 5% of all African HIV-infected 
pregnant women are receiving the treatment they need. There is an urgent requirement to 
develop simple and sustainable strategies for initiation and delivery of HIV care and 
therapy to large numbers of patients. In high-income countries, where the availability of 
anti-HIV drugs is widespread, those persons who are in touch with the resources and 
opportunities they need to initiate treatment might choose not to participate in therapy for 
a number of reasons, including not wanting to suffer the adverse effects of antiretroviral 
drugs and not being able to adhere to the burden of strict drug regimens. Adherence to 
drug regimes is not only difficult in terms of complicated rules and procedures, it is also 
incredibly time consuming. The proportion of person-time on HAART increased from 
22% in 1997 to 57% in 2001 and is even greater than that today (CASCADE 
Collaboration 2003). Also, a large fraction of HIV-positive people are not on therapy 
when they should be due to lack of awareness of their serostatus. Even for those 
individuals who are on anti-HIV therapy, there are many factors associated with 
antiretroviral drugs, including complicated therapeutic regimens; depression; alcohol and 
drug use; and changes in daily routines, that may cause low adherence to treatment which 
then compromises the effectiveness of HAART (Kleeberger et a l 2004).
A significant problem associated with HAART, and the adherence to HAART, is the 
adverse effects of drugs which may result in increasing morbidity and a reduced quality 
of life. Virtually all of the current anti-HIV (antiretroviral) drugs available in the United 
Kingdom can produce side effects, some of which are severe. Adverse effects of 
antiretroviral agents may be considered early (occurring within 3-6 months of therapy) or 
late (occurring in individuals who are established on and tolerating a drug for some time). 
Most early toxicities, such as nausea and diarrhoea, rash and sleep disturbances, are 
predictable, transient and of mild to moderate intensity. These adverse events are 
generally manageable with advice and palliative drugs, only occasionally do they require
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treatment modification. Late potential side-effects of HAART, such as hepatotoxicity, 
impaired glucose metabolism and diabetes mellitus, hyperlactatemia, hyperlipidemia and 
fat redistribution (Palacio et al. 2004), anaemia, peripheral neuropathy, pancreatitis, 
lipoatrophy, and lactic acidosis, whilst occurring in only a few individuals, are less 
amenable to management with palliative drugs and generally lead to therapy 
modifications or treatment interruption. Additionally, some of these late side-effects are 
potentially life-threatening and can lead to permanent disability or stigmatising 
morphological changes (Moyle & Boffito 2004). Adverse effects such as these may lead 
to suboptimal adherence to antiretroviral treatment, where adherence to these 
antiretroviral drugs is crucial to suppress virus levels (Kumarasamy 2004). Virological 
failure is generally defined as concentrations of HIV-1 RNA in plasma continuously 
above the level of detection (50-200 copies per mL) after at least 16-24 weeks of 
HAART. Failure in this way is common in clinical practice, with rates of 30-70% 
reported in many clinic-based cohorts, due to viral replication dynamics in the presence 
of incompletely suppressive antiretroviral therapy, that is: high viral replication rates; 
high mutability; and high plasticity (Deeks 2003). The sequential use of effective 
monotherapy is perhaps the most common cause of virological failure during the early 
HAART era. One study concluded that virological failure was common in patients with 
less than 80% adherence and rare in those with greater than 95% adherence. These 
findings are perturbing as the mean proportion is about 70% adherence. Virological 
failure rates have lowered recently possibly due to: the availability of more effective 
regimens; greater clinical expertise; and a better grasp among patients and clinicians on 
the value of adherence (Deeks 2003).
Adherence to antiretroviral drugs is also vitally important with respect to preventing drug 
resistance (Kumarasamy 2004); less than optimum drug exposure allows the virus to 
replicate in the presence of a selective pressure, thus leading to the emergence of drug- 
resistant variants (Deeks 2003). No recent outpatient visit; younger age; depression; and 
lower educational levels are all independent determinants of decreasing adherence. 
Furthermore, previous non-adherence predicts non-adherence at the next visit. Besides 
education, providers should assess and treat depression to enhance continued adherence 
to optimise the effectiveness of HAART (Kleeberger et al. 2004). Abdool Karim et al.
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(2004) discuss the integration of HIV and TB care as a proposed strategy to improve the 
adherence to anti-HIV drugs. The simplest and most successful way, however, to ensure 
complete adherence and, consequently, minimise drug resistance and maximise therapy 
outcomes is through directly-observed HIV therapy (Kumarasamy 2004).
Drug Resistance
HAART is now widely used to treat HIV-1 infection. However, resistance to one or 
more of the drugs being used commonly arises during the course of treatment due to the 
selection of viral variants carrying mutations in key codons (where a codon is a sequence 
of nucleotides constituting genetic code) associated with reduced drug susceptibility 
(Cane et al. 2004). For an overview of some of the definitions and principles behind the 
biology of drug resistance see Deeks (2003) who discusses viral replication dynamics, 
viral fitness and viral latency. Barouch & Letvin (2004) report that viruses that carry 
mutations have increased replicative capacity and might, therefore, replace the original 
virus in the circulation. Two recent studies (Leslie et al. 2004 and Freidrich et al. 2004) 
address the issue of whether HIV with mutations in dominant cytotoxic T lymphocyte 
(CTL) epitopes (where an epitope is a site on the surface of an antigen molecule to which 
a single antibody molecule binds) is transmissible from one individual to another. 
Together, the data suggest that there is a fitness cost associated with maintaining the 
mutations, thus, the mutant virus reverts to wild-type sequences in recipients where there 
is an absence of immune selection pressure. By contrast, the mutant virus is maintained 
in donors as a result of ongoing selection pressure exerted by CTL specific for the 
wildtype epitopes. The lower fitness and infectivity of the drug-resistant variant 
compared with the wild-type variant, as well as lower viral loads in partially treated 
patients compared with untreated patients, may contribute to a lower than expected rate 
of transmission of drug-resistant HIV-1 (Deeks 2003).
HIV drug resistance is, however, increasing. The percentage of treatment-naive patients 
infected with drug-resistant HIV rose from 10% in 1996 to 14% in 2001 (AIDS Weekly
2003). Among patients for whom drug therapy is not working, the percentage with 
resistance to any one drug has remained stable (at 70-80%) since 1996. The greatest 
concern is the number resistant to all three classes of drugs -  increasing from 1% in 1996 
to 14% in 2001 (AIDS Weekly 2003). Resistance testing of HIV-1 is now recommended
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following treatment failure and also in some circumstances at primary infection. For 
more information on resistance testing see Cane et al. (2004). In patients for whom HIV 
replication is not suppressed after exposure to several drug classes, background treatment 
strategies remain unclear. Deeks (2003) suggests the following treatment strategies:
• First HAART failure -  All patients probably have at least two opportunities to 
achieve complete or near-complete viral suppression.
• Multiple HAART failure -  More and more drugs are needed to suppress HIV-1 in 
such patients, leading to more complex regimens, inconvenient dosing schedules, 
greater toxicity, and higher costs. Broadly speaking, there are 3 ways to treat a 
motivated patient with multi-drug resistant HIV-1:
1) Multi-drug salvage regimens with the aim of complete suppression.
2) Partial viral suppression and ‘when to switch’.
3) Structured treatment interruptions.
Salvage therapy, or rescue therapy, (that is, any regimen designed to suppress drug- 
resistant HIV-1 in a patient who has previously been treated with at least one HAART 
regimen) commonly fails to suppress HIV-1 since patients who could not adhere to a 
simple initial regimen are unlikely to manage more complicated salvage regimens. Plus, 
given the added complexity of newly resistant HIV-1, the barriers to a successful 
virological response worsen with each new regimen.
Treatment interruption is a topic that is constantly debated and seems to hold no strict 
format. Abrams & Kuhn (2003) have shown that in adults the interruption of treatment 
started during primary infection gives promising results. However, in children this has 
not yet been proven to be the case. Continuous HAART is associated with slower 
progression to death and AIDS in comparison with interrupted HAART, however, 
occasional treatment interruptions shorter than 3 months do not increase the risk of death, 
in fact short-term disease progression does not change and may even improve slightly 
(Van Sighem et a l 2003). Viral latency argues against long-term treatment interruption 
as a means of restoring drug-sensitive virus (Deeks 2003).
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In patients for whom viral-load suppression to below the level of detection is not 
possible, achievement and upkeep of a CD4 count above 200 per pL becomes the primary 
aim. Long-term virological suppression is unlikely to be viable for many patients with 
three-class drug failure (as supported by recent findings from the T-20 vs Optimized 
Regimen Only Trials by Lalezari et al. (2003) & Lazzerin et al. (2003)), therefore, in 
such patients, the goal of therapy needs to be adapted to preservation and, if possible, 
increasing the CD4-cell count with the long-term objective of maintaining low mortality. 
The problems of serious adverse events, adherence to complicated regimens and absence 
of virological effect have not yet influenced mortality and morbidity in the population. 
The long-term effects of HAART are still unknown -  predictions cannot be validated 
with currently available data and might be too optimistic considering the risk of toxicities 
and resistance (Van Sighem et al. 2003).
1.4.4 Up and Coming Treatment Therapies
There are approximately two dozen new anti-HIV drugs presently in development, as 
listed by the pharmaceutical research and manufacturer’s association. They include:
• new protease inhibitors
• more potent and less toxic RT inhibitors
• new categories of drugs:
o fusion inhibitors -  interfere with HIV’s ability to enter a cell 
o integrase inhibitors -  impede HIV’s ability to insert its genes into a cells DNA
Also, scientists are learning more about immune modulators and therapeutic vaccines.
On May 17th 2002, the National Institute of Allergy and Infectious Diseases (NIAID) 
announced the new contract award in its HIV Vaccine Design and Development Teams 
(HVDDT). Over the next five years $22.8 Million will be provided for Wyeth Vaccines 
to expand research on a vaccine candidate that has been proven to prevent an AIDS like
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disease in monkeys. Researchers are hopeful that this vaccine will stimulate both parts of 
the immune system, that is, stimulate both:
1) antibodies to neutralize any free-floating HIV
2) specialized immune cells to eliminate any cells that HIV still manages to infect
This particular vaccine candidate originated from the Yale University laboratory of 
NIAID grantee John K. Rose, PhD. Between 1997 and 2002,6 potential vaccines have 
been tested around the world, and it is expected that, from 2002-2005, more than a dozen 
further potential vaccines will be ready for testing. NIAID Director, Anthony S. Fauci, 
M.D., believes that “HIV vaccine research is our best hope, along with other prevention 
efforts, to slow the spread of HIV... These trials will lead to a vaccine, perhaps not in a 
year or two, or even three years, but we will get there”.
1.5 Strategies and Interventions to combat the HIV/AIDS epidemic
2001 was the 20 year anniversary of AIDS, and yet the epidemic is still in its early stages. 
There is proof that effective responses are possible, but only when full-scale action is 
taken. Unless this action is taken, the epidemic will continue to grow. Margaret I. 
Johnston, PhD, associate director for HIV/AIDS vaccines, NIAID, states that “HIV 
continues to spread unabated in many parts of the world... The public needs to 
understand that AIDS is not under control”.
Viral load and CD4 monitoring combined with prompt ART when required should have 
been minimising the infectious hazard of diagnosed cases. However, the expected 
benefits from high coverage of combination ART in the diagnosed HIV infected 
population seem to have been negated by increasing high-risk sexual behaviour among 
some homo/bisexual men (Murphy et al. 2004). Effective interventions are needed to 
prevent acquisition of HIV infection in men who have sex with men. To date, no 
behavioural interventions specifically for this risk group have been implemented. The 
EXPLORE Study Team, in 2004, performed a randomised controlled study to investigate 
the effects of a behavioural intervention to reduce acquisition of HIV infection among
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MSM. The overall estimate of a difference of 18.2% was uncovered, with more 
favourable estimates of effect in the first 12-18 months. This suggests that prevention of 
HIV infection among MSM, by a behavioural intervention, is a feasible option.
1.5.1 Prevention and Awareness
Among the young people of Britain, rising rates of STI’s and increases in risk-taking 
behaviour continue to demonstrate the potential for HIV transmission and indicate that 
sexual health promotion for young people is, at present, not achieving desired results 
(Dougan et al. 2004). HIV prevention is built on behaviour changes, a response at the 
population level to the epidemic and to avoid risk; it can be supported and catalyzed but 
is not delivered as a traditional intervention. Other interventions, including voluntary 
counselling and testing services (VCT), care support networks, and even treatment, are 
greatly enhanced if HIV prevention creates the basic population response to be mobilized 
(Low-Beer 2004). HIV prevention can be highly successful; changing the course of an 
epidemic over a matter of years even in resource-poor settings. It has been shown that 
wide social communication leads to declines in casual sex of up to 65%. Uganda remains 
the best example of changes in population behaviours and communication, reducing HIV 
prevalence on a national level from 21.1% to 9.7% from 1991-98 and down further to 
6.4% in 2001 (Low-Beer 2004). There have also been documented reductions in 
Thailand (by 55%, in casual and commercial sex, 1990-1993), Zambia (by 27% among 
male youth, 1996-99) and amongst the homosexual population in the USA. It is hoped 
that current initiatives to reduce STI’s and promote safer sex may reverse HIV incidence. 
Unlinked Anonymous Prevalence Monitoring Programme (UAPMP) data indicate that 
59% of previously undiagnosed HIV infections remain undiagnosed after the clinic visit, 
representing many missed opportunities to intervene and reduce HIV transmission 
(Murphy et al. 2004). Expanded access to treatment has the potential to attract millions 
of people into health-care settings and so offers critical new opportunities to 
simultaneously strengthen HIV-prevention efforts by delivering and reinforcing HIV- 
prevention messages. The widespread availability to HIV treatment will provide new 
incentives for HIV testing, which in turn will increase opportunities for counselling on 
HIV prevention. Increased knowledge of serostatus will subsequently enable prevention
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programmes to develop interventions that are specifically tailored to the different needs 
of HIV-positive, HIV-negative and untested individuals (Gayle & Lange 2004). 
Sustainable treatment over the medium term depends on successful prevention. Gayle & 
Lange argue that to achieve a maintainable response to HIV/AIDS, prevention and 
treatment services must be brought to scale simultaneously. Unless annual HIV 
incidence falls sharply, treatment programs will be unable to keep pace with the number 
of people in need, and will become financially unsustainable. As antiretroviral therapy 
reduces AIDS deaths in areas where treatment is available, the disease may seem less 
threatening, thus leading to potential increases in sexually risky behavior resulting in the 
number of people living with HIV growing. Furthermore, as HIV-infected people on 
antiretroviral therapy become healthier, they are likely to become more sexually active, 
potentially creating additional opportunities for HIV transmission to occur. Studies 
attribute the increase in unprotected sex, at least in part, to the perception among many 
that HIV/AIDS is no longer as serious as it once was (Gayle & Lange 2004).
To stem further increases in HIV incidence, the UK Government needs to concentrate on 
the modernisation of sexual health services; the UK Department of Health’s Sexual 
Health Strategy is aiming for a 25% fall in newly acquired HIV infections in England by 
2007. Unlike with other infectious diseases, an infected person with HIV must act in 
certain ways to pass the virus on; it is here that the Government can act with education 
and services to prevent this onwards transmission (Power 2004).
1.5.2 Reducing costs of treatments and surveillance
Most of the public health challenges of HIV/AIDS can be, at least partially, dealt with 
using prevention and awareness campaigns, as discussed previously. Some of the main 
public health challenges in the UK as detailed by the CDSC (2002) are listed below:
1) Increasing numbers of diagnosed HIV infected people
2) Large and increasing impact of migration from high prevalence areas
3) Rising costs of care
4) Continuing transmission through MSM and increasing sexual risk taking
5) Numbers of newly diagnosed HIV infected individuals with advanced disease.
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With reference to 3) on the previous page, a large proportion of costs of HAART arise in 
the postponement of ADDS resulting in a steep increase in the number of people requiring 
long-term treatment (CDSC 2002). The success of HAART and the growing number of 
new cases of HIV transmission has meant that there has been a 101% increase in demand 
for HIV care since 1997 (Carter 2003).
GlaxoSmithKline Pic (GSK) and the German drug manufacturer Boehringer Ingelheim 
have agreed to grant licences for production, import, sale and distribution of generic 
AIDS drugs in South Africa, after being charged with anti-competitive sales practices and 
excessive pricing by AIDS activists, including the Treatment Action Campaign, in 2002. 
This will undoubtedly help bring inexpensive medicines to millions of people living with 
HIV/AIDS in sub-Saharan Africa (Nelson 2003). Companies (including Cipla, who 
launched the first generic antiretroviral drug, zidovudine, in 1994, and has since then 
launched 10 different antiretroviral and fixed-dose combinations of antiretroviral drugs as 
single pills) have reduced the cost of combination HIV-antiretroviral treatment by such 
an extent, in the last year or two, that HAART can now be bought for less than US$250 a 
year. Falling prices of therapy are enabling physicians in the developing world to offer 
triple antiretroviral regimens to greater number of patients, who desperately need the life- 
saving drugs (Kumarasamy 2004). However, despite the cost of first-line combination 
generic antiretrovirals being less than $250 a year, the cost of the second-line 
combinations with protease inhibitors is ten times that amount. This large disparity in 
price will present a great challenge for resource-constrained settings in the scaling up of 
antiretroviral delivery. Immunological and virological monitoring of HIV-infected 
patients on HAART is critical. The cost of a CD4 cell-count is around $25 a test, and 
measuring viral load costs $100 a test. The cost of monitoring is higher than the cost of 
generic antiretrovirals in some resource poor countries (Kumarasamy 2004), hence, there 
is significant importance of identifying alternative assays that could guide treatment 
decisions (Mofenson et a l 2003).
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1.5.3 Three-by-Five Initiative
In September, 2003, at the second UN General Assembly Special Session on HIV/AIDS, 
WHO and UNAIDS declared the lack of treatment in low and middle income countries to 
be a global health emergency and launched the “3 by 5” initiative, which aimed to enrole 
3 million people on ART by the end of 2005 (Gutierrez et al. 2004). That means that the 
UN’s new AIDS strategy aims to increase the number of people receiving antiretroviral 
treatment from only 7%, of nearly 6 million people, to 50%. Although AIDS is treatable, 
less than 5% of the 40 million people living with AIDS have access to antiretrovirals.
The 34 countries targeted by the initiative are home to 94% of people needing treatment 
in the developing world (Mukheijee 2004). Baragona (2003), in an article for 
VOANews, explains that, under this plan, WHO’s objectives are to: provide simple, 
standardised procedures that will make it easier to get more people treated and tested; 
provide technical help to countries on setting goals, finding money, hiring and training 
local workers and improving facilities; and help control costs by establishing global and 
regional networks of buyers. The report by Gutierrez et al. (2004) estimates that between 
US$5.1 billion and US$5.9 billion will be needed by the end of 2005 to provide the 
required antiretroviral therapy and support programmes, in addition to covering country- 
level administrative and logistic costs in order for 3 by 5 to work. Yet, to date, less than 
$2.3 billion has been paid to the Global Fund (Mukheijee 2004).
1.5.4 Similarities with other STI’s
Between 1996 and 2002, the incidence of sexually transmitted infections (STI’s), 
excluding HIV, rose by 43%. These data tell us that more and more people are having 
unsafe sex, hence serving as an early warning of the future path of HIV/AIDS. 
Furthermore, as well as causing disease and infertility, infection with other STI’s may 
facilitate the transmission of HIV (Dougan et al. 2004), thus, the spread of HIV may be 
amplified by the increased prevalence of sexually transmitted diseases in the community. 
It is possible that the presence of both ulcerating and non-ulcerating sexually transmitted 
diseases (STD’s) increase the risk of HIV infection three- to five-fold (Wasserheit 1992 
and Laga et al. 1994). Effective STD control plans and the monitoring of HIV 
prevalence in STI patients is essential to HIV prevention (EuroHIV 2003).
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In 2004, Pugh et al. produced a paper describing eight cases of infectious syphilis which 
were identified as two unrelated clusters in Walsall, West Midlands (population 250,000), 
over the four months from December 2002 to March 2003, illustrating the 
epidemiological diversity of the ongoing syphilis epidemic and emphasizing the need for 
continued vigilance to the potential of infection in high risk groups. In England, 
diagnosis of infectious syphilis began to rise in the late 1990’s -  congenital syphilis is 
rare in the UK, and few cases have been reported - cases of primary, secondary, and 
latent syphilis increased by 431% between 1998 and 2001. This increase was disrupted 
by a number of individual outbreaks, with clusters of infections also being reported. 
English outbreaks were associated with high rates of partner change within risk groups 
and simultaneous HIV infection that may well occur since it is possible that syphilis 
enhances HIV transmission.
Gupta et al. (2004) discuss the lessons one can learn from multi-drug resistant 
tuberculosis, which has many similarities with HIV/AIDS, including: serious adverse 
events from multidrug treatment; comprehensive management strategy for prevention and 
treatment; and the threat of drug resistance at individual and population levels. 
Furthermore, the diseases share management requirements that are particularly difficult to 
meet in resource-constrained regions, such as: long-term follow-up and assessment of 
patients; adequate supply, availability and affordability of drugs and diagnostic tools; 
intensive patient support to endure adherence to treatment; the need for laboratory 
monitoring; and the absence of evaluated, evidence-based policy for management.
The Green Light Committee (GLC) is a partnership formulated by the international 
community, designed to foster access to treatment for multidrug-resistant tuberculosis via 
an integration of the negotiated concessional prices and a system for ensuring proper use 
of second-line drugs. The GLC operates as a sole coordinating entity for the global 
multidrug resistant tuberculosis issue. As the international community moves rapidly to 
bridge the HIV/AIDS treatment gap by strengthening health systems, strategies 
developed for TB could help ensure that affordable, high-quality antiretroviral reach 
programmes are used appropriately.
Murphy et al. state in their report in 2004 that the substantial increase in homosexually- 
acquired gonorrhoea in 2000/2001, compared to earlier years, was sustained in 2002, and
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their data suggest that this sensitive indicator of increased behavioural risk among 
homo/bisexual men was accompanied by an increase in HIV incidence. This underlines 
the importance of strengthening HIV prevention messages in response to adverse changes 
in the incidence of acute STI’s. With dramatic increases in chlamydia rates among young 
women over the past decade, and the highest rates of gonorrhoea and concurrent 
partnerships among young people, concern about the potential for HIV transmission 
remains (Dougan et al. 2004).
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CHAPTER 2 
HIV/AIDS EPIDEMIC MODELS AND 
DATA
2.1 Mathematical and Statistical techniques to model epidemics
Once the AIDS data has been adjusted for both under-reporting and reporting delay, one 
can perform mathematical and statistical techniques, or projection methods, in order to 
reproduce that data and, thus, make predictions about certain ‘what-if scenarios. 
Numerous statistical methodologies have been produced for investigation into the 
HIV/AIDS epidemic, of which the three most common methods are back-calculation, 
using both data from the past and knowledge about disease development (i.e. the 
incubation period); extrapolation (or curve-fitting), using only data from the past and not 
knowledge about the present disease; and compartmental (or transmission) modelling, 
which uses knowledge necessary for back-calculation techniques and information 
concerning modes of transmission and their probabilities. All methodologies, according 
to Jager et a l (1993), involve trend analysis of observed AIDS incidence; re-enactment of 
HIV movements; models for transmission and spread of the disease; and estimation of 
key parameters for models reciting the development of disease stages. Bibliographies by 
Whithers (1989) and Fusaro et al (1989) provide in depth explanations of these 
approaches, enclosing original ideas useful in quantitative methodology for infectious 
disease in general. Anderson (1989) and Gail & Brookmeyer (1988) also give 
annotations of some mathematical and statistical research as well as Castillo-Chavez 
(1989) who edited a thorough assessment of statistical and mathematical methodologies 
in HIV/AIDS modelling (Jager et a l 1993). It is the technique of compartmental 
modelling that will be applied throughout this thesis in order to model and predict the 
path of the HIV/AIDS epidemic. The other two methods are described briefly in the 
following sub-sections of this chapter. Also discussed is a fairly new approach to 
modelling infectious diseases using phylodynamics.
39
2.1.1 Extrapolation
Some authors use what is viewed as the simplest technique for predicting AIDS 
(Solomon 1996), that is, extrapolation of empirical curves fitted to observed AIDS 
incidence data (or some other well-defined data points). Curves that are most often used 
are the exponential (for the early years of the epidemic), exponential with a quadratic 
component, the logistic and the linear logistic (Department of Health and The Welsh 
Office 1988, cited in Heisterkamp et al. 1992). At the beginning of the epidemic, when 
exponential curves are usually fitted, the growth rate can be denoted by a(t) = ea+^ , 
where aft) is the number of new diagnoses at time t, with constant doubling time log 2/fi. 
Solomon (1996) states that this curve can be advantageous due to its mathematical 
simplicity and approximate relation to the solution of a number of simple theoretical 
models which encompass features of the ‘at risk’ population. Agreeing with epidemic 
theory, the growth rate decelerates and so further mathematical formulae contain sub­
exponential growth. Solomon (1996) then goes on to detail that, in the mid to late 
1980’s, observed AIDS diagnoses rates were fitted using a variety of curves based on the
exponential, for instance, the quadratic exponential model aft) = e a+^ t~yt . In this curve, 
the rate of new diagnoses of cases rises to a peak before dropping symmetrically to zero. 
For recipients of blood or blood products, amongst whom nearly all new infections 
ceased in Australia (and elsewhere) when widespread screening of donated blood was 
introduced in 1985, the model is a satisfactory approximation to the trend of new 
diagnoses of AIDS (Solomon and Wilson 1993). In Australia, and in England and Wales, 
the linear logistic model has provided the best fits to observed AIDS incidence; the rate 
of new cases of AIDS is assumed to pass from exponential to linear growth relevant in 
the second phase of the epidemic, according to the expression a(t) =(a + /*y(> + er *). 
Distinctions between geographical regions, transmission groups and other categorical 
effects can be simply calculated by comparing the appropriate parameter estimates. 
Solomon (1996) informs us that alterations in the definition of AIDS, the introduction 
and availability of treatments, and other temporal changes, may be included by using 
change-point models (Solomon et al. 1990). The Report of a Working Group (1988); 
Solomon et al. (1990); and Taylor (1989) all provide further information on this area. 
Where the observed amounts are significantly large, one can fit nonparametric curves.
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Examples of this are the application of Lowess (locally weighted scatterplot smoother) to 
smooth observed AIDS data with the intent to describe patterns in AIDS incidence 
(Cleveland 1979). See, for example, Rosenberg et a l (1992) and work by Zeger et a l
(1989) who used splines to model the US AIDS data. Other researchers suggest 
semiparametric curves, combining parametric and nonparametric components (De 
Angelis et a l 1993), or propose fitting piecewise constant, linear or nonlinear models. 
Despite being, arguably, the most straightforward approach to forecasting AIDS data 
(Hethcote & Van Ark 1980 and Brookmeyer & Gail 1994), there are limitations to the 
method that Brookmeyer and Gail (1994) discuss fully. In extrapolation, a model is fitted 
to the AIDS data, from this model we can expand and forecast future AIDS cases. 
Numerous models will fit the current available AIDS data perfectly, as described above, 
however, when predicting the long-term numbers we may find the results differ greatly. 
Also, it can not be assumed that the model will fit future AIDS data. In spite of which 
curve is applied for the fit of the growth rate, knowledge of important characteristics of 
the epidemic cannot be directly included in this technique, unlike for epidemic models, 
which endeavour to replicate the true pattern of HIV infection, and the back-calculation 
method, which can involve ‘external’ information observed from surveys, cohorts and 
other studies (Solomon 1996). Despite this, extrapolation can be used to foresee short­
term outcomes, although even these results need to be drawn with care and interpreted 
cautiously. The smoothness of the AIDS data, due to the infection rate being convoluted 
with the Incubation Period Distribution, or IPD, (Brookmeyer & Gail 1994) lends itself to 
the method of extrapolation. However, abrupt changes in AIDS incidence can occur, as 
seen in the US in 1993 due to the alteration in the surveillance definition of AIDS and the 
introduction of effective anti-HIV therapy in 1996. Thus, even a short-term extrapolation 
would be inadequate at predicting such changes.
2.1.2 Back-calculation
Mathematically speaking, back-calculation lies between extrapolation and compartmental 
modelling in terms of its complexity. It is one of the most used techniques when 
modelling observed AIDS incidence with the aim of predicting future values, as 
demonstrated by Brookmeyer & Gail (1988); Brookmeyer & Damiano (1989); and Isham
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(1989). Taylor (1989), Solomon & Wilson (1990) and others also used back-calculation 
early on to reconstruct the size and shape of the past HIV infection curve from AIDS 
incidence data and from this predict future AIDS incidence. Becker et al. (1991) discuss 
the advantages and disadvantages of the various prediction procedures and give results 
from a non-parametric back-projection method where only the incubation time 
distribution is known. They determine that using the non-parametric method one can 
only predict the minimum size of the epidemic, as no information is applied for future 
HIV-incidence. Like the actuarial method, the method of back-calculation uses 
knowledge of the route of infection. In addition to this, it uses information about the 
incubation time distribution, and it is normal to identify an empirical curve for either the 
AIDS incidence or HIV incidence in order to retrieve future projections (Heisterkamp et 
al. 1992). Proposals from both Brookmeyer & Liao (1990b) and Solomon & Wilson
(1990), suggest including other information in the process also, such as early treatment. 
The principle of back-calculation is that an estimate of the HIV incidence can be obtained 
by incorporating the observed AIDS incidence data and an estimate of the IPD with the 
use of back-calculation. Knowledge of any two of the distributions can determine the 
third and once the past infection curve has been recreated, using back-calculation, the 
equation, as shown below in equation (2.1), is used again in order to forecast future AIDS 
incidence, usually for periods of up to 5 years (Solomon 1996). The convolution 
equation used for back-calculation is as follows:
where
A(t) = expected cumulative number of AIDS cases diagnosed by time t; 
g(s) = infection rate at time s and;
F(t) = cumulative distribution of the incubation period.
Note that the incubation period must be less than t-s, since for every individual diagnosed 
with AIDS by time t, infection must have occurred prior to this, at time s (Brookmeyer & 
Gail 1994). This equation, in words by Solomon (1996), gives the basis of back-
(2 .1)
0
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calculation: “that a process of infection has occurred, and is possibly still occurring, in 
the population under study, and that infection with the virus is followed by the lengthy 
and variable incubation period until (at least in a majority of cases) an AIDS-defining 
illness is diagnosed”. Solomon (1996) then goes on to say that it is still too early to 
decide whether some people will remain infected forever, without ever developing an 
AIDS-defining illness.
Brookmeyer & Gail (1994) state five limitations of the back-calculation method:
1) No predictions can be made for the future HIV infection rate,
2) Little information about recent infection rate,
3) The IPD is assumed known,
4) The IPD is assumed stationary,
5) Requires accurate AIDS incidence data.
Deterministic deconvolution (‘deterministic’ since the approach assumes no random 
variability in the cumulative AIDS data and ‘deconvolution’ referring to using known 
A(t) and F(t) to solve for g(s)) is the most simple form of back-calculation. However, it 
is not without its problems, consequently statistical deconvolution is the preferred method 
in both the discrete and continous cases. The general mathematical case for discrete 
deterministic deconvolution is shown in equation (2.2), this equation is solved to find 
estimates of the number of HIV infections in year i as a linear system of n equations in n 
unknowns.
<Xj=gJj+g2fJ-i+-" + gjfi  (2-2)
where
Oj = number of new AIDS cases diagnosed in the jth year, 
gi = unknown number of individuals infected at the beginning of the i^ year, 
fi = F(i)-F(i-1) = probability that an individual develops AIDS during the i* year 
of HIV infection.
From equation (2.2) above, it can be seen that the number of new AIDS cases diagnosed 
in year 1 of the epidemic can be written as ai = gift. Solving this for the number of
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individuals infected at the beginning o f  year 1, i.e. the initial number o f infectives:
Since fi, the probability that an individual develops AIDS during the first year of HIV 
infection, is very small, the process is ill-conditioned.
Brookmeyer & Gail (1994); Gail & Rosenberg (1992); and Baccheti et al. (1993) provide 
a detailed and informative explanation of the back-calculation method, along with many 
other publications.
2.1.3 Phylodynamics
Chronic or persistent infections, such as HIV, show a relatively slow increase in the 
number of cases, without the peaks and the troughs associated with acute infections. 
Clewly explains, in his 2004 paper entitled: “phylodynamics: a conjunction of 
epidemiology and evolution?”, that, for chronic infections, phylogenetic trees can be 
constructed based on sequences from different individuals (i.e. between-host population 
phylogenetics) or sequences evolving within an individual patient (i.e. within-host 
individual phylogenetics). These two types of trees are not congruent. The population 
tree reflects the temporal and spatial dynamics of the disease, whereas the individual tree 
is a reflection of immune selection occurring within the host. Grenfall et al. (2004) 
address the problem of how to construct a model that will accommodate the different 
phylogenetic trees and temporal and spatial epidemic data -  they call this type of 
modelling, Phylodynamics. A key phylodynamic parameter defined by Grenfall et al. is 
the Evolutionary Infectivity Profile (EIP) which is a measure of the transmission rate of 
immunologically selected microbial mutations. It may be expressed mathematically, as 
shown in equation (2.3) below, as a function of the pathogen population size, its mutation 
rate and the strength of the immune response of the host.
(2.3)
Where m = mutation rate;
N = viral population size; 
t = time.
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It is suggested by Grenfall et al. that determining the EIP of an infection will help in 
vaccine design, drug therapy and countering emergent diseases. Different phylodynamic 
patterns that may be observed are described by Clewly as follows:
• Infection with no immune response and no adaptation occurs;
• Limited immune response and high adaptability of the pathogen, seen in the 
course of an HIV infection;
• Infection rapidly cleared because of strong immunological response in an 
experienced host.
Phylodynamics is intended to provide a means whereby phylogenetic and 
epidemiological models can be unified, thereby allowing a new understanding of the 
transmission of infectious disease.
2.1.4 Modelling the HIV/AIDS Epidemic
The model building approach, or compartmental modelling, is one of the main 
methodologies which operational researchers are interested in, in particular of the three 
aforementioned key methodologies (back-calculation, curve fitting and transmission 
modelling). It aids comprehension of the structure of the epidemic and understanding of 
how complicating aspects might affect the global spread of the disease. Such factors may 
include heterogeneity in sexual behaviour, variable infectiousness, changing sexual 
behaviour and the nature of partner formation (mixing) (Dangerfield & Roberts 1994). 
Transmission modelling is significantly useful in view of ambiguity, complexity, 
inadequate data and resource use. In order for this modelling technique to excel in areas 
such as: disease prevention; early detection and screening programmes; evaluation of 
treatments; allocation of resources; and improved patient monitoring and care (Brailsford 
& Shahani 1994), information on a number of features of the mechanisms concerned (for 
instance: infection; disease progression; risk group; risk behaviour; and modes of 
transmission) is necessary. Habitually, models of this type investigate the consequences 
of various what-if scenarios qualitatively and/or quantitatively (Anderson 1989; Bailey 
1992a; Dietz 1991; Anderson & May 1992; Druten et al. 1990 and; Jager & Ruitenberg
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1992). When models are suitably fitted to a particular HIV/AIDS epidemic, they can be 
used for medium-term forecasts, as illustrated by Bailey (1992a) to Switzerland, Hethcote 
et al. (1991) to San Francisco, Heisterkamp et al. (1992) to Amsterdam and Verdecchia et 
al. (1992) to Italy.
Assumptions are implied concerning the means by which transmission of HIV occurs. 
These assumptions also regulate the modelled population characterized by the observed 
AIDS cases. Thus, dynamic models must be employed to well-defined (e.g. 
geographically and categorically) real populations adhering to the postulates implied 
(Jager et al. 1993). Bailey (1992a) presented a model of HIV/AIDS, intended for 
practical public health applications, with a close connection between local data and 
compartmental modelling. This model proposed by Bailey includes different risk-groups 
(intravenous drug users (IVDU’s); homosexual/bisexual men, high and low risk; and 
heterosexuals); estimates model parameters; and incorporates a correction for reporting 
delay and under-reporting. Consequently, it utilizes AIDS case data and data from death 
certificate investigation. Models should employ various sources of information and 
modify model dynamics and statistical techniques to a specific local situation (Jager et al.
1993). More recent methodological progress permits the construction of realistic 
situations, using (sub) epidemics linked with socio-economic impacts (Boom et al. 1992). 
Mathematical models designed and developed for infectious diseases by researchers since 
the early 20th century (Bailey 1975; Hethcote & Van Ark 1980 and Anderson 1982) can 
be invaluable in the creation and justification of theories. Thus, the procedure demands 
complete understanding of the main dynamics involved in the growth of an infectious 
disease in order to create a simplified mathematical interpretation of a vastly complex 
situation with comprehensible assumptions. It is imperative to maintain as simple a 
model as possible, in spite of how complex the reality of the situation may be. The 
inclusion of too many non-essential parameters will mean more uncertainty in the model 
due to the greater amount of estimation required. The invention of a compartmental 
model of the AIDS epidemic which embraces the three key transmission groups, or 
exposure categories, affected (male homosexuals, intravenous drug users and non- 
monogamous heterosexuals) would be moderately complicated. Numerous relations 
between heterosexuals themselves and with members of other transmission groups (e.g.
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the activities of bisexuals and persons who have sex with infected IV drug users) and the 
larger number of parameters within the model cause difficulties. This generates problems 
for estimation either by direct methods or by fitting the model to time series data 
(Dangerfield & Roberts 1994). This work, like that of Dangerfield & Roberts (1989, 
1996) and Roberts & Dangerfield (1990a, 1990b) has involved the development of a 
transmission model of AIDS spread in the male homosexual community only, due to the 
inherent complexity involved in formulating a transmission model which embraces all 
three main groups of susceptibles (homosexuals, intravenous drug users and 
heterosexuals). The research by Dangerfield & Roberts (1996) has three main objectives:
i. An international comparison of the parameter values obtained as a result of fitting 
a model to time-series data from a number of different countries;
ii. A comparison of the optimised parameter values with those derived from clinical 
studies and sample surveys;
iii. A comparison with the projections made by the other two approaches to 
modelling AIDS epidemiology insofar as they offer projections disaggregated by 
risk group.
2.2 Introduction to the Cardiff HIV/AIDS Epidemic Model
2.2.1 Compartmental modelling of HIV/AIDS
Traditionally, infectious disease is modelled using SIR, or SIS, models. These involve 
dividing the population into sub-populations, those who are: Susceptible to the disease; 
Infected with the disease and Recovered from the disease (i.e. once again Susceptible to 
the disease). For HIV/AIDS, individuals do not recover from the disease; hence we use 
an SI model. Also, the infected state is divided into HIV infected and AIDS categories 
due to the significant difference in health status. Plus, we incorporate a ‘Death from 
AIDS’ state to signify that AIDS is a terminal illness. Thus, the states considered for 
modelling the HIV/AIDS epidemic are as shown in Figure 2.1. There are movements 
between the compartments as illustrated by the directional arrows and, as for any model
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consisting of a set of states, there exists a set of rules determining how an individual 
transfers from one state to another (Brailsford & Shahani 1994).
Susceptible
HIV Infective
AIDS
Death from AIDS
Figure 2.1 The four basic states in the epidemiological model for HIV/AIDS.
These four sub-populations can then be split further to create various other sub­
populations, as seen in publications by Hethcote & Van Ark (1980); Griffiths et al. 
(1990); Wheeler (1990); Hethcote et al.(1991); Bailey (1993, 1994a, 1994b, 1997); 
Griffiths & Williams (1994); Pasqualucci et a l (1998) and Rossi & Schinaia (1998). For 
the model implemented here, the sub-populations are split into those individuals who 
indulge in High Risk activities and those who adopt Low Risk behaviour. Roberts & 
Dangerfield (1990b) go even further and divide the sub-populations into three risk 
behaviour groups: high, moderate and low. Also, the infected sub-population can be 
sub-divided into a number of smaller sections in order to illustrate the various stages of 
disease progression that an individual may pass through before being classified as having 
contracted AIDS. Brailsford & Shahani (1994) provide a description of the natural 
history models in use during the early 1990’s and go into detail explaining three different
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types of model that they have developed, with varying degrees of complexity, in order to 
meet the different needs of their intended users. The Cardiff model shares similarities 
with these models described by Brailsford & Shahani (1994) since they are essentially 
semi-Markov processes representing the uncertainty and variability witnessed during the 
course of HIV infection. Garnett (2002) provides an easily comprehendible description 
of mathematical models, their creation and use, for the purpose of modelling sexually 
transmitted diseases, defining all relevant mathematical and technical terms within the 
article. Garnett reports that mathematical compartmental models “serve a number of 
roles in understanding sexually transmitted infection epidemiology and control... 
providing an explicit framework within which to develop and communicate an 
understanding of infectious disease transmission dynamics.” This same article by Garnett 
goes on to include the construction of a simple deterministic compartmental mathematical 
model of an infection in a homogenous population and its analytical solution, providing a 
useful reference for the introduction of the Cardiff model.
2.2.2 The Cardiff HIV/AIDS Epidemic Model
The Cardiff Model is displayed in Figure 2.2 overleaf. Within the Cardiff Model the 
same principles are applied as discussed previously; the homosexual population is 
divided into Susceptibles, Infectives, AIDS and Death from AIDS sub-populations, and 
for each of these states an individual can either be participating in high risk behaviour or 
low risk behaviour. As displayed in Figure 2.2, the sub-populations are denoted by:
X(t) = The number of High Risk Susceptibles at time t 
Y(t) = The number of High Risk Infectives at time t 
A(t) = The number of High Risk AIDS cases at time t 
W(t) = The number of Low Risk Susceptibles at time t 
V(t) = The number of Low Risk Infectives at time t 
Z(t) = The number of Low Risk AIDS cases at time t
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^  B1 >(  EXIT )
1
Death
from
AIDS
Figure 2.2 The Cardiff HIV/AIDS Epidemic Model
When discussing High Risk and Low Risk behaviour amongst homosexual men, what is 
implied is the significant difference in the degree of exposure to the HIV virus subject to 
the activities that the individual is participating in at that time. For instance, homosexuals 
within the High Risk category may be practising unsafe sex with numerous and frequent 
partners, whilst a homosexual within the Low Risk category might be participating in 
safe sex, or in a stable long-term relationship. Following an individual through the
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Cardiff model, that individual can stay within the sub-population they are in, transfer to 
another sub-population with an adjoining arrow, exit the model from causes other than 
AIDS, (e.g. no longer a homosexual or dying from causes other than AIDS), or exit the 
model due to AIDS i.e. death from AIDS.
There are a number of basic assumptions implied in the creation of the Cardiff Model as 
seen in Figure 2.2, including the assumption that an individual can only enter the model if 
participating in High Risk activities and a Susceptible can only become infected with 
HIV if participating in High Risk activities. This allows a High Risk Susceptible to 
lessen their risky behaviour and move to the Low Risk Susceptible category, where they 
will not become infected with HIV unless they revert to their previous High Risk 
behaviour. At this point it is worth noting that it is assumed an individual can move from 
High Risk to Low Risk in all sub-populations; however, it is not expected for an 
individual to return to their prior high risk behaviour at any point, except on contraction 
with full-blown AIDS. Hence, within Figure 2.2, there is no transfer direction from the 
Low Risk sub-populations to the High Risk sub-populations, with the exception of the 
movement from the Low Risk Infective sub-population, V(t), to the High Risk AIDS case 
sub-population, A(t), dictated by the parameter g. The evidence behind this possible 
increase in risky sexual behaviour on diagnosis with AIDS is provided by Snary (2000), 
Lowrie (2000), Wheeler (1990) and Griffiths et al. (1990, 2000) who all include this 
transfer rate, albeit small (g = 0 . 1 ), to reflect the change in attitude that might be 
associated with the prognosis of AIDS. The assumption that an individual will not, 
otherwise, return to their previous High Risk behaviour follows on from work completed 
by Snary (2000), who states that ‘to keep the compartmental model as simple as possible 
and to constrain the number of parameters within the model it is assumed that a 
homosexual will transfer from high to low risk only’.
For each possible movement through the Cardiff model, there is an associated parameter. 
These parameters are shown in Figure 2.2, placed next to their repective directional 
arrows. Each is listed and defined on the following page:
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A = the Entry Rate into the Cardiff model,
|Xi = the rate that a Susceptible exits the model from causes other than AIDS,
(4,2 = the rate that an Infective exits the model from causes other than AIDS,
(43 = the rate that an AIDS case exits the model from causes other than AIDS,
Vi = the rate that a High Risk Susceptible transfers to the Low Risk category,
V2 = the rate that a High Risk Infective transfers to the Low Risk category,
V3 = the rate that a High Risk AIDS case transfers to the Low Risk category, 
a = the proportion of High Risk Susceptibles who continue to practice in High 
Risk behaviour once they become infected with HIV, 
b = the proportion of High Risk Infectives who continue to practice in High Risk 
behaviour once they are diagnosed as AIDS cases, 
g = the proportion of Low Risk Infectives who start to practice in High Risk 
behaviour once they are diagnosed as AIDS cases, 
a  = the incidence rate, represents the rate at which homosexual men become 
infected within a time interval, 8 t, 
y = the incubation rate,
cd = the death rate, or the AIDS Survival Time.
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The parameters, A and a, will be discussed in much more detail in the following section, 
but meanwhile, to give an idea of the calculation of A and a:
A = AA/9 7 5 , where X is the arrival rate and N 1978 is the total homosexual 
population in 1978; and
Y{t) + A(t) . 0 . , . r  . . . ^ (0  + ^ (0• a  = pc  —-----—-----, where pc is the mfectivity rate an d --------- ------—
X(t) + Y(t) + A{t) X(t) + Y(t) + A(t)
represents the proportion of High Risk HIV infected individuals at time t.
Each of the sub-populations has a differential-difference equation associated with it; 
these differential-difference equations for the basic Cardiff HIV/AIDS Epidemic model, 
as seen in Figure 2.2, are given below in equations (2Aa)-(2Aj):
dX(%  = A -o X (t) - (v , +m )X (t) ...(2.4a)
dY(%  = aaX (t)-(Y + v2 + n 2 )Y(t) ...(2.4b)
dA(% ,t = bYY(t) + gyv (l) - ( v 3 +H, +a>)A(t) ...(2.4c)
dW(%  = v>X (t)" ^ W(t) •••(2-4d) 
dV(%  = (1 -  a)aX(t) + v 2Y (t)-(y  + n 2 )V(t) ... (2.4e)
= (1 - b ) r Y(t) + (1 - g ) r v (t) + v 3A(t) - ( n 3 +<»)Z(t) ,..(2.4f)
Equations (2.4a)-(2.4f) can then be rearranged using first principles to obtain the set of 
discrete-time equations (2.5a)-(2.5f) seen overleaf:
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X(t + <*) = X (t)  + [a  -  (/i, + v, )X(t) -  aX  (/)]<* ... (2.5a)
Y(t + a) = Y(t) + [aaX(t) -  {y + v2 + //2 ) r ( 0 } »  ... (2.5ft)
4 ( f +  a )  =  ^ ( 0  +  [ f t r I ' ( 0  +  S ? * ' ( 0 - ( > ' 3  + / < 3  +  . . . ( 2 . 5 c )
W(t + St) = W(t) + [w, X(t) -  W(tj\5t ... (2.5 </)
K(< + A) = ^(/) + [(1 -  a)aAT(/) + v2Y(t) - ( /  +Mi F « ] «  • • • (2-5e)
Z(l + « )  = 2(l) + [ ( l - W )  + ( l - ? W l )  + M ( ' ) - ( f t  +m)Z(t)}5t ...(2 .5 /)
Throughout this thesis, the equations have been solved for each time interval 5t (8 t is 
taken as 1 week, over a period of 50 years). When solving these equations for each 8 t, 
HIV Incidence, HIV Prevalence, AIDS Incidence and AIDS Prevalence can be estimated.
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HIV Incidence refers to the number of new HIV cases per year and is given by X (/),
i = i
where X(i) (i = 1 ,2 ,..., 52) denotes the number of High Risk Susceptibles present in 
week i of the particular year under consideration. Similarly, AIDS Incidence, that is, the 
number of new cases of AIDS per year (i.e. the rate at which Infectives are diagnosed as 
AIDS cases multiplied by the total number of High and Low Risk Infectives) is given
52 52
by r ^ L ( i )  + (i) , where Y(i) and V(i) denote the total number of High Risk and
. 1=1 f=i
Low Risk Infectives, respectively, present in week i of the year under consideration. The 
term prevalence refers to the number of cases alive at time t. Thus, HIV/AIDS 
Prevalence is given by Y(t) + V(t) + A(t) + Z(t), whereas AIDS Prevalence alone is 
defined as A(t) + Z(t).
When solving the differential-difference equations via Euler’s method (first principles), 
the value that we choose as our time increment, 5t, can have a significant effect on the 
modelling procedure and output. If too big, then events may occur that are not 
recognised or noted within the model since occurrence takes place within one time 
interval i.e. a homosexual may become infected and die from AIDS within one time step.
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Alternatively, if 8 t is too small then rounding errors can take place (Snary 2000). 
Throughout this thesis, a time interval of 1 week is used (i.e. 8 t = 1/52) in accordance 
with work by Snary and Bailey. Note that England (1997) showed that Euler’s method 
provided sufficient accuracy of results when compared to more sophisticated models of 
numerical solutions of these equations, such as the Runge-Kutta 4th order method.
2.3 HIV and AIDS data
2.3.1 The Dataset
The Public Health Laboratory Service (PHLS), at the Communicable Disease 
Surveillance Centre (CDSC), and the European Non-Aggregate AIDS Data Set 
(ENAADS), gathered by the European Centre for the Epidemiological Monitoring of 
AIDS, provide UK data which can then be employed for a mathematical and statistical 
investigation into the HIV/AIDS epidemic. The PHLS collects information including 
reported HIV infections, AIDS diagnoses, AIDS mortalities, AIDS indicator diseases. It 
segregates this data into regions within the UK for different transmission groups. 
Appendix 2.1 tabulates the UK data, for homo/bisexual men, implemented throughout 
this thesis, with AIDS incidence and HIV incidence extracted from the ENAADS dataset 
and deaths from AIDS obtained through contact with the CDSC. It is this data that the 
Cardiff HIV/ADDS model is based on and fitted to, employing maximum likelihood 
techniques for the estimation of certain parameters and a minimisation of ^ -square 
summation to obtain the best fit possible.
ENAADS
Fifty-two countries in the European region of the World Health Organization (WHO) 
conduct joint surveillance of AIDS at the WHO-EC Collaborating Centre on 
AIDS/European Centre for the Epidemiological Monitoring of AIDS (ECEMA), Saint- 
Maurice, established in 1984. Surveillance is based on reporting of anonymous 
individual data. One institution per country reports AIDS cases to ECEMA and sends 
anonymous individual data on all AIDS cases reported nationally since the beginning of 
the epidemic. These data, which are extracted from the national AIDS data sets, are
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merged to form the European Non-Aggregate AIDS Data Set (ENAADS). The data in 
ENAADS were presented quarterly, and more recently at 6 -month intervals, in the report 
‘HIV/AIDS Surveillance in Europe*. A total of 38 countries (including the UK) provide 
data on each individual AIDS case. The range of the information recorded in the 
ENAADS data set is listed below:
• Country of national report
• Sex
• Age group at diagnosis
• Year of diagnosis
• Quarter of diagnosis
• Vital Status (classifying an individual as dead or not known to be dead)
• Year of death
• Test for HIV-1
• Test for HIV-2
• Transmission category
• Transmission sub-category or heterosexual contact category
• Transmission category of mother for mother-to-child cases
• Year of national report
• Quarter of national report
• Exact age at diagnosis
• AIDS indicator disease present at the diagnosis of AIDS
The definition used to classify HIV positive individuals as AIDS cases, for this dataset, is 
described in detail in section 1.1.3, i.e. the 1993 European AIDS Surveillance Case 
Definition. The dataset is released at half-year intervals with the end of year report for 
2003 used within this thesis. As in Snary (2000), it is the UK AIDS cases for 
homosexual/bisexual men that provide the observed AIDS incidence data for this work 
and the UK new HIV diagnoses for homosexual/bisexual men that provide the HIV data 
(from 1995 onwards).
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HIV data
Since the use of HAART became widespread in 1996, trends in AIDS incidence numbers 
have become less reflective of underlying trends in the HIV transmission (CDC 2002). 
Surveillance data on newly diagnosed HIV infections provide a more complete picture of 
the epidemic and the need for prevention and care than that provided by data on AIDS 
cases. Data on newly diagnosed HIV infections, however, should be interpreted with 
caution since they may not represent HIV incidence (i.e. new infections) and because 
they depend heavily on patterns of HIV testing and reporting which differ between 
countries (EuroHIV 2003). Determining HIV incidence (the number of new HIV 
infections) is difficult due to the long incubation period (IP) and lack of severe symptoms 
until much later on in the progression of the disease. Hence, many individuals are not 
aware of their serostatus. At present it is estimated that about a third of HIV-positive 
people do not know that they are infected, or, if they do know that they are HIV-positive, 
do not know their exact date of infection. Even though there may be a discrepancy 
between reported HIV cases and HIV incidence, new HIV diagnoses figures can still 
provide a rough guide for the number of HIV infections occurring. New diagnoses data 
on HIV among homo/bisexual men, is provided from the Health Protection Agency (HPA 
2003) and EuroHIV (2003). The data dates from 1985 through to 2002, and demonstrates 
a reasonably stable level of approximately 1500 new diagnoses of HIV per year. It is 
suspected that HIV incidence prior to 1985 was not as settled as the apparent trend after 
this date. In fact, back-projections suggest that HIV incidence rose from 1978 onwards, 
to a peak, at around 1982, with about 3500 to 4000 new cases of HIV infection occurring 
in this year.
Surveillance programmes on HIV infection include: unlinked seroprevalence surveys 
(DH 1996); diagnostic HIV-testing reports and laboratory surveillance (Waight et al 
1992, Goldberg et al 1992, Van Duynhoven et a l 1996, DH 1996, Smith et a l 1994 and 
McDonald et a l 1994); as well as anonymous (repeated) surveys and monitoring in 
targeted sentinel populations, such as attendees of sexually transmitted diseases (STD) 
clinics, IDU’s, and pregnant women (DH 1996, Fennema et a l 1995, Wiessing et al 
1996 and Bindels et a l 1996). For specific purposes, surveillance of HIV infection can 
be supplemented or extended by immunological or virological data (Lehner et a l 1997).
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HIV incidence estimates can be obtained from: 1) observing seroconversions in a 
longitudinal study; 2) inferring incidence from serial cross-sectional surveys; 3) using 
capture-recapture methods in serial surveys; 4) back-calculation from reported AIDS 
cases; and 5) identifying recent seroconverters from a cross-sectional sample using two 
antibody tests of differing sensitivity for HIV antibodies. The fifth method listed here is 
relatively new and is described by the CDC as the serologic testing algorithm for recent 
HIV seroconversion (STARHS) (CDC 2002 and Schwarcz et al. 2001). STARHS is 
discussed briefly in section 1.2.1 of this thesis and consists of two HIV enzyme 
immunoassays: one is a current, highly sensitive, standard test that can detect HIV 
antibodies within a month of infection and the other has been made an insensitive 
(“detuned”) experimental test that may identify antibodies 129 days to 170 days after the 
first test. As the measure of antibody in peripheral blood grows progressively in the early 
weeks and months of HIV infection, a newly infected person will test positive on the 
sensitive assay and negative on the detuned assay. If the average time a newly infected 
person will be positive on the first test, and negative on the second, is known, an 
annualised incidence rate can be extrapolated from the cross-sectional samples. False 
positive seroconversions can occur in individuals with late-stage HIV infection, in which 
antibody levels decline, and in persons receiving antiretroviral treatment. However, 
despite the limitations, STARHS has grown in use because it is the only method that 
allows an incidence estimate from a single cross-sectional sample and could potentially 
establish whether infection has occurred within the past year. Public health experts, at 
the Centres for Disease Control and Prevention, claim that STARHS can assist with 
tracking trends in HIV infection more accurately by suggesting emerging epidemics, thus 
improving the focus on intervention efforts. The STARHS technique has been validated 
for use with HIV subtype B infections, the subtype found in almost all UK bom 
homo/bisexual men. However, when used in determining the incidence of HIV infection 
among heterosexuals, the reliability of the STARHS technique can be problematic due to 
the high degree of HIV subtype diversity in this population. Median age and CD4 count 
at diagnosis can also be employed as indirect markers of HIV incidence as both can be 
used to specify whether newly diagnosed infections are either predominantly recent or 
long-standing and to assess how this changes over time (HPA 2003).
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HIV prevalence (the number of people living with HIV at a certain time) is easier to 
calculate than HIV incidence (AIDS Knowledge Base 1999); however, they may not be 
as informative about the effects of prevention efforts and the future of the epidemic. 
Prevalence of HIV infection in the United States overall has been estimated by two 
different methods. The first method is to collect results from serosurveys in different 
populations and different geographic regions, merge them with estimates of the size of 
the populations at risk, and produce a total estimate that amalgamates all the data. This 
method has three main limitations: 1 ) the majority of serosurveys are not population- 
based and are difficult to generalise beyond the venue in which the HIV testing was 
completed; 2 ) coverage of geographic regions and specific sub-populations at risk is not 
complete; and 3) the sizes of the populations at risk are not known with any accuracy.
The second approach to estimating HIV prevalence uses back-calculation; it combines the 
available data on the numbers of reported AIDS cases and the IPD of AIDS in order to 
determine the number of HIV infections occurring in past years (CDC 1995). With 
information on past HIV infections and AIDS cases, plus the use of the IPD again, 
current HIV prevalence can be estimated. This approach needs adequately complete 
surveillance of AIDS cases and an accurate estimate of the IPD. It is limited by its 
inability to approximate HIV infections in recent years with any precision and, more 
significantly, the effect of antiretroviral therapy on the IPD has rendered back-calculation 
currently ineffective in estimating prevalence. Table 2.1 overleaf provides figures of UK 
HIV prevalence witnessed in the years 1999 (DH 2000); 2001 (DH 2001a); and 2002 
(HPA 2003). HPA (2003) describes how these figures were calculated, i.e. through 
combining the data from Unlinked Anonymous Surveys with estimates of the size of the 
population in various exposure categories derived from the National Survey of Sexual 
Attitudes and Lifestyles (NATSAL) and Census 2001 population estimates (National 
Statistics). The total population of England and Wales, aged 16-44, is divided into 
mutually exclusive behavioural categories relevant to HIV infection risk. The 
undiagnosed HIV prevalence for each group is multiplied by its population size to get the 
total number of undiagnosed HIV infections which is then added to the prevalent 
diagnosed HIV infections from each group, derived from SOPHID (Survey of Prevalent 
HIV Infections Diagnosed). These estimates are scaled up to include adults aged over 44
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Table 2.1 Estimates of prevalent HIV infections amongst adults in the United 
Kingdom at the end of 1999; 2001 and 2002, HPA (2003).
1999 20011 2002
Exposure
Category
Number
Diagnosed2
Number Un­
diagnosed3'4
Total Number
Diagnosed2
Number Un­
diagnosed3’4
Total Number
Diagnosed2
Number Un­
diagnosed3,4
Total
Homo/bisexual
men
12,900 4300(25%) 17200 15,300 4500(23%) 19800 17,100 5500 (24%) 22600
IDU
Males and 
females
1500 100(6%) 1600 1400 300(18%) 1700 1400 300(18%) 1700
Heterosexuals
Male 2800 3600(56%) 6400 4400 4500(51%) 8900 5800 4800 (45%) 10,600
African
Non-African
2700
1700
2400
2100
5100
3800
3800
2000
2500
2300
6300
4300
Female 4100 3300 (45%) 7400 6900 3700(35%) 10,600 9300 4600(33%) 13900
African
Non-African
4900
2000
2000
1700
6900
3700
6800
2500
2300
2300
9100
4800
Total 6900 6900(50%) 13800 11,300 8200 (42%) 19500 15100 9400 (38%) 24500
Blood Products5
Male and Female 600 0 (0%) 600 700 0 (0%) 700 700 0 (0%) 700
Grand Total 21,900 11,300
(34%)
33,200 28,700 13,000
(31%)
41,700 34,300 15,200
(31%)
49,500
1 2001 re-estimated using newly developed adjustments.
Numbers diagnosed were obtained from SOPHID and SCIEH, adjusted for under­
reporting and failure to access services.
3 Numbers undiagnosed derived for England, Wales and Scotland using data from Natsal 
2000 (32) and the Unlinked Anonymous programme in an extension of the method 
previously described (Petruckevitch et al. Genitourinary Medicine 1997; 73: 348-54).
4 Numbers undiagnosed for Northern Ireland derived by using exposure specific factors.
5 All cases infected through blood and blood products or tissue were assumed to be 
diagnosed.
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and elsewhere in the UK. Note that since undiagnosed HIV estimates are not available 
for each of the behavioural groups, prevalence estimates are derived through adjusting the 
Unlinked Anonymous estimates using behavioural survey data. In 2002, just under half 
(46%) of the HIV infections in adults were among homo/bisexual men (Table 2.1). 24% 
(5500) of these homo/bisexual men were unaware of their infection, accounting for 36% 
of the estimated 15,200 undiagnosed prevalent infections. Another important point to 
note from Table 2.1 is the estimated 24,500 adults who acquired their infection through 
heterosexual contact by 2002, of which 9,400 (38%) were unaware of their infection; the 
highest proportion of undiagnosed infection was in this category with 33% of female and 
45% of male heterosexuals unaware of their infection. Black-African men and women 
accounted for 63% (15,400) of the total prevalent infections in heterosexuals and 51% 
(4800) of the undiagnosed heterosexual infections. Over all exposure categories, at the 
end of 2002, an estimated 49,500 adults aged over 15 were living with HIV in the UK, 
15,200 (31%) of whom were unaware of their infection.
AIDS data
In comparison to HIV data, AIDS figures can be considered to be fairly reliable. The 
severe AIDS-defming conditions, such as PCP and KS which necessitate medical 
intervention, make it much more probable for diagnosis of AIDS to be documented. The 
changes in the European Centre for the Epidemiological Monitoring of AIDS (Ancelle- 
Park 1993) definition of AIDS, as discussed earlier in section 1.1.3, have fortunately not 
had a large impact on the AIDS data; in fact, the surveillance of cases with AIDS has 
remained important for trend assessment because of the relative constancy of the case- 
definition and completeness of the data. However, the expansion of the US definition of 
AIDS in 1993 (CDC 1992a) created an immediate artificial increase in AIDS incidence 
data which then decreased in 1994/1995 (AIDS Knowledge Base 1999). Such 
fluctuations due to changes in the AIDS definition complicate the interpretation of the 
AIDS data since the observed data are not consistent over time. Also, datasets based on 
separate definitions are only examinable in comparison to one another after serious 
alterations (Jager et a l 1993).
Cautious examination of AIDS incidence data can help to depict sub-epidemics, for 
example, by exposure group, geography, race or ethnicity (Cantoni et a l 1995 and CDC
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Figure 2.3 AIDS incidence in homo/bisexual men in the UK by year of diagnosis
1997b). Analysis of AIDS cases in transmission categories labelled ‘other’ and 
‘undetermined’ has been used to study rare or supposedly new modes of transmission 
(CDC 1994). Figure 2.3, above, shows the new AIDS cases in homo/bisexual men 
(excluding homo/bisexual IVDU’s) in the UK, by year of diagnosis (EuroHIV 2003). 
Anonymous, individual data on all cases reported in the UK (and the other 51 countries 
of the WHO European Region) since the beginning of the epidemic are reported to 
EuroHIV every 6 months, according to a standard data file specification. After 
validation, these data merge to form the European Non-Aggregate AIDS Data Set 
(ENAADS) which is the main dataset used throughout this thesis and which the data 
applied in Figure 2.3 was extracted from (as listed in Appendix 2.1). The analysis of 
AIDS case data shown in Figure 2.3 involves empirical problems, such as data quality 
(AIDS data, despite its improved reliability compared with HIV data, suffers from under­
reporting and reporting delay, as discussed below) and the unknown outcomes of human 
intervention (for instance, prevention and early treatment with antiretroviral drugs), and 
methodological problems, which may stem from inadequate knowledge about the
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progression of disease restricting the deduction of a more complete and accurate 
representation of the HIV epidemic from AIDS case data (Jager et al. 1993).
2.3.2 Under-reporting and Reporting Delay
As mentioned above, some of the main difficulties with AIDS cases data analysis relate 
to the quality of the AIDS data, i.e. incompleteness of reported data due to reporting 
delay and under-reporting, which both result in an underestimation of the size of the 
epidemic (Jager et a l 1993). Under-reporting is a result of AIDS cases never being 
reported to the PHLS at the CDSC. McAnulty et al. (1992) suggests that the reasons for 
non-reporting of AIDS cases include the difficulty of the reporting procedure, the 
complicated AIDS definition and the concern about maintaining patient confidentiality. 
Jager et al. (1993) go further and imply that under-reporting may be caused by 
“inadequate routine public health reporting systems; the wilful reduction of observed 
numbers; inadequate and/or inaccessible health services that fail to detect people with 
AIDS; lack of standardised procedures (between regions) for the clinical diagnosis of 
AIDS; and the use of unspecific case definitions”. The level of under-reporting is 
country specific and adjustments in Europe range from 0% to 25% (EuroHIV 2003). For 
the UK, the Day Report (1993, 1996) assumes an under-reporting rate of 13%, which 
coincides with estimates produced by Evans & McCormick (1994) who state that 12-14% 
of AIDS cases are not reported. Chin (1991) proposed that the estimated cumulative 
numbers of AIDS cases in Africa up to 1991 was 970,000 cases, whereas only 129,066 
cases had been reported, suggesting that AIDS case reporting in developing countries is 
extremely unreliable and are, consequently, of restricted worth in terms of health 
planning. Under-reporting may have an effect on the reported incidence of AIDS over 
the entire epidemic and the real magnitude of the HIV epidemic might also be 
underestimated since infected people could die before acquiring AIDS (Jager et al. 1993). 
It is widely recognised that a reporting delay exists between the time a physician 
diagnoses a new case of AIDS and reports the fact to the AIDS surveillance centre for the 
country concerned. This reporting delay results in difficulties for the analysis of AIDS 
case data, as suggested above. Over 90% of reports of first UK diagnoses of HIV/AIDS 
for a given year are received at PHLS-CDSC by the end of June in the following year.
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The remaining diagnoses may not be reported for several years (CDSC 2002). Modellers 
invariably work with the data for reported cases of AIDS due to the reliability of the date 
of report, and the fact that sometimes reported cases are not filed with an associated date 
of diagnosis. An adjustment is required, of course, either by amending the reported data 
prior to using them for fitting (this is the method used throughout this thesis) or by 
specifically modelling the reporting delay endogenously (Dangerfield & Roberts 1994). 
Downs et a l (1988), Rosenberg (1990), Harris (1987), Heisterkamp et a l (1989) and 
Brookmeyer & Liao (1990a) have developed techniques for directly estimating AIDS 
incidence adjusted for delay. Whereas, Cox & Medley (1989) produced expected future 
AIDS incidence by approximating the delay distribution, and combining this with a 
relevant curve fit for estimations.
2.4 Parameters within the Cardiff HIV/AIDS Epidemic Model
2.4.1 The Entry Rate
As previously defined, the entry rate term, A, is calculated in its simplest form using the 
expression A = AN 1 9 7 3. We assume that A = pi, implying that arrival into the model 
equals the exit from the model in absence of the HIV/AIDS epidemic i.e. if the 
HIV/AIDS epidemic was non-existent, then the size of the Susceptible population would 
be expected to remain relatively stable, with no cause for significant increases or 
decreases. The term N 1 9 7 3, the size of the high risk homosexual population at the start of 
the epidemic (at time t = 0 ), is a constant which involves some difficulty in estimating. 
The use of N 1978 is further detailed in work by Anderson (1982) and Bailey (1991, 1992°, 
1993, 1994a, 1994b, 1997), who also use the form AN1978 for the entry rate. Another 
expression for the entry rate could be A = A[X(t)+Y(t)+A(t)], where X(t)+Y(t)+A(t) 
represents the number of homosexuals taking part in high risk activities at time t. The 
assumption here is that entry into the High Risk Susceptibles equals deaths in High Risk 
categories from causes other than AIDS, given that A = pi = P2 = P3 - This form of the 
arrival rate is time-dependent and will decrease as the population decreases, i.e. in the 
latter stages of the epidemic. Snary (2000) goes into more detail comparing these two
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different versions of an entry rate and concludes that the form A = AN 197s is the more 
realistic option. Later on in this thesis, further discussion of this parameter will take 
place, including the estimation of X, N 1978 and/or A.
2.4.2 The rate of transition from High Risk to Low Risk
An attribute of this HIV/AIDS epidemic model, not evident in all other infectious disease 
models, is the capability of Susceptibles, Infectives and AIDS cases to move between two 
levels of at-risk behaviour (Griffiths & Williams 1994). Furthermore, within this model 
it is only possible to transfer from High Risk to Low Risk behaviour except on diagnosis 
with AIDS, that is, it is not expected for an individual to revisit their previous risky 
behaviour once they have relocated into the low risk category. One such circumstance, 
where an individual may move from a High Risk category to a Low Risk category, could 
be as a result of media campaigns encouraging homosexuals to change their lifestyles 
from participating in High Risk sexual activities to Low Risk (Griffiths & Williams
1994). The parameters for each of the sub-populations (Susceptibles, Infectives and 
AIDS cases) relating to the transition from High Risk to Low Risk, as shown in Figure
2.2 in section 2.2.2, are Vi, V2 and V3 respectively. The assumption that homosexuals will 
not go back to their prior High Risk behaviour, except on diagnosis with AIDS, eases the 
complexity of the model and restricts the number of parameters to be estimated, which is 
beneficial. Snary (2000) remarks that there is some suggestion that homosexual men can 
relapse to their previous unsafe behaviour, as illustrated by the trends in other sexual 
diseases; in particular, rectal gonorrhoea reports saw a rise in the years 1990 and 1991 
(Riley 1991; Waugh 1991; CDR 1998). An alteration in attitudes, and consequently 
behaviour, of this kind could be caused by a number of factors, including: complacency; 
lack of concern due to the introduction of new treatments (Kelly et al. 1998 and Van de 
Yen et al. 1999) and a drop in media coverage.
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2.4.3 The proportions of individuals who become or stay High Risk
Parameters a, b and g, see Figure 2.2, will be discussed here. To begin with, the 
parameter a is of significance because of the effect it has on the number of newly HIV 
infected homosexuals who continue to partake in high risk sexual activities, as opposed to 
changing their behaviour to low risk. Thus, this parameter directly influences the number 
of infectives in both the High Risk and Low Risk sub-populations. As a consequence of 
this, the parameter also has an impact on HIV incidence, due to the incidence rate, a, as 
seen in equation (2.6) below. Furthermore, due to the affect that a has on the other 
categories in the model, all of the sub-populations will be determined, by some extent, by 
the value of parameter a. It can be argued that since most individuals are not aware of 
their precise date of HIV infection, they will continue to practice high risk sexual 
activities, even after they have contracted HIV. Additionally, even if aware of their new 
infection status, homosexuals may choose to continue practicing high risk behaviour. 
Thus, it is expected that a will take a high value; Snary (2000) employs a value of a = 0.9. 
The parameter that represents the proportion of High Risk Infectives, b, who continue to 
participate in high risk sexual activities on being diagnosed as having contracted AIDS, 
and the parameter that reflects the proportion of Low Risk Infectives, g, who on diagnosis 
with AIDS decide to commence participating in high risk sexual activities, are considered 
next. Any alteration in the value of the parameters b and/or g would mostly affect the 
two sub-populations A(t) and Z(t); that is, High Risk AIDS cases and Low Risk AIDS 
cases respectively. To see the effect that these parameters have on the populations, refer 
to Snary (2000) who experiments with setting b = g = 0. This means that all existing 
AIDS cases are Low Risk, i.e. all in the category Z(t), since no infected homosexuals 
progressing to AIDS, continued or began participating in high risk sexual activities.
More likely than both b and g being equal to zero, are the values b = 0.5 and g = 0.1, 
which were suggested by Wheeler (1990); England (1997) and Lowrie (2000). This 
implies that half of those infected, practising high risk behaviour, will continue to do so 
once diagnosed with having full blown AIDS, and that 10% of Low Risk Infectives will 
change their lifestyles and commence high risk behaviour, once AIDS is diagnosed.
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2.4.4 The Incidence Rate
Let us consider the parameter denoted by a, which represents the rate at which 
homosexual men become infected in a time interval 5t. In this model, it is assumed that 
a, denoting the rate at which High Risk Susceptibles move to the infected, takes the form:
a  = pc [Y(t)+A(t)]/[X(t)+Y(t)+A(t)] ... (2.6)
As is apparent from equation (2.6), a  is strongly dependant on the term pc, the infectivity 
rate where p is the transmission rate per sexual contact and c is the mean number of 
sexual contacts per unit time. The infectivity rate is discussed in detail in the next section 
of this chapter, section 2.4.5. The latter term within this expression for a,
[Y(t)+A(t)]/[X(t)+Y(t)+A(t)], represents the probability that a particular partner chosen at 
random is in fact infected with HIV or AIDS (Griffiths & Williams 1994).
2.4.5 The Infectivity Rate
The infectivity rate is a product of the rate at which a Susceptible contracts the virus from 
an infected partner during each sexual contact, p, and the average number of sexual 
contacts, or acts, per unit time, c. Anderson (1988) contended that Pc is approximately 
equal to 1, which was initially the value used in the majority of models depicting the 
epidemic. This suggested value for pc stems from derived estimates of p = 0.1 and c =
10. However, many authors, including Winklestein et a l (1988), distinguished a 
noticeable variation in behaviour from about 1985 onwards, possibly due to the increase 
in advertising campaigns creating a larger amount of public awareness of the HIV/AIDS 
virus (Garfield 1994). Consequently, Pc was assumed to diminish to a value of 
approximately 0.4 in the model dating from 1985 (Griffiths & Williams 1994). Snary 
(2000) shows the significant impact the value of the infectivity rate has on the size of the 
HIV/AIDS epidemic by implementing different values of pc into a model with all other 
parameters remaining equal. Within this work by Snary, Pc is assumed constant, but due 
to the possible changes in behaviour, as discussed above, this is not a realistic 
assumption. In order to assess and quantify these changes in behaviour, the number of 
reported cases of rectal gonorrhoea in homosexuals can be used as a good indicator of
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unprotected sexual activity. Reports to the Communicable Disease Surveillance Centre 
(CDSC) declined between 1985 and 1989, as expected, however, they then increased in 
1990 and 1991. Evans et a l (1993) collated information on rectal gonorrhoea; hepatitis 
B; newly diagnosed HIV; seroconversions in men who have sex with men; and new 
episodes of gonorrhoea and syphilis, in a study they performed confirming that all of 
these indicators reveal a consistent trend of worsening sexual behaviour from 1990 
onwards, with increasing numbers of individuals participating in risky sexual activities. 
The improved sexual behaviour and attitudes during the mid and late 1980’s meant that 
the AIDS epidemic did not reach the feared extremes that were originally predicted; 
however, the relaxation in homosexual routines will cause the course of the epidemic to 
change once more; any deterioration back to the pre-1985 value of Pc would result in 
another breakout of the epidemic (Griffiths &Williams 1994), this time perhaps reaching 
the levels that were so feared before.
2.4.6 The Incubation Rate
The AIDS incubation period is classified by Dangerfield (1999) as the delay in time 
between an individual being infected with HIV and the ensuing diagnosis with AIDS. 
Thus, the incubation rate is defined as the rate at which HIV Infectives transfer to AIDS 
cases. Consequently, the incubation time is a vital constituent of any HIV/AIDS 
epidemic model and is, unfortunately, particularly hard to estimate due to the fact that 
most infectives are unaware of their exact time of HIV infection. In 1999, Dangerfield 
assumed the incubation period (IP) to be approximately ten years, with this average 
duration increasing due to treatment being widely accessible to those who are HIV- 
positive. Since 1987, studies have shown that treatments have lengthened the incubation 
period by a significant amount as expected due to their aim of prolonging life (Gail et al. 
1990 and Keet et al. 1996). From the time when cocktail therapies became widely 
available in 1996, the IP has increased even further; in fact, the increasing length of 
survival time is ongoing due to the changing population to one starting antiretroviral 
therapy earlier in the progression of HIV, with more treatment-naive patients initiating 
combination therapy. Also, the IP is expected to gradually lengthen over time, due to 
increased knowledge, experience and understanding of when to start treatments, when to
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‘switch’ treatments (due to lack of virological response or adverse events) and what to 
switch treatments to, i.e. an unique and different combination of anti-HIV drugs which 
would be most effective for specific individuals dependant upon such factors as treatment 
history. The length of the incubation period is discussed in greater detail later on in this 
thesis, as it poses some of the most important issues within our model.
It is possible for reliable estimates of the incubation period to be obtained; Beral et al. 
(1998) and Porter et al. (1999) are two studies amongst many that use dates of 
seroconversion to estimate the incubation period instead of the exact date of infection 
whilst Longini et al. (1989a) estimated the incubation period using a transfusion cohort. 
Cohorts of haemophiliacs or transfusion recipients are often used to estimate the 
incubation period as they can offer dependable information on the date of infection with 
HIV. Also, individuals with both negative and positive HIV tests can also be of use since 
one can assume the date of infection is the mid-point between these two tests 
(Brookmeyer & Gail 1994).
Assuming that the incubation period has a negative exponential distribution, the mean 
incubation rate, y, is modelled by simply taking the reciprocal of the mean incubation 
period. The assumption here is that the value y is independent of whether an infected 
individual is in either the high or low risk categories. Previously, some researchers have 
suggested that the Weibull distribution is suitable for modelling the incubation period, 
maybe due to the fact that this distribution is widely used in other survival studies. Over 
the years, however, Gamma distributions have become more renowned for their aptness, 
given that the hazard of AIDS is now known to rise but then plateau after eight years 
following seroconversion. One reliable estimate was given by Hendriks et al. in 1993 
who assumed a gamma incubation period distribution (IPD); using data from a cohort of 
homosexual men they proposed a treatment-free IP of 10.2 years. It is not feasible to 
depict either a Weibull or a Gamma distribution in integro-differential equation format. 
However, it is possible to render an Erlang distribution into integro-differential equation 
format, which is fortunately an appropriate distribution for the incubation period as it is 
simply a gamma distribution with an integer shape coefficient and presents a hazard 
function which increases at a slowing rate (Dangerfield 1999).
Heisterkamp et al. (1992) discuss the idea of introducing two different time scales into an
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HIV/AIDS model; they are calendar time and time since infection for each individual. 
This development within a model would lead to several integral-differential equations 
(Blythe & Anderson 1989b) which would be complicated to analyse. Nevertheless, by 
implementing the distributed modelling approach, as shown by Blythe & Anderson 
(1989a, 1989b) and Bailey (1964), they are easily accommodated. The population 
segregates into its customary classes (Susceptibles, Infectives and AIDS cases), where 
each category in turn is split into a series of sub-divisions with incubation duration 
defined by a negative exponential distribution. Then, since a sum of identical negative 
exponential distributions is equivalently a gamma distribution (or after a suitable 
reparameterization, a ^-distribution as used by Bailey in 1964), a good estimate to the 
incubation distribution is achieved, as discussed above. In fact, Blythe and Anderson 
(1989b) demonstrate the use of a weighted sum of negative exponential distributions to 
account for the distribution of the incubation period. Longini et al. (1989a, 19895) 
propose a Markov stage model for CDC classes and give estimators for the duration of 
each stage (Heisterkamp et al. 1992). This approach will be incorporated throughout this 
thesis and is discussed in greater detail within the next section of this chapter.
2.4.7 The Death Rate
The mean death rate (that is, the rate at which AIDS cases die from AIDS), i.e. the 
reciprocal of the mean AIDS survival time, is another crucial parameter within the 
HIV/AIDS epidemic model. The official definition of the AIDS survival time is the 
length of time from the diagnosis of AIDS to AIDS-related death. It permits the 
calculation of AIDS prevalence, that is, the number of people living with AIDS at a 
particular point in time. As expected, due to the introduction of recent treatments and 
therapies for numerous AIDS defining conditions, the value of the death rate has 
decreased (CDC 1997°, 1999aand Fischl et al. 1987). It is expressed by co = l/(mean 
AIDS survival time) and, unlike for the IP described above, due to the reliability of data 
on the time of AIDS diagnosis and AIDS death, both AIDS survival time and the death 
rate, are reasonably uncomplicated to approximate.
In the past the AIDS survival time was predicted at being no longer than a year due to the 
severity of the damage on the immune system caused by HIV. In fact, the AIDS
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Table 2,2 Median UK AIDS Survival time (years) for year of diagnosis.
CALENDAR
YEAR
ENAADS BECK E T  
AL, 1994
HILLMAN ET  
AL, 1997
ROGERS E T  
AL, 1997
1982 1.01 1.22 0.887
1983 0.867 1.22 0.887
1984 0.982 1.22 0.783 0.887
1985 1.19 1.22 0.783 0.887
1986 0.968 1.22 0.783 0.887
1987 1.41 1.75 2.27 1.53
1988 1.63 1.75 2.27 1.63
1989 1.78 1.75 2.27 1.69
1990 1.90 2.27 1.62
1991 1.90 2.27 1.62
1992 1.93 2.27
1993 1.75 2.27
1994 2.16
Knowledge base (1999) estimated the mean survival time to be between 10 and 13 
months prior to 1986. Many studies note the increase in survival time from 1987 
onwards, including those by Beck et al. (1994b); Hillman et a l (1997) and Rogers et a l 
(1997), as shown in Table 2.2 above. Straight comparisons are not applicable between 
these datasets represented in Table 2.2 since methods of survival analysis, data, risk 
groups and AIDS defining criteria may differ. However, all datasets agree that from 
1987 onwards the AIDS survival has increased.
It is worth noting at this point that although the death rate has a significant effect on the 
model with respect to the numbers whom die from AIDS and, consequently, the AIDS 
prevalence, a change in value of the death rate, to, will not alter the rest of the model 
predictions by a largely significant amount, i.e. AIDS incidence, HIV incidence and HIV
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prevalence. Snary (2000) shows how different values for the death rate affect the AIDS 
prevalence numbers in her thesis; not surprisingly, Snary illustrates that ‘the longer the 
AIDS survival time (or the smaller the death rate) the higher the peak for the AIDS 
prevalence’.
2.5 The Introduction of a Staged Incubation Period Distribution
2.5.1 The introduction of Stages
Since the start of the epidemic, the natural history of HIV infection has been viewed as a 
staged process (Longini et al. 1996). This section discusses dividing both the High and 
Low Risk Infective sub-populations, Y(t) and V(t), into m stages, thus modelling an 
Erlang type distribution as the incubation period distribution (IPD), as seen in Figure 2.4, 
overleaf.
The Cardiff HIV/AIDS epidemic model in Figure 2.4 illustrates the incorporation of m 
stages within the infective categories. This proposal of sub-dividing one of the 
populations within the model into a number of stages results from the theory of Erlang 
queues (Snary 2000). The Erlang distribution (Em) has overall mean rate y and is 
mathematically equivalent to m negative exponential phases, each of mean rate my. The 
probability density function (p.d.f.) of the Erlang distribution is expressed as follows:
= m r i m y t y - ' e ’”' 
( k - 1)!
For notation, let the transition rate per unit time from stage i to stage i+1 be y*, where i = 
1, ..., m and stage m+1 relates to AIDS. This notation is applied due to the assumption 
that there is only ‘ 1-step’ forward movements between stages. Also, we denote Yj(t) and 
Vj(t) (with i= l , ..., m) to be the number of HIV Infectives in stage i of the High Risk and 
Low Risk sub-categories respectively.
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Figure 2.4 The Cardiff Model with m stages in the Infective sub-populations.
The same assumptions as previously employed to the basic (one stage) Cardiff 
HIV/AIDS model are applied here. Further assumptions for this staged model include the 
concepts that a homosexual will enter the HIV Infective category via stage 1, of either 
High or Low Risk infection, and must be in the final stage of HIV infection before AIDS 
can be contracted. In Section 2.5.2, IPD’s which permit a progression to AIDS from 
other stages of HIV infection, as well as the end stage, will be discussed.
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The introduction of stages into the Cardiff Model has therefore affected some of the 
associated differential-difference equations. Specifically, equations relating to the HIV 
Infective sub-populations, Y(t) and V(t), and the AIDS case sub-populations, A(t) and 
Z(t), have undergone alterations; the modified versions of which are as shown in 
equations (2.7a)-(2.7d) below. Additionally, the expression for AIDS Incidence is also 
slightly different due to the introduction of stages, as can be seen in equation (2.7e). One 
of the many benefits of having individual equations, belonging to each sub-category of 
the HIV Infective populations, is that by solving equations (2.7a)-(2.7d) the HIV 
prevalence for each stage of HIV progression can be obtained. Sabin et al. (1994) state 
that this knowledge of numbers within each stage of HIV infection can be implemented, 
and deemed valuable, in areas such as health care planning. For instance, information on 
how many HIV Infectives there are in the later stages of HIV disease will provide good 
estimates for future AIDS incidence which can then be used in budgeting potential health 
care and treatment costs.
w here
1=1
y, ( ' + <*) = Yt (/) + [aaX(t) -  O', )Yt (f)]«
irl«+*)=r,(0+IrM^ -i(0- 0', +ih+vjY,vfrt i = 2, ...,m
(2.7a)
where
i=1
V\ (< +  <*) =  V, (t) + [(1 -  a)aX(t) + v2Y, (/) -  (r , + )Vt«)]«
vl(t+a) = vi(t)+\r ,^ ( t ) + v 1Y,(t)-(r, + a )»;«)]« «= 2,.. . ,*
(2.76)
A(t + <») = A(t) + [bymYm (t) + g ymVm (t) -  (v, + /j,+  6))A(t)]ft ■ ■ ■ (2.7 c)
Z(t + St) = Z(t) + [(1 - b ) y j m(t) + (1 -  g)ym VM (t) + v3 A (t)-  ( ^  + «)Z (/)]a - (2 .1  d)
AIDS Incidence = ym
1=1 i= i
•(2.7c)
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As for HIV infectives, individuals within the AIDS case population can also be sub­
divided into stages of AIDS progression indicating a deterioration of health. However, 
once an individual has been diagnosed as having contracted full-blown AIDS, it is 
expected that survival time is relatively short at approximately only 1 or 2 years. For this 
reason, AIDS stages have not been incorporated in the Cardiff model. In concordance 
with Snary (2000), the research within this thesis is mostly concerned with the effect that 
new treatments have imposed on the HIV incubation period and on the AIDS survival 
time, taken as a whole.
2.5.2 Staged Incubation Period Distributions
In order to create the stages within HIV progression, markers such as CD4 T+ cell count, 
viral load and the amount of health care that an individual is receiving, offer themselves 
as natural tools of definition. The most commonly used marker for an incubation period 
distribution is CD4 T+ cell count; this has been used by Longini et a l (1991, 1993,
1996), Hendriks et a l (1996), Satten & Longini (1996) and Snary (2000).
The initiative of a staged model has not only been effectively put into operation within 
the HIV/AIDS epidemic but also other diseases such as cancer (Longini et a l 1989a).
The Walter Reed staging system was developed in 1986 (Redfield et a l 1986), and 
various staging systems have been in practice ever since. An accepted mathematical tool 
for modelling a process, such as HIV, is a staged Markov model, which has been 
exercised in the following fundamental topics, quoted below, of HIV/AIDS research 
(Longini et a l 1996):
‘1. To describe the natural history of HIV infection (Longini et a l 1989a, 1989b, 
Longini 1990, Longini et a l 1991);
2. To evaluate the effect of covariates on stage-specific progression rates, such as 
therapy (Longini et a l 1993);
3. To predict the stage-specific course of the HIV epidemic in selected populations 
(Longini et a l 1992) and in the USA as a whole (CDC 1992b, Brookmeyer 1991);
4. To estimate HIV incidence from infection surveys (Satten & Longini 1994);
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5. To provide estimates for HIV transmission models used to estimate transmission 
probabilities (Longini et al. 1989b) and to investigate the dynamics of the HIV 
epidemic (Hethcote et al. 1991, Jacquez et al. 1988, Koopman et al. 1991).’
Hendriks (1999) states that a staged Markov model consists of the three main aspects 
listed below:
■ A set of stages,
■ Waiting time distributions within each stage,
■ Probability distributions of transferring stage once the waiting time is over.
Hendriks et al. (1996) and Hendriks (1999) affirm that an advantage associated with the 
use of Markov models is their full use of data. Arguments exist against the use of a 
Markov chain for the purpose of modelling the HIV IP, including the suggestion that 
under a Markov model, incorporating CD4+ T cell count, the time until death (or AIDS) 
is conditionally independent of time since infection (Brookmeyer & Gail 1994). Further 
discussions on the benefits and limitations of Markov models can be found in the 
following publications: Brookmeyer & Gail (1994); Hendriks et al. (1996); and Satten & 
Longini (1996).
The application of a staged IP, particularly when stages are defined by CD4+ T cell 
count, makes it possible for the model to include antiretroviral treatment and prophylaxis 
against opportunistic infections. In fact, the use of a Markov model, despite the 
aforementioned disadvantages, allows the absorption of advised disease staging.
The following subsections within this chapter briefly review some of the staged Markov 
models developed as HIV incubation distributions as proposed by a number of 
researchers, including Longini et al., Hendriks et al. and Satten & Longini. The work 
undertaken in this thesis incorporates the use of a deterministic model, thus such 
distributions for the incubation period are not applicable. However, the possible 
movements of transfer between the stages of HIV can be applied to both stochastic and 
deterministic models and are, consequently, of interest when investigating the incubation 
period in greater detail.
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Longini et al.
A regular occurrence in Longini’s incubation period distributions is the concept of ‘ 1- 
step’ forward movements only. For every individual within the model, the length of time 
in each stage, contained by the Markov chain, is produced by means of the rate associated 
with that specific stage (obtained via maximum likelihood techniques). Thus, the 
probability density function (p.d.f.), or probability distribution, can be established; the 
mean incubation period, the variance and the mean rate (y) can also be determined. 
Longini has considered both a 3- and a 6 -stage model. The 3-stage IP, as illustrated in 
Figure 2.5, below, was developed by Longini et al. (1989a, 1989b) and was one of the 
first staged Markov models.
1 2 3
Infected but 
antibody 
negative
Infected 
antibody 
positive but 
asymptomatic
Infected 
antibody 
positive but 
symptomatic
AIDS Death
Figure 2.5 Representation of Longini’s 3-stage incubation period distribution.
The three different states, numbered in Figure 2.5, comprise stages indicative of the 
progression of HIV infection; the two other stages included within this flow diagram 
signify the diagnosis of AIDS and where death has resulted due to AIDS.
Snary (2000) provides comparisons between this Longini distribution, the Erlang 
distribution and 3 Exponential distributions in series; the Longini 3-stage distribution is 
then incorporated into the Cardiff HIV/AIDS model to demonstrate the use and results 
when utilizing such an IPD. The same comparisons and analysis are performed by Snary 
when investigating the Longini 6 -stage Incubation Period Distributions (Longini et al. 
1993, 1996) as illustrated in Figure 2.6 overleaf.
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Figure 2.6 Representation of Longini’s 6-stage IPD, stages defined by CD4 Count
These use the idea that HIV can be expressed as a chain of advancing, monotonic states, 
reflected in a mean decline of CD4 cells over time. As with the 3-stage distribution, a 
Markov model is fitted to the data using maximum likelihood techniques which operate 
using the formulation of the likelihood function, with respect to an individual's 
progression through HIV. There are 3 different adaptations of this 6 -stage model; each 
having identical monthly transition rates belonging to the first three stages of HIV 
infection. The first version estimates the transition rates without provisions for therapy or 
calendar time. The other two approaches both estimate the parameters with stratification 
for calendar time, thus controlling the effect of time-related biases, with one allowing for 
therapy and the other not.
Hendriks etaL
A 6 -stage Markov model, using CD4 count as the marker to define the stages in HIV, is 
employed by Hendriks et a l (19%) and Hendriks (1999), in the same way as Longini, as 
discussed in the previous section. The observed CD4 count data is smoothed before 
maximum likelihood procedures are put into operation to compute estimates of the 
transition rates (y) linking stages. Dissimilar to Longini’s ‘ l-step’ forward motion only, 
Hendriks incorporates a more complicated invertible continuous-time Markov model, as 
displayed in Figure 2.7.
701-900 1 [*501-700 I fTsi-SOO | 1*201-350 | j 0 - 2 0 0 1 |  AIDS |
Figure Z  7 Representation of Hendrik's IPD, stages defined by CD4 count (cells/pl).
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One of the assumptions for this model is that an individual can transfer to and from stages 
adjacent to the stage the individual belongs to, i.e. it is possible to move both forwards 
and backwards in 1-step movements. Longini assumed the necessity of an HIV infective 
existing in the last stage of HIV infection before the possibility of contracting full-blown 
AIDS, however, as apparent from Figure 2.7, the idea within the Hendriks IPD is that an 
individual can progress to AIDS from any of the stages 4, 5 or 6 , with associated rates of 
7 4 ,7 , 7 5 ,7  and 7 6 ,7 , respectively. The final feature to note, with Hendriks’ IPD, is the 
inclusion of a treatment effect, as with the third Longini 6 -stage IPD. Snary (2000) gives 
a much more in-depth review of this distribution for the incubation period and introduces 
it to the Cardiff HIV/AIDS epidemic model -  resulting in the differential-difference 
equations being altered to allow for the possible progression to AIDS from stages other 
than stage 6  and the backward 1 -step transitions.
Satten & Longini
These distributions, as illustrated in Figures 2.8(a) and 2.8(b) overleaf, like those 
produced by Longini and Hendriks, consist of 6  CD4 cell count marker-defined stages. 
However, one distinct variation, between the Satten & Longini distribution and those 
created by Longini and Hendriks, is the employment of the statistical procedure of errors- 
in-variables so as to overcome noisy data and calculate estimates of monthly stage 
transition rates (Longini and Hendriks conquered this problem by primarily smoothing 
the data). There are two variations of the Satten & Longini IPD; one is unidirectional 
(Figure 2.8(a)), whilst the other is bidirectional (Figure 2.8(b)).
The Unidirectional model, as shown in Figure 2.8(a), is composed of forward movements 
only, progressing one stage at a time through HIV progression. The second model shown 
here, in Figure 2.8(b), is Satten & Longini’s Bidirectional model, which permits a 
homosexual to transfer to an adjacent stage in either direction, forwards or backwards. In 
both models it has been assumed possible to progress to AIDS from any stage with a CD4 
count of less than 700 cells/pi, i.e. from any of stages 3,4, 5 or 6 . A treatment effect was 
considered in both of these models, and it was found that only the transition rate 7 6 ,7 , that 
is, the rate of transition between stage 6  and AIDS, was significantly influenced by anti- 
HIV treatment. Snary (2000) applied both of these distributions to the Cardiff HIV/AIDS 
model, making the appropriate modifications in the differential-difference equations,
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Figure 2.8(a) Representation of the Unidirectional Satten &Longini IPD.
5,4
AIDS |
Figure 2.8(b) Representation of the Bidirectional Satten & Longini IPD.
noting that the Unidirectional IP is merely a sub-model of the Bidirectional IP, with all 
backward transition rates set equal to zero. It may also be worth noting at this point that 
Satten & Longini found the Bidirectional model to create a significantly better fit.
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A.2.1 Table of Observed AIDS incidence, HIV incidence and deaths
from AIDS data
YEAR AIDS INCIDENCE 
ENAADS
HIV INCIDENCE 
ENAADS
DEATHS FROM AIDS 
CDSC
1979 1
1980 0
1981 4
1982 11
1983 24
1984 99
1985 201 108
1986 396 237
1987 551 317
1988 719 355
1989 795 562
1990 897 654
1991 966 781
1992 1081 874
1993 1151 1056
1994 1190 1159
1995 1071 1443 1095
1996 808 1693 890
1997 559 1551 390
1998 349 1506 239
1999 311 1362 224
2000 308 1464 215
2001 207 1534 186
2002 213 1966 139
2003 179 1967 155
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CHAPTER 3 
5-PARAMETER MAXIMUM LIKELIHOOD 
TECHNIQUES WITHIN THE CARDIFF 
MODEL
3.1 Introduction
As previously discussed, numerous parameters within the Cardiff HIV/AIDS Epidemic 
model are problematical with reference to obtaining reliable values for them. Of 
particular interest is the infectivity parameter, pc, which denotes the degree of high-risk 
sexual behaviour that results in the contraction of HIV. As a ‘sociological’ parameter, pc 
is dependent on public awareness of HIV infection within the homosexual population and 
is thus difficult to quantify.
Other parameters of significance within the model that have proven a challenge to 
estimate include the entry rate into the model, A; the initial number of HIV infectives at 
the start of the epidemic, a 1 9 7 3 ; and the lengthening proportion, r, placed on the 
incubation period compared with its duration at the non-treatment stage. In addition, the 
death rate, go, despite being measurable through recorded yearly AIDS diagnoses and 
deaths from AIDS, needs some consideration due to the fact that its value varies over 
time with the advancement of treatments.
The entry rate, A, in its simplest form, is taken as the product of the arrival rate, A, and 
the number of High Risk homosexuals in the population at the start of the epidemic,
Ni9 7 8) that is, A = AN j 9 7 3 . The interpretation of the entry rate in this form, however, may 
be deemed too simplistic and consequently unrealistic. Griffiths et al. (1990) question 
the application of this entry rate within the model, due to the idea that enrolment to the 
High Risk Susceptible sub-population, X(t), varies over time as a direct result of publicity 
and changing attitudes towards the virus. One alternative form of the entry rate is 
A = A[X(t)+Y(t)+A(t)]. This generates a lower peak of the AIDS epidemic than
82
A = AN 1978 produces since the term X(t)+Y(t)+A(t) depicts the total number of 
individuals within any of the high risk sub-populations at time t. This expression for the 
entry rate is time-dependant and will decrease as the population decreases accordingly, 
specifically towards the latter stages of the epidemic. To incorporate the idea of various 
perceived entry rates into the model, two different methodologies, and consequently two 
different sets of parameters, have been considered and implemented throughout this 
work. Firstly, A and N 1978 are estimated separately and their product taken to be the total 
entry rate into the epidemic, A. Secondly, the overall entry rate, A, is modelled as an 
independent single parameter, taking on whichever form it may be concluded to hold. In 
conjunction with this, A is assumed equal to pi (due to the concept that the constant rate 
of arriving into the Susceptible category is equal to the constant rate of exiting from the 
Susceptible category, as a result of natural death or emigration from the model if the 
AIDS epidemic was not existent), for which the value is derived from population 
statistics, and N 1978 is assumed a fixed value of 10,000. This will probably mean that 
A £  AN1 9 7 8 , unless due to unlikely coincidence.
The parameter ai9 7 8 , which refers to the number of HIV positive homosexuals (including 
AIDS cases) within the UK at the end of 1978, is also subject to interpretation and is 
consequently problematic in specification. This parameter will be examined in detail 
within this chapter owing to the fact that the total number of HIV positive homosexuals at 
the start of the epidemic necessitates distribution over all 6  of the HIV stages, as well as 
the AIDS stage.
The death rate, co, can be calculated annually from data given that, by definition,
(0 = 1 / mean AIDS survival time, with both the date of diagnosis for AIDS and the 
endpoint of AIDS (death) documented and deemed reliable records. However, due to the 
continual improvements in treatments, the mean AIDS survival time changes year upon 
year, thus the death rate varies in accordance with the development of new treatments and 
therapies. Hence, it is considered here as a parameter for estimation, with data on deaths 
from AIDS being used to verify, or justify, the results drawn. Later work, in Chapter 4, 
investigates this parameter in greater detail, including it within the model as a variable 
parameter, estimated not by the MLE technique but within a separate analysis providing a 
comparison between its estimated value, as produced by the model, and its computed
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value, obtained from available AIDS data.
The final parameter to be considered within this chapter is the parameter r, which is 
defined as the proportional increase in the length of the HIV incubation period (defined 
as the time between initial infection with HIV and the eventual onset of AIDS) due to the 
introduction of antiretroviral treatments prolonging life and postponing the progression to 
AIDS or any AIDS defining illness. Within the Cardiff model, assuming a constant 
staged incubation period (where Yi = 7 2  = • • • = Ym), we have:
where yi are the transition rates between stages assumed equal in value;
m is the total number of stages;
IP is the incubation period prior to treatments;
r is the proportion the IP is lengthened due to the introduction of treatments.
Note that when r = 1, the transition rates are calculated as they were previously, without 
considering the treatment effect on the IP. Also, note that estimating the parameter r is 
equivalent to estimating the duration of each of the 6  stages within the lengthened 
incubation period assuming they are all equal ( 1 /yi = I / 7 2  = ... = I/7 6 ), or estimating the 
transition rates between stages, as formulated above assuming equality ( 7 1  = 7 2  = ... = 7 6 ) 
This chapter considers maximum likelihood techniques in order to estimate the 
parameters discussed above. Numerous researchers, including Bailey (1991, 1992c) and 
Griffiths & Williams (1995), have implemented this method of maximum likelihood to 
estimate parameters within an epidemic model, such as the Cardiff HIV/AIDS Epidemic 
model. It is important to note that the practice of maximum likelihood is independent of 
the model. One limitation of the Maximum Likelihood Estimate (MLE) technique is the 
assumption that parameters remain static. For many of the parameters within the model 
this is not the case, predominantly since the introduction of treatments. Moreover,
i = 1
or i = 1 ,..., m
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parameters and distributions are unlikely to be constant due to media campaigns, public 
awareness and attitudes affecting behavioural patterns over time (Griffiths & Williams 
1994). One way of overcoming this disadvantage of the method is to consider a number 
of MLE’s based upon different time eras that are linked together, thus allowing new 
values for parameters to be investigated at certain time intervals based on behavioural 
changes and the introduction of treatments. This is contemplated later on in the thesis, 
specifically within Chapter 4.
Dangerfield & Roberts (1994) used parameter optimisation in a system dynamics 
approach in order to fit their model (in the analysis of five countries) to the data from 
each of the five countries individually. Much of the analysis work completed by 
Dangerfield and Roberts involved optimising the parameters of a transmission model of 
AIDS spread in the homosexual population (Dangerfield & Roberts 1989; Roberts & 
Dangerfield 1990a). The process of this was described by Dangerfield & Roberts in 1994 
as ‘numerically intensive work ... where the benefits from the enormous increase in 
desktop computing power can be realised ... it involves an iterative heuristic search 
algorithm applied to the multi-dimensional parameter space’. The algorithm employed 
by Dangerfield & Roberts was originally formulated by Hooke & Jeeves in 1961 and 
allows the optimisation of parameters as they change value through time; this 
advantageous characteristic was then instigated by Dangerfield & Roberts (1994,1996) 
in their estimation of the following parameters (described here using the notation 
previously identified within the Cardiff model):
1 . c, the mean number of different contacts per unit time,
2. X(t)+W(t), the size of the susceptible population,
3. p, the probability of passing on HIV infection (this differs from that within the 
Cardiff model; here it is considered as three separate probabilities with respect to 
the definite stages in the natural history of HIV throughout the long incubation 
period),
4. The durations of the second and third phases of the assumed three-stage 
incubation period distribution (that is, 1 / 7 2  and 1 /7 3 , where m = 3 ).
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The nature of the model used by Dangerfield & Roberts (1994), and similarly of the 
Cardiff model implemented throughout this thesis, permits both prevalence and incidence 
estimates to be made and, providing the set of parameters are assumed not to vary in the 
immediate future, it is acceptable to predict the epidemics’ outlook over the upcoming 
years so as to estimate AIDS incidence, as well as HIV incidence, AIDS/HIV prevalence 
and deaths from AIDS.
The Cardiff HIV/AIDS epidemic model is used to obtain AIDS incidence, HIV incidence 
and deaths from AIDS, which are attuned consistent with the parameters to be estimated 
in order to produce an excellent fit with the observed data attained from ENAADS (AIDS 
and HIV incidence) and CDSC (deaths from AIDS). The observed data utilized for this 
fit has formerly been adjusted for under-reporting and reporting delays (EuroHIV 2003). 
However, data over the most recent years may still be deemed unreliable; hence, the 
model will cover the years 1979-2002 only. Using yearly data from these sources 
provides 24 observations for AIDS incidence (1979-2002); 18 observations for deaths 
from AIDS (1985-2002) and only 8  observations for HIV incidence (1995-2002). This 
small number of observations on which to create the expected AIDS incidence, expected 
HIV incidence and expected deaths from AIDS, will result in a small number of degrees 
of freedom within the x2 goodness of fit test, if too many parameters are estimated at one 
time. Snary (2000) investigates using smaller time intervals of 6  months in order to 
increase the number of degrees of freedom within the x2 goodness of fit test. The 6 - 
monthly observed data, however, was somewhat erratic and posed problems when trying 
to acquire a good, smooth, fit between the observed and the expected data. Comparisons 
between using different time intervals showed the Maximum Likelihood Estimates to be 
alike; hence, yearly data and results are stated and analysed within this work.
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3.2 The MLE Technique
The first factor within the Maximum Likelihood technique which necessitates 
deliberation is the statistical distribution to be used to model observed AIDS incidence 
within each small time period of 1 year, as employed within this work. The Poisson 
distribution (as implemented by Bailey 1991, 1992°; Griffiths & Williams 1995; Griffiths 
et al. 2000; Lowrie 2000; and Snary 2000) offers itself as a suitable distribution to model 
the number of new AIDS cases for each time period for two main reasons:
A. the AIDS data are fundamentally count data,
B. one essential criterion for the theory of maximum likelihood is that the observed 
data are independent.
Note, with respect to B above, that the AIDS data may not actually be independent 
(Bailey 1992c); however, in order to adopt the approach of maximum likelihood for the 
estimation of parameters within the model and to maintain simplicity, the assumption that 
the observed data are independent is exercised. This assumption is made not only within 
this thesis, but also in the published accounts of Bailey (1991, 1992c); Griffiths & 
Williams (1995); Griffiths et al. (2000); Lowrie (2000); and Snary (2000). The observed 
AIDS data, used throughout this thesis, is abstracted from the ENAADS dataset 
(EuroHIV 2003) and is depicted in the probability distribution function (p.d.f.) of the 
Poisson distribution below (equation (3.1)). Also included within this expression of the 
p.d.f are the expected AIDS cases which are obtained by solving the differential- 
difference equations within the epidemic model, i.e. they are the output from the model 
with which we are creating the best fit possible to the observed data. The probability 
distribution function (p.d.f.) of the Poisson distribution is as follows:
/ ( a ,)  = ——;— , i = l,2,. ..,r  ...(3.1)
ar
where aj, a2 , ..., ay = observed AIDS cases for T successive time periods, 
ai, <*2 , . . . ,  or = expected AIDS cases for T successive time periods.
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The theory included within this section, describing the MLE technique, is extracted from 
work by Bailey (1991, 1992°). As the title of the estimation method being considered 
within this chapter suggests, the next step in deriving the maximum likelihood estimates 
is to determine the expression for the log likelihood of this Poisson model (equation (3.2) 
below). This log-likelihood is then maximized subject to the expected AIDS cases, that 
is, the oj terms.
| j* , ~cl • 1 y
L = logl F I a  e, \ = Z k  lo8 a . - |og(a r)} ...(3.2)
[i=i a r  J 1=1
The expected AIDS cases are the terms created by the model itself and from the fact that 
the model is adjusted in accordance with the parameters to be estimated, it follows that 
the expected AIDS cases are dependent upon the parameters subject to estimation. In 
other words, denoting by 0 j, j = 1 , ..., n, the set of n parameters in the epidemic model to 
be estimated, and by 0  the vector of these n parameters, we see that the a; are dependent 
upon the 0j. Accordingly, in order to maximise the log-likelihood, the expression L has 
to be differentiated by each of the parameters to be estimated, 0 j , and the results set to 
zero to give a set of n simultaneous equations. So, the two vectors below are created:
' A "SL/S0 ,"
Oi SL/S01
£  = I
s  =
J
A . _SL/S0n_
If it is not possible to solve these simultaneous equations explicitly, then iterative 
numerical methods like Newton-Raphson can be used (Kendall & Stuart 1973).
First, consider the scenario of only 1 time period, in which the parameters are to be 
estimated. This provides an understanding of the basic procedure involved in a clear and 
uncomplicated notation. After the one-period rationale has been described, the scenario 
where the parameters are estimated over more than 1 time period is considered.
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Univariate scenario
Let 0q be the initial approximation to the MLE 0 . In the univariate case, the vectors 0 and
<2 ,S consist of the element(s), 0 and —  respectively, where L = In f  is the log-likelihood
80
(as derived previously) to be maximised.
( 8 \ * f \  _ f5 1 n / (x ;0 ) ' j1
II 80 )
A
Given the condition that 0 is the maximum likelihood of 0, the result seen in equation 
(3.3a) is known. Additionally, implementing Taylor’s series, the expression for the 
derivative of the log-likelihood can be approximated as seen in equation (3.3b).
S \ n f ( x , 0 )
80
=  0 (3.3a)
8 \ n f ( x , 0 )  8 \ n f ( x ; 0 o)
80 80 + (0 - 0o)
8 2 In f ( x \ 0 Q) 
802
(33b)
Furthermore, by rearranging equation (3.3b) in terms of 0, using the fact that the subject 
derivative at present in equation (3.3b) is equal to zero (as shown in equation (3.3a)), we 
obtain equation (3.4) below. Of particular interest in equation (3.4) is the comparison 
between the denominator on the right hand side of the formulae and the definition of the 
information matrix, I, identified below equation (3.4), where E denotes the expected 
value of the function.
8 \n f(x ;0 o)
50 /  ...(3.4)o In / (x; 0Q)
I  = -E 8 2\n f(x ;0 )  
802
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It is apparent from this comparison that the expected value of the second derivative term 
shown in equation (3.4) is equivalent to -I(0o), and since a change in the value of 0 has 
little, or no, effect on this second derivative term, the expected value can replace this 
derivative within the equation for 6 . Thus, for the univariate case, the iterative procedure 
is expressed as follows:
Multivariate scenario
Let Oj be the initial approximation to the MLE . Then, for large enough T (i.e. a large
Next, for the multivariate case, it can be noted that the variance-covariance matrix, V, is 
equal to the inverse of the information matrix, I, which is defined in the multivariate case 
as:
By using the theory on approximate solutions of likelihood equations (Kendall & Stuart 
1973), as seen in the description for the univariate scenario, the iterative procedure, using 
the same notation as above, is thus evaluated to be:
S\nf{x-,en)
...(3.5)
number of successive time periods), 0} is asymptotically unbiased and efficient, that is:
S\nf(x-e„)
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SL/S0,
To simplify, the vector S, is reintroduced into the notation: S =
<Sln f(x ;0„ )
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[SL/S0,
Then, the iterative procedure seen in equation (3.6) below, commonly known as the 
method of scoring for parameters, is formed and implemented to calculate the estimates 
of the parameters 0 j, j = 1 , 2 , . . . ,  n.
3.3 5-Parameter MLE
Section 3.2 demonstrates the theory behind the computation involved within the 
maximum likelihood technique and shows the scoring method iterative formula to be:
In order to perform MLE on the parameters to be estimated, the theory within section 3.2 
needs to be put into effect. This is accomplished using Visual Basic (VB), employing 
Excel Spreadsheets as the output domain, i.e. a program is written in VB incorporating all 
the differential-difference equations (thus creating the model of expected AIDS, HIV and 
deaths) and computing the theory of MLE, as seen in section 3.2. The aim of the 
program is not only to illustrate the expected HIV/AIDS epidemic against the observed 
HIV/AIDS epidemic, but also to incorporate the method of maximum likelihood to model 
the expected data on to the observed data by providing a guide for changes in value of 
particular, chosen, parameters and, thus, producing better, and eventually the best, 
possible fits between Observed and Expected HIV, AIDS and deaths data.
£(£ )= = t . + r ' s ...(3.6)
= fi. +L S. ...(3.7)
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In this section, the theory presented in part 3.2 is explored to determine the equivalent 
computational formulae that can be put into practice. Then, finally, this computational 
method is utilized to estimate 5 different parameters within the model, at the same time.
T 8L T 8L^From section 3.2, it is known that L = V  LU), th u s  = V  . Hence, for the
i t  SOj i f  86 j
univariate case, the log-likelihood expression, assuming the Poisson distribution, is:
L(i) = a, log a, - a i -log (a;!)
Differentiating this log-likelihood, L(,), with respect to the parameters to be estimated, 0j, 
using the chain rule (since a} is a function of 0j) gives the elements in matrix S:
8L(l) 1 8a; 8a , ^S f  = —— = a 
7 80j 1 a t 80j 80j
—  —  1 
v«. ) 56j
S a - . . .(3 .8 )
It is worth noting, at this point, that since there is no unequivocal expression for aj, there
Sais no explicit expression for- ^ - . For the work within this model, a more liberal
interpretation of these partial derivatives is adopted. In real terms, the partial 
8a
derivatives, , represent a measurement of effect that a small change in parameter
Savalue, 0j, has on the expected AIDS cases, dj. In other words, requires calculation
by first principles from the differential-difference equations in the epidemic model. This 
is input into the VB program using the following operation:
AIDS Cases with old parameter value - AIDS Cases with new parameter value 
Small Change in parameter value
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This evaluation of the partial derivatives allows a numerical approximation of the partial 
derivative terms to be made, thus enabling the completion of the calculation of the 
elements within S. See Appendix 3.1 for the VB script of these partial derivatives and 
their role in the MLE process.
The product of S and I'1, within the iterative formula (equation (3.7)), also needs 
evaluating in order to be computed numerically. In the univariate case, it is known from 
the definition of I, that:
r(0Jjk - E
s 2lU) '  
s e . s e . ,
\  J k J
Hence, the second derivative term needs to be investigated in order to determine I in 
computational form. This means differentiating Sj(,) with respect to 0k, using the product 
rule, such that:
2T(»8 1}
so jse ,
— — i
\ ai j
d a , a . Sa, da,____ > I___ I___ I
SOjSO, af SO, S0k
Now, using the knowledge that, by definition, E(aO = a*, the univariate case gives:
7(0 = -Ejk ^
S 2Lm N
s e . s e . ,\  J k j
= -E a;
\ ' . a '
S 2a i a; Sa , Sa,
S0jS0k a 2 S0J 80k y
1 8al Sat 
a t 80j 80k
Again, the partial derivatives, within this computation of the Ijk(,) elements, have no 
explicit expression and so the same principle of interpretation is imposed, as it was for 
the partial derivatives within the calculation of the Sj(l) elements. Finally, generalizing for 
the multivariate case gives equations (3.9):
j=l
i
\ a i ,
Sa,
SO,
i= Zi=l
1 Sat Sat 
a  i S0J se t
where j ,k  = l,2 ,...,n .
,..(3.9)
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Applying this computation to the scenario where n = 5, that is, there exist 5 parameters to 
be estimated at the same time, involves the inversion of a 5x5 matrix (i.e. I 1). This 
inversion slows the length of time the VB program takes to run; the formula for the 
inversion is complicated and, subsequently, time consuming to ascertain the procedure is 
working correctly and accurately. Alternatively, outputting the I elements into an Excel 
Spreadsheet, inverting the matrix within the sheet and then reading back into the program 
the I' 1 elements, is a much more efficient method for completion of the inverse. Also, 
another advantage of computing the 5 x 5 inverse in this manner is the ease of 
assessment; by simply performing a multiplication of the matrices I and I 1 within the 
Excel Spreadsheet one can ensure the result is always equal to the Identity matrix.
Hence, the approach involving the interaction with an Excel Spreadsheet is employed 
throughout this MLE work.
3.4 Estimating Parameters in the Cardiff Model
This section describes the creation of the Cardiff HIV/AIDS model, the computation of 
the differential-difference equations and the application of MLE theory for 5 parameters, 
as seen in sections 3.2 and 3.3, within a VB program. The underlying assumptions must 
be clarified and any restrictions on the parameter values require declaration. See 
Appendix 3.1 for snippets of the VB program script that are employed for this work.
The first set of 5 parameters to be estimated is:
• N 1978 = the number of high-risk homosexuals in 1978,
• X = the arrival rate of homosexuals into the Susceptible sub-population,
• ai9 7 8 = the number of HIV positive homosexuals at the end of year 1978,
• Pc = the infectivity parameter,
• r = the proportion the IP lengthens due to the introduction of treatments.
Then, to incorporate the concept of estimating the entry rate, A, as a single entity without 
strict definition, X and N 1978 are withdrawn from the estimation process and replaced by
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A. In addition, the death rate, co, is introduced into the MLE procedure to make up the 5 
parameters. That is, the second set of 5 parameters for estimation is:
• A = the entry rate into the High Risk Susceptible sub-population,
• ai9 7 8  = the number of HIV positive homosexuals at the end of year 1978,
• Pc = the infectivity parameter,
• r = the proportion the IP lengthens due to the introduction of treatments,
• co = the death rate from the AIDS case sub-populations.
In order to perform this estimation, primarily the models’ initial conditions need to be set. 
The initial parameter values and settings for the program are as follows, based upon a 
combination of work by Snary (2000), Lowrie (2000) and Griffiths et al. (2000) or gained 
directly from population statistics.
• IP = Mean length of incubation period in years prior to the introduction of 
treatments = 11.4 (Snary 2000),
• pi = rate at which homosexuals exit the susceptible category from causes other 
than AIDS = 0.003 (DH1 2002),
• g2 = rate at which homosexuals exit the High and Low Risk Infective categories 
from causes other than AIDS = 0.03 (Snary 2000 and Lowrie 2000, to 2.d.p.),
• V2 = rate at which High Risk Infectives become Low Risk Infectives =0.1 (Snary 
2000),
• V3 = rate at which High Risk AIDS cases become Low Risk AIDS cases = 0.5 
(Snary 2000 and Griffiths et al. 2000),
• b = proportion of High Risk Infectives whom, on diagnosis with AIDS, continue 
their High Risk behaviour = 0.5 (Snary 2000),
• g = proportion of Low Risk Infectives whom, on diagnosis with AIDS, change 
their behaviour to High Risk = 0.1 (Snary 2000),
• co = death rate = 1 (Snary 2000),
• m = number of stages in HIV infection = 6  (Snary 2000).
Inspecting the values of the parameters listed on the previous page, it is apparent that they 
have been rounded to a small degree of accuracy. Whilst a few of the parameter values 
already possess this nicety with no need for adjustment, others have been subject to 
rounding due to the notion that the parameter values are estimations. A sensitivity 
analysis on all the parameter values listed on the previous page was completed, taking it 
in turn to change the value of each parameter and running the program, noting the effect 
on the previously minimised chi-square. In general, a change in parameter value, for 
most of the parameters, by 0.01 resulted in the MLE chi-square increasing by no more 
than 0.00001. Hence, it was decided that the parameter values do not need to be valued 
to a large number of decimal places within the work since small differences in value do 
not have a significant effect on the HIV/AIDS model outputs.
In Chapter 2 of this thesis, all parameters within the Cardiff HIV/AIDS model were 
listed. It is worthy of note that not all those parameters are apparent in the initial 
conditions listed here, even when allowing for the 5 parameters to be estimated. This is 
partly due to the assumption that Low Risk Susceptibles play no part within this model, 
i.e. W(t) is not considered here, or more precisely, the transfer allowed from X(t) to W(t) 
at rate Vi is designated a value of 0. This simplification has meant that the exit rate from 
the (High Risk) Susceptibles within the model considered here, pi, is the only exit rate 
from this sub-population without an individual progressing further through the model and 
contracting HIV. Consequently, within the programming of this model, the differential- 
difference equation relating to W(t) is not included. The value of pi was determined 
from population statistics (DH1 2002) by calculating a ratio for the number of deaths 
within the total population, aged 15-64, in the UK. This figure, averaged over all age 
groups, was approximately 3 in 1000, hence pi = 0.003. Note that for the male 
homosexual population the death rate from causes other than AIDS may be marginally 
greater than for the general UK population taken as a whole. However, any evidence of 
this is not supported by the list of reported causes of death attained from the Department 
of Health (DH1 2002). As for the other parameters, a sensitivity analysis has been 
performed with respect to the value of the parameter pi and it was confirmed that a small 
change in value does not significantly affect the model outputs. Consequently, any minor 
difference in the value of pi that may be observed, when considering the male
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homosexual population only, is deemed negligible, hence fi\ is designated the value of 
0.003. Other missing parameters within this model include: the proportion, a, of High 
Risk susceptibles who on diagnosis with HIV maintain their High Risk behaviour, which 
is assumed a value of 1 since no immediate change in behaviour (from High Risk to Low 
Risk) can be expected when a High Risk Susceptible becomes infected with HIV due to 
the principle that an homosexual is not immediately aware of their status change, i.e. HIV 
diagnosis is rarely at the same time as infection; and the rate at which homosexuals exit 
the High and Low Risk AIDS categories, p.3 , from causes other than AIDS, which is 
deemed negligible in comparison with the size of the death rate, go, and consequently is 
assumed a value of 0 .
The above assumptions create a model that is easy to understand and allows attention to 
be paid to the HIV infective sub-populations and the movements between the stages of 
HIV. Note that these assumptions do not affect the expected AIDS incidence, HIV 
incidence or death figures, which are the numbers that the model produces with the 
objective of fitting the relevant observed data. Nor should these assumptions interfere 
with other outputs of the program, such as HIV prevalence statistics. Figure 3.1, 
overleaf, provides a diagrammatic view of the simplified Cardiff HIV/AIDS model that is 
being instigated throughout this chapter, with the dashed directional arrows and faded 
compartments representing the movements which no longer occur subject to the above 
named assumptions.
Using the ENAADS dataset as the source of the observed AIDS incidence data, the first 
reported case of AIDS in the UK was in 1979. Thus, this is considered as the first year of 
the HIV/AIDS epidemic and so 1978 is employed as the base year (i.e. when t = 0). One 
notion in operation for the construction of the model is that during the base year, since 
the HIV/AIDS epidemic has not yet begun, all individuals would be assumed to be 
partaking in high-risk sexual activities, due to the lack of awareness of HIV/AIDS. This 
means that all homosexuals who are HIV positive in 1978 are considered to belong to one 
of the High Risk sub-populations. Therefore, it is assumed that V(1978) = Z(1978) = 0, 
that is, all Low Risk sub-population groups within the model of HIV/AIDS are assumed 
to be empty. Following this conjecture, that all homosexuals are High Risk at the start of 
the epidemic, is the assumption that N 1978 = X(1978)+Y(1978)+A(1978).
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Figure 3.1 Simplified version of the Cardiff HIV/AIDS Epidemic model
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For the estimation of the first set of 5 parameters, listed previously, the entry rate into the 
model is assumed to be A = AN1 9 7 8 , adhering to the first methodology for categorizing the 
entry rate as discussed in section 2.4.1. The incubation period, for this estimation work, 
is assumed to be constant staged, that is, the incubation rate between each stage i and i+ 1  
is unvarying, i.e. Yi =  Y 2 =  • • •  =  Ym, and since IP = 11.4 and m = 6 , then the constant 
transition rate between stages is Yi = 6/11.4 ~ 0.526 (3dp), when r = 1. This is equivalent 
to stating that the constant time per stage is 1/ Yi = 11.4/6 = 1.9 years.
The final issue to clarify, before production of the computational model can begin, is that 
of the estimation of the number of HIV positive homosexuals, and AIDS case 
homosexuals, in each stage at the end of year 1978, that is Yj(1978) and A(1978) 
respectively. It is a reasonable assumption that Yi(1978) > Y2(1978) > ... > Ym(1978) > 
A(1978) and that each of these are small since the epidemic has barely commenced. To 
determine how many of the total number of initial HIV infectives and AIDS cases, ai9 7g, 
are within each of these stages, it is useful to refer to work by Bailey, which Snary (2000) 
also incorporated into her model of the HIV/AIDS Epidemic. To begin with, using the 
observation that the number of infectives in 1978 is small and that the number of AIDS 
cases in 1978 is even smaller, approximately zero, the term aX, within the differential- 
difference equations, can be reduced to the form shown below:
aX  = Be +  ^  «  BcY 
X  + Y + A
where X = the number of High Risk Susceptibles in 1978;
Y = the number of High Risk Infectives in 1978;
A = the number of High Risk AIDS cases in 1978.
Substituting this expression for aX back into the original differential-difference equations 
linearises them into the system of equations shown overleaf, with the same notation as 
used above.
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^ -  = A - / k Y - filX  
at
^  = p c Y -(r ,+ M i)Y ,
^ r  = r,Y,-i -{r ,+ M i)Y „  i = 2,...,m  
at
^  = Ys¥m ~(a> + M,)A
dYIn order to create an expression for— , all equations for Yj above (i = 1, m) must be
dt
m
summed together, i.e. Y = ^ JYi , and simplified to give:
j=i
dY  = y d %_ 
dt dt
= f i c Y - ( / s +M2)Y{ + y sYx - < J s  +M2W2 + / s Y 2 “ O', + M2 ) Y3 + - - '+ rsYm-1 “ O', +M2)Ym 
= f i c Y - Mlf iYt - r sYm
= ( j k - V 2) Y - r sYm ...(3.10)
Noting that Ym, in 1978, is small, Bailey decided to abandon the term ysYm from this
dYsimplified expression for— . Thus,
dt
^ - « { p c - H t )Y ...(3.11)
dt
Consequently, the solution of this variable separable type differential equation is found to 
be Y = ke{pc~^)x, where k is the constant of integration. This solution was acquired by 
reorganising and integrating both sides of the differential equation (3.11), before taking
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anti-logs. Then, this expression for Y can be substituted back into the equations for Yj to 
give the final proportions. Taking the scenario where i = 1, we get:
at
or
+  O ', + Ml )y, = fickeifc-at
The (integrating-factor type) differential equation shown here can be solved at time t = 0,
Beas seen below, where p  = — :
Similarly,
ftck pk
(ys +0c) 1 + p
pkK =
a + py
kA =
(1 +p)'
...(3.12)
Next, the constant of integration, k, needs to be evaluated. One suggestion for the value 
of k is based upon the dependence of the formulae on the number of stages, m. To 
illustrate this, imagine the case where m —» oo and k ^  0 ; for each stage there exists a 
constant of integration, thus, when summed over all m stages, the total constant of 
integration tends to infinity. This is not a feasible option and so, assuming k = 0 seems a 
reasonable assumption. Another way of evaluating k is accomplished by assuming an
infinite number of HIV stages when investigating the relationship Y = ^ Y t , such that 
equations (3.12) hold.
M
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Also,
Y = ? ,Y ,
i=1
pk pk pk+ -  , v, +
(! + /») (1 + p )2 (1 + p )3
f*  . 1 1Jl + ^  T + ~------— + ,
0 + p ) i  (1 + p )  0 + p )
pk f 1 1
(l + /» ) l l-V ( l  + A>)J
= k
=^!&{<r^rr0
Next, drawing on the assumption stated previously, that a1978 = I'; + A , it becomes
i=i
apparent that ai97 8  = k. With this finding, the argument for the assumption that k = 0 is 
supported when considering the situation before the epidemic begins when there are no 
HIV infectives or AIDS cases.
Now that it has been identified that a ^ g  = k, the proportions for the number of High Risk 
Infectives in each of the stages of HIV infection and AIDS, at the start of the epidemic, 
with m = 6 in the Cardiff model, are as shown in equations (3.13), in the form of the 
geometric distribution:
K = _^ 197S>£_ i = l,...,6
' (1+P)1’
..(3.13)
A = 1978
( i + p y
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3.5 Fitting the Cardiff Model
The initial conditions, assumptions and proportions, as discussed thus far, are stated in 
Appendix 3.1 where the program for the model and consequent MLE calculations is 
summarised. The differential-difference equations for X, Y, V, A and Z are also depicted 
in Appendix 3.1, as are the calculations for the 5-parameter MLE, i.e. the partial 
derivatives; the elements within the I matrix; the elements within the S matrix; and the 
subsequent correction values.
Another mechanism to solve this optimization problem (other than MLE in VB), is to use 
an ‘add-in’ called Solver within Microsoft Excel (Microsoft Excel User’s Guide 1993- 
1994). In order to use this application, however, the entire model must be formulated and 
inputted into the cells of an Excel Spreadsheet. The differential-difference equations, the 
objective function, variables and constraints, are entered directly into the worksheet.
This process is incredibly extensive and becomes extremely convoluted, as the model 
gets more and more complex. Consequently, the method of Solver can be considered as 
error-prone, especially in comparison to the much simpler and easier to understand 
method of formulation within a computer program. Solver also has the disadvantage that, 
other than an estimate for each parameter, no other deductions within the model can be 
acquired; the method of scoring, on the other hand, allows much further investigation to 
be undertaken due to the availability and accessibility of the calculated information 
matrix and its inverse, I and I'1.
Nevertheless, Solver is a very powerful tool and its use within the modelling of the 
HIV/AIDS epidemic should not be underestimated. The objective function can be set as 
the log-likelihood (L) and maximized subject to changing the parameter values. This is 
in accordance with the method of MLE, with the exception that the optimization is 
performed by Solver and not by the scoring method as shown in equation (3.7). Within 
this thesis, Solver is used as a tool for verification, whilst the method of scoring is the 
predominant technique applied for estimating parameters.
In either approach (whether using Solver or the iterative formula seen in equation (3.7)), 
the parameters to be estimated are subject to constraints. That is, they are bound by 
predetermined conditions such that they remain realistic in value. At present, within this 
simplified model, where each parameter is to be estimated only once at the start of the
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epidemic, the restrictions placed upon them are as shown below:
• A > 0, non-negativity (or, if considered individually, N 1978 > 0 and 
A > 0 for non-negativity),
• 0  < a 1978 < 1 0 0 0 , non-negativity plus an upper boundary for realism,
• 0  < pc < 2 , non-negativity (since both p > 0  and c > 0 ) plus an upper 
boundary for realism,
• r > 1, r restricted to only increase the IP due to the introduction of 
treatments,
• cd > 0 , non-negativity.
Note that as the model becomes more complicated, the number of constraints will 
increase. For instance, if the total time period of the epidemic (1979-2002) is split into 
two time eras, pre-treatment (1979-1995) and post-treatment (1996-2002), relating to the 
introduction of highly effective combination treatments, and if the parameters were re- 
estimated for the second time period, it would be expected that co would decrease and r 
would increase in value. Hence, the constraints © 0  > © 1  and r0  < ri would be introduced, 
where © 0  relates to the death rate prior to the introduction of treatments; © 1  to the death 
rate after the introduction of treatments; ro to the proportion of increase of the IP prior to 
the introduction of treatments; and ri to the proportion of increase of the IP after the 
introduction of treatments.
Within this section the Cardiff model, as shown in Figure 3.1, is fitted to the yearly 
AIDS, HIV and deaths data for Calendar years 1979-2002,1995-2002 and 1985-2002, 
respectively, to calculate estimates of 5 parameters over the entire time period. Firstly, 
the parameters N 1 9 7 8, A, ai9 7 8 , pc and r are considered, under the assumption that 
A = AN1 9 7 8. The results for this estimation and consequent fit are shown and investigated 
in section 3.5.1. Secondly, the parameters A, ai9 78, Pc, r and © are estimated, where, 
here, the assumption is of a more complex entry rate, specifically, A ^  AN 1 9 7 8 . The 
results for this estimation are shown and investigated in section 3.5.2.
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3.5.1 Estimation of the 5 parameters: N i^  X, aira* Pc and r.
Applying the initial conditions for parameters, as displayed in section 3.4, and the 
assumption that Yi = Y2  -  -  Ym» where in this case m = 6  (based on a constant staged
incubation period of length 11.4 years, in accordance with Snary (2000) who extracted 
the figure from work by Bailey (1992°)), the iterative formula in equation (3.7),
&n+l -  0 n + r lS , is employed to create a set of estimates for the parameters N ^ ,  X,
a 1 9 7 8, pc and r. These parameter estimates are calculated from yearly AIDS incidence 
data (1979-2002) using maximum likelihood techniques, with HIV incidence data (1995- 
2002) and deaths from AIDS data (1985-2002) included in the calculation of the chi- 
square value to be minimised. The program was run through numerous iterations before 
arriving at a set of optimal parameter values creating the best combined fit for AIDS 
incidence and HIV incidence data. The program was then run a second time, this time 
including deaths from AIDS data into the fitting process, producing the best combined fit 
for AIDS incidence, HTV incidence and deaths from AIDS data. The two resultant sets of 
parameter values, subject to constraints, are as listed in Table 3.1, overleaf. Note that the 
only changes in MLE value, including deaths from AIDS data into die overall fit of the 
model, are with respect to the parameters N 197* and X, that is, with regards to the entry 
rate into the High Risk Susceptible sub-population, which reduces its value from 
A = XNi9 7 8  = 1298 to 1149 (a decline of about 11.5% on its original value). Also, both 
ai9 7 8  and pc reach their upper limits, as defined in the constraints imposed to ensure 
realism and reduce ambiguity. If these restrictions were not enforced then both a ^  and 
Pc would have increased to values greater than 1000 and 2, respectively.
The respective minimised chi-square values, for these sets of parameters observed in 
Table 3.1, are arranged in Table 3.2 on the next page. It is noticeable from this table that 
the introduction of the deaths from AIDS data into the overall fit compensates the fit 
between observed and expected HIV incidence for an improvement in fit for both AIDS 
incidence and deaths from AIDS. In fret, the lack of fit between observed and expected 
new HIV cases more than doubles (from a chi-square value of approximately 640 to 
about 1437), whilst for both AIDS cases and deaths from AIDS the fit improves by a 
count of over 400 and 500 respectively in terms of their chi-square sums. The x2  figure 
subject to optimization for each case is highlighted in Table 32 . In general, the effect of
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Model fitted to AIDS incidence 
and HIV incidence
Model fitted to AIDS incidence, 
HIV incidence and deaths from 
AIDS
Nl978 11,800 11,490
X 0 . 1 1 0 . 1
a 1978 1 0 0 0 1 0 0 0
PC 2 2
r 1.27 1.27
Table 3.1 Final Parameter Estimates as produced for the Cardiff Model using MLE.
Model fitted to AIDS 
incidence and HIV 
incidence
Model fitted to AIDS 
incidence, HIV incidence 
and deaths from AIDS
AIDS incidence x2 2938.735 2512.975
HIV incidence x* 639.946 1436.800
AIDS +HIV incidence x2 3578.681 3949.775
Deaths from AIDS x2 3793.855 3260.507
Total Overall x2 7372.536 7210.282
Table 3.2 Total x2 values relating to final MLE’s.
allowing for deaths from AIDS data, in the fitting of the model, is of a fall in total overall 
chi-square by 162.254, suggesting an improvement in the HIV/AIDS epidemic model 
taken as a whole when compared to just fitting HIV and AIDS incidence data. 
Consequently, a lower level of entry rate, as implied by the second set of parameter 
values listed in Table 3.1, suggesting smaller amounts for N 1 9 7 8 and A,, can be viewed as 
more preferable than that suggested during the fit of AIDS and HIV data alone.
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Also, it is important to note that the total chi-square can equal different values dependent 
on whether the observed and expected data, over all three datasets, were summed over 
time prior to or after the chi-square calculation, as shown in equation (3.14).
£ ( 0 , - E a)2/ E a +Y i (Oh - E „ f l E „  + ' £ ( 0 D- E Df / E D ...(3.14)
* £ [ (  Oa + Oh +Od) - ( E a +Eh +Ed )]2 I(Ea +Eh + Ed )
where,
Oa = Observed AIDS incidence data 
Oh = Observed HIV incidence data 
Od = Observed Death from AIDS data 
Ea = Expected AIDS incidence data 
Eh = Expected HIV incidence data 
Ed = Expected Death from AIDS data
For the chi-square summation, and minimization, here, the first form of the total chi- 
square, on the left hand side of equation (3.14), is utilized, as apparent in Table 3.2.
In Appendix 3.1, it is seen that the partial derivatives within the MLE methodology 
incorporate AIDS incidence data only, i.e. the effect a small change in parameter value 
has on new AIDS cases over the time period 1979-2002. The other datasets (HIV 
incidence and deaths from AIDS) are introduced into the fit via the chi-square calculation 
and minimisation. Also, in later work, for some parameters a small change in value will 
have little effect on the expected AIDS incidence data and hence will result in near zero 
value partial derivatives, which then gives rise to difficulties within the program due to 
the attempt to divide by zero. In particular, co only marginally affects AIDS incidence 
and HIV incidence, thus, it only significantly affects the model when deaths from AIDS 
data is included in the chi-square optimisation. This is discussed in more detail in the 
next sub-section of this chapter.
The fit between expected and observed AIDS Incidence, HIV Incidence and deaths from 
AIDS is illustrated in Figures 3.2a, 3.2b and 3.2c respectively.
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Figure 3.2a Fit between expected and observed AIDS incidence subject to 5- 
parameter estimation on Ni978, X, ai9 78, pc and r.
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Figure 3.2b Fit between expected and observed HIV incidence subject to 5-
parameter estimation on Ni978, X, ai978, pc and r.
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Figure 3.2c Fit between expected and observed deaths from AIDS subject to 5 
parameter estimation on Ni978, k, ai978, Pc and r.
It is apparent that the expected AIDS incidence, shown in Figure 3.2a, does not reach the 
peak of the number of AIDS cases that were observed in 1994, that is, just less than 1200 
new AIDS cases within this year. In fact, the expected AIDS cases only reach a 
maximum of about 1078 new AIDS cases in 1995 when the sum of AIDS and HIV x2 is 
minimized and 997 new AIDS cases in 1994 for the optimization of the total x2, relating 
to the sum of AIDS, HIV and deaths from AIDS chi-squares. This deficit within the 
expected AIDS incidence is due to the dramatic drop witnessed in observed AIDS 
incidence post 1995 resulting from the introduction of combination treatments. The 
model has created the best fit possible by averaging out this fall with not reaching the 
levels it should be at prior to 1995. This is a consequence of only estimating the set of 
parameters once over the entire time period. If values of parameters were allowed to 
change over time, then an improved fit would be witnessed. Chapter 4 goes into this in 
more detail.
HIV incidence, seen in Figure 3.2b, is more difficult to get a known good fit for due to 
the fact that only data from 1995 onwards is available from the ENAADS dataset. HIV
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diagnosis numbers can be obtained for years prior to 1995, however, HIV incidence must 
not be confused with new HIV diagnoses, as the time of incidence is often different to the 
time of diagnosis. Here, the ENAADS dataset is used as the source of HIV incidence 
data for homosexual men in the UK in order to keep consistency with the AIDS case 
data. However, new HIV diagnosis data, from CDSC, can be used as an indication 
towards the suspected shape and numbers of the HIV incidence curve, prior to 1995. It is 
probable that a shape, like that seen in the expected HIV incidence curve depicted in 
Figure 3.2b, occurs, however, the peak here seems to be a little early (1980) and a little 
high (6107 and 5854 new HIV cases per year for minimized AIDS and HIV x2 and AIDS, 
HIV and deaths x2, respectively) when compared with suggested trends investigated by 
Snary (2000); Downs & Houweling (1997); Day Report (1996) and De Angelis et al. 
(1998), whom all, in general, recommend that HIV incidence numbers peak in 1982/1983 
at a level of about 3500-4500 new HIV cases per year. Post 1983, owing to a 
government campaign promoting safe sex in 1985/1986 (Johnson & Gill 1989; Evans et 
al. 1993), levels of HIV incidence are assumed to have fallen quite rapidly and, in more 
recent years, have maintained their reasonably low, and stable, levels of about 1500 new 
cases of HIV each year.
The fit for deaths from AIDS, Figure 3.2c, is similar to that for AIDS incidence, in that 
post-1995 there exists a sharp decline in the number of deaths observed in accordance 
with the introduction of highly active antiretroviral treatments. The number of deaths 
from AIDS reaches a peak of approximately 1150 homosexuals in 1994, and drops to a 
rate of just over 200 individuals per year by 1998. The model has tried to compensate for 
this dramatic fall by limiting the peak of the expected number of deaths to 1071 for the 
optimization of the AIDS and HIV x2 and 989 for the optimization of the AIDS, HIV and 
deaths from AIDS x2, thus creating an averaging effect over the entire time period.
Again, this lack of capability of the model to reach the levels it needs in order to create a 
good fit with the observed data is due to the static nature of the parameter values within 
the model. Yet, due to the introduction of new therapies and changing sexual behaviours, 
the assumption that parameters remain constant over time is unrealistic.
Figure 3.3, overleaf, shows the expected numbers within the sub-populations, X(t), Y(t), 
V(t), A(t) and Z(t), as the epidemic progresses through time. Each of these sub-
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Figure 3.3 Sub-population prevalence trajectories subject to 5-parameter estimation 
on Ni978, X, a 1978, pc and r.
populations (High Risk Susceptibles, High Risk and Low Risk Infectives and High Risk 
and Low Risk AIDS cases respectively) follow a plausible trend in numbers, as evident in 
Figure 3.3, when considering that each curve in the diagram illustrates the prevalence of 
individuals in their respective category. That is: X(t) represents the number of people 
susceptible to the HIV/AIDS virus at time t; Y(t) represents the number of people who 
are infected with HIV and are participating in High Risk sexual activities at time t; V(t) 
represents the number of individuals who are infected with HIV and are participating in 
Low Risk sexual activities at time t; A(t) represents the number of homosexuals who are 
living with AIDS and are participating in High Risk sexual activities at time t; and Z(t) 
represents the number of homosexuals who are living with AIDS and are participating in 
Low Risk sexual activities at time t. It would be anticipated that Y(t) would increase 
rapidly over the first few years of the epidemic (1978-1984) before slowing its growth 
and maintaining a reasonably high level of High Risk individuals living with HIV. 
Accordingly, as the total population begins to be infected with HIV, the number of 
susceptible individuals within X(t) would be expected to decrease rapidly at the start of
X(t), AIDS+HIV c h im in  
Y(t), AIDS+HIV c h im in  
A(t), AIDS+HIV c h im in  
V (t), AIDS+HIV ch i m in  
Z(t), AIDS+HIV c h im in  
X(t), AIDS+HIV+deaths ch i m in  
Y(t), A IDS+HIV+deaths ch i m in  
A(t), AIDS+HIV + d e a th s  ch i m in  
V(t), AIDS+HIV+deaths ch i m in  
Z(t), AIDS+HIV+deaths ch i m in
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the epidemic (over the same time period that Y(t) increases) and remain a constant low 
level over time. V(t), A(t) and Z(t) are all likely to rise in their levels as the epidemic 
progresses, but not as steeply as Y(t) due to the fact that individuals can only become low 
risk once HIV is contracted (the V(t) sub-population is extracted from the Y(t) sub­
population) and, similarly, homosexuals can only progress to AIDS once they have 
contracted HIV (the A(t) and Z(t) sub-populations are withdrawn from the Y(t) and V(t) 
sub-populations). Figure 3.3 coincides with the assumed patterns for each of the sub­
populations, but when looking at combined HIV prevalence numbers and comparing with 
observed data, there are some discrepancies with the model predictions. Y(t) + V(t) 
represents HIV prevalence alone and Y(t) + V(t) + A(t) + Z(t) represents HIV and AIDS 
prevalence combined. In the final year modelled, 2002, overall HIV prevalence 
(Y(t) + V(t) + A(t) + Z(t)), from Figure 3.3, rounded to the nearest integer, is roughly 
8075 + 7119+ 120 + 822 = 16,136 individuals for AIDS and HIV X2 minimised and 
approximately 7153 + 6343 + 120 + 740 = 14,356 individuals for AIDS, HIV and deaths 
from AIDS x2 minimised. However, statistics from the Department of Health (DH 2002) 
present HIV prevalence as 17,100 individuals diagnosed and living with HIV in 2002. 
This figure does not allow for the proportion of homosexuals believed to be unaware of 
their infection, thus an approximated 5500 (24%) is added to the diagnosed amount to 
obtain an estimate for total HIV prevalence in 2002 o f22,600 homo/bisexual men living 
with HIV. This means the expected prevalence figures created by the model with 5- 
parameter estimation, are significantly understated. This is not the only cause for 
concern with the expected prevalence numbers, when comparing the expected prevalence 
figures, as represented in Figure 3.3, with the observed HIV prevalence data that can be 
obtained from publications by the Department of Health (DH), the CDSC and the PHLS, 
over the last few years, it is apparent that the observed data suggest an increasing trend in 
prevalence figures, whilst the Cardiff model, within this chapter, has produced decreasing 
prevalence estimates over the most recent years. These are both problems created by the 
restriction on the parameters to maintain one value over the entire time period (1979- 
2 0 0 2 ), work later on in the thesis investigates this further.
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3.5.2 Estimation of the 5 parameters: A, airo, pc, r and a .
For the estimation of the 5 parameters, A, ai978, 0c, r and <d, the same initial conditions 
hold as they did in section 3.5.1. However, here, we use additional fixed parameter 
values; X = 0.003 (in accordance with pi) and Niro -  10,000, since these two values are 
no longer being estimated within the MLE process. This abides by the idea that 
A f  XN]ro» since the entry rate, A, is being estimated as a separate entity within the MLE 
process. The implication of the fixed value for N iro, is that the initial value of tire 
susceptible population, X(t), is equal to N iro - YOLDSUM (see Appendix 3.1), where 
YOLDSUM is the total number of HIV infectives at the start of tire epidemic, with Niro 
= 10,000, as opposed to Niro = A /  X = A / 0.003. This is the only point within the model 
differential-difference equations that Niro is considered as an independent parameter, 
elsewhere it is always assumed to be a function of A. The fixed value of X = 0.003, has 
no influence on the differential-difference equations at any stage throughout the model, 
since it is only considered within the expression for A. This means that defining X = pi is 
trivial within this computation of the model, and has no effect on the model outputs. Yet, 
the concept that X = 0.003, does allow the assumption that A i-  XNiro while maintaining 
tire theory that X = pi, thus modelling a scenario where tire entry rate is more complex. 
The parameter estimates creating the best fit subject to tire minimization of two different
A
X values are shown in Table 3.3, with the respective chi-square figures represented in 
Table 3.4, including the highlighted summed x2‘s exposed to optimization. As mentioned 
before, the effect of a small change in value o f co on AIDS and HIV incidence is minimal, 
thus, when optimizing the parameter values subject to the minimization of tire AIDS and 
HIV x2, altering the value of the death rate from its original value of 1 has no impact on 
the x2 sum o f3429.969. Consequently, for the consideration of AIDS and HIV incidence 
alone, in the minimization of the chi-square, the death rate has kept its value of I since 
changing this parameter value has no effect. When deaths from AIDS are brought into 
consideration, the value of the death rate reduces to its new optimal value of 0.97 to 
create a minimized overall x2 value o f6944.805. Therefore, tire change in value of to 
specifically affects the deaths from AIDS x2- Together with this modification in the value 
of the death rate, the only other parameter included in the estimation process that changes 
value with the introduction o f deaths from AIDS into the x2 calculations, is the overall
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Model fitted to AIDS incidence 
and HIV incidence
Model fitted to AIDS incidence, 
HIV incidence and deaths from 
AIDS
A 1350 1 2 1 0
a 1978 1 0 0 0 1 0 0 0
pc 2 2
r 1.23 1.23
( 0 1 0.97
Table 3.3 Final Parameter Estimates as produced for the Cardiff Model using MLE.
Model fitted to AIDS 
incidence and HIV 
incidence
Model fitted to AIDS 
incidence, HIV incidence 
and deaths from AIDS
AIDS incidence x2 2965.181 2585.294
HIV incidence x2 464.788 1050.858
AIDS +HIV incidence x* 3429.969 3636.152
Deaths from AIDS x2 3764.150 3308.653
Total Overall x2 7194.119 6944.805
Table 3.4 Total x2 values relating to final MLE’s.
entry rate into the High Risk Susceptibles, A, which falls from a value of 1350 to 1210.
In accordance with these alterations in parameter values, the HIV incidence fit has 
worsened (with the HIV chi-square sum more than doubling, from a value of roughly 465 
to 1051) whilst both the AIDS incidence fit and deaths from AIDS fit have improved.
The overall minimized total x2 value of about 6945 is the lowest of all the scenarios 
considered within this chapter; this suggests that the entry rate, A, is best considered as a
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single quantity within the estimation process and not as a product of X and N 1 9 7 8, and that 
deaths from AIDS data, as well as HIV incidence and AIDS incidence data, should be 
incorporated within the chi-square minimisation process in order to obtain the best 
overall fit.
Figures 3.4a, 3.4b and 3.4c show the fits for AIDS incidence, HIV incidence and deaths 
from AIDS respectively. Due to the similarity within both sets of 5-parameter MLE’s, 
the expected AIDS cases, new HIV cases and deaths from AIDS numbers, together with 
their consequent fits to the observed data, are very similar. Additionally, identical lines 
of reasoning as those proposed in section 3.5.1 explaining the poor fit between observed 
and expected AIDS incidence and deaths from AIDS, post-1995, are applicable here also. 
Namely, the lack of fit for each dataset can be associated with the assumption that all 
parameter values remain constant over time, despite the introduction of highly active 
antiretroviral treatments. Consequently, averaged parameter estimates during the MLE 
process are created, resulting in the expected data curves not reaching the extreme values, 
and not rapidly declining after the introduction of treatments, as witnessed in the 
observed data. In general, the main noticeable difference between the trajectories of 
AIDS incidence, HIV incidence and deaths from AIDS seen in Figures 3.2a, 3.2b and 
3.2c, respectively, and those seen in Figures 3.4a, 3.4b and 3.4c, is that when the second 
set of parameters is estimated all peaks of new AIDS cases, new HIV cases, new deaths 
from AIDS and sub-population prevalence’s are lower than they are for the estimation of 
the first set of parameters. Keeping the same scale on the paired graphs makes this 
disparity more obvious to the eye. Figure 3.3, as seen in section 3.5.1, also shares strong 
similarities with the model outputs produced with the 5-parameters estimated in this 
section, as seen in Figure 3.5. The shape of the prevalence curves for this set of 5- 
parameter estimation, for each of the sub-populations X(t), Y(t), Y(t), A(t), and Z(t) are 
the same as seen in Figure 3.3, with a marginal improvement in height i.e. total HIV 
prevalence in 2002 (rounded to nearest integer) = Y(2002) + V(2002) + A(2002) + 
Z(2002) = 8288 + 6978 + 129 + 829 = 16,224 (compared with 16,136 in section 3.5.1) 
for the minimization of the AIDS and HIV x2 and 7432 + 6290 + 129 + 779 = 14,630 
(compared with 14,356 in section 3.5.1) for the minimization of the AIDS, HIV and 
deaths from AIDS x2* However, the expected prevalences still show a slight
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parameter estimation on A, ai978, pc, r and co.
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Figure 3.5 Sub-population prevalence trajectories subject to 5-parameter estimation 
on A, ai9 7g, pc, r and to.
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declining trend in numbers, which compared with observed data is known to be untrue. 
The growth in prevalence could be as a result of a reduced death rate in this second set of 
estimated parameters (cd = 0.97 from a previous value of 1). A lower death rate implies 
fewer people leaving the model, which means that more individuals are staying within the 
A(t) and Z(t) sub-populations (i.e. people are living with AIDS for longer periods of 
time), thus, at time t, more people will be living with HIV/AIDS than they were 
previously. Also, a slightly larger entry rate (A = 1149 in section 3.5.1 when estimating X 
and N 1978 separately, assuming A = AN 1 9 7 8 , but under the assumption that A ^  AN 19 7 8 , 
estimating the entry rate independently, A = 1210) concurs with more people entering the 
model, resulting in a larger number of Susceptibles, thus implying more infections of 
HIV which results in more people living with HIV/AIDS at any one point in time.
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A.3.1 Visual Basic Script within the program of the Cardiff Model
Within this appendix, only the most important parts of the program are depicted since the 
program in its entirety is extremely long, totalling more than 1000 lines of code. The 
Visual Basic Script within the program of the Cardiff Model and subsequent MLE code 
was developed completely from scratch for the purpose of this work, taking more than 1 2  
months to yield the final version. A copy of this program is available from the author on 
request; contact the School of Mathematics, within Cardiff University, for further details 
at: Mathematics@cardiff.ac.uk.
First, define the initial conditions. The parameters that are to be estimated are shown in 
coloured text.
NDT% = 52 
DT = (1 / NDT%) 
nyrs% = 50 
Incub = 11.4 
lam = 0.1 
LAMSTOR = lam 
mul = 0.003 
mu2 = (0.03+ 0.1) 
nu2 = 0.1 
nu3 = 0.5 
theta = 0.03
b = 0.5 ‘proportion
g = 0.1 ‘proportion
omeg = 1
m% = 6
r=  1.27
RSTOR = r
rl = r * Incub
gam = (m% / rl)
Betac = 2
BETACSTOR = Betac 
N =  11490 
NSTOR = N 
LN = N* lam 
year0% = 1978 
YINIT= 1000 
YINITSTOR = YINIT 
NOBS% = 24
‘number of time steps per year 
‘time increment 
‘duration in years 
‘incubation period (in yrs)
‘arrival rate per year to susceptibles, X 
‘store value of X
‘exit rate per year from susceptibles,
‘exit rate from High Risk Infectives, p2 +
‘entry rate to LR infectives from HR infectives, x>2 
‘entry rate to LR AIDS cases from HR AIDS cases, 0 3  
‘exit rate from low risk infectives, p.2 
of HR infectives who stay HR on diagnosis with AIDS 
of LR infectives who become HR on diagnosis with AIDS 
‘death rate, co
‘number of incubation stages 
‘treatment effect on all y\
‘store value of r
‘lengthened incubation period due to treatment 
‘incubation rate per stage, yi 
‘ Infectivity rate, pc 
‘store value of Pc
‘Initial size of high-risk population, N 1978 
‘store value of N 1978 
‘calculation of the entry rate, A 
‘start year
‘initial number of high-risk infectives, ai978
‘store value of a 1978
‘Number of years of AIDS data
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NHOBS% = 24 ‘Number of years of HIV data
NDOBS% = 24 ‘Number of years of Deaths data
INCN = 0.001 ‘Increment for N
INCB = 0.01 ‘Increment for Pc
INCY0 = 0.01 ‘Increment for Y0
INCR = 0.01 ‘Increment for r
INCLAM = 0.01 ‘Increment for X
Next, definition o f arrays, including the observed data sets, before initial conditions and 
values fo r  all sub-populations, including the allocation o f  the initial infectives, are set.
Rho = Betac / gam ‘calculation of p
Rhol = 1 4 -  Rho ‘calculation of pi = 1 + p
YOLD(l) = (YINIT * Rho) / Rhol ‘allocation of initial infectives
For J2% = 2 To m%:
YOLD(J2%) = YOLD(J2% -1) / Rhol:
Next J2%
YOLDSUM = 0 ‘calculation of total number of infectives
For J2% = 1 To m%:
YOLDSUM = YOLDSUM + YOLD(J2%):
Next J2%
XOLD = N -  YOLDSUM ‘initial value for the susceptible population
Main Program, calculation o f  differential-difference equations.
For J% = 1 To nyrs% * NDT%
Year% = Int((J% / NDT%) + 0 .001)
MX = mul * XOLD
BCXY = (Betac * XOLD * SYOLD / (XOLD + SYOLD))
XNEW = XOLD + ((LN - MX - BCXY) * DT)
‘calculation of X(t) 
YNEW(l) = YOLD(l) + (BCXY - ((gam + mu2) * YOLD(l))) * DT
‘ calculation of Y i (t)
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VNEW(l) = VOLD(l) + (nu2 * YOLD(l) - (gam + theta) * VOLD(l)) * DT
‘calculation of Vi(t)
For i% = 2 To m%
YNEW(i%) = YOLD(i%) + (gam * YOLD(i% -1) - (gam + mu2) * YOLD(i%)) *
DT
‘calculation of Yi(t), i=2,.. . , 6  
VNEW(i%) = VOLD(i%) + (gam * VOLD(i% - 1 ) +  nu2 * YOLD(i%) - (gam + 
theta) * VOLD(i%)) * DT
‘calculation of Vj(t), i=2,.. . , 6
Next i%
For i% = 1 To m%
SYNEW = SYNEW + YNEW(i%)
S VNEW = SVNEW + VNEW(i%)
Next i%
AZNEW = AZOLD + (b*gam*YOLD(m%) + g*gam*VOLD(m%) -  (omeg + nu3) * 
AZOLD) * DT
‘calculation of A(t)
ZNEW = ZOLD + ((1 - b)*gam* YOLD(m%) + (1 - g)*gam*VOLD(m%) + nu3 * 
AZOLD -  omeg * ZOLD) * DT
‘calculation of Z(t)
NEWAZ = gam * (YOLD(m%) + VOLD(m%)) * DT
‘new AIDS cases per time increment
NEWY1 = BCXY * DT
‘new HIV infectives per time increment 
NEWD = (omeg * (AZOLD + ZOLD)) * DT
‘new deaths per time increment 
AIDSUM = AIDSUM + NEWAZ ‘total AIDS cases
HIVSUM = HIVSUM + NEWY1 ‘total HIV infectives
DEATHSUM = DEATHSUM + NEWD ‘total deaths
If J% Mod NDT% = 0 Then 
Jl%  = Jl%  + 1
NEWAIDS(J1 %) = AIDSUM -  CUMAIDS ‘New expected AIDS cases
NEWHTV(J1%) = HIVSUM -  CUMHIV ‘New expected HIV infections
NEWDEATHS(J 1 %) = DEATHSUM -  CUMDEATH ‘New expected Deaths
Re-set values before next iteration. 5 parameter MLE calculations.
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For i% = 1 To nyrs%
NEWAIDSTOR(i%) = NEWAIDS(i%)
NEWDEATHSTOR(i%) = NEWDEATHS(i%)
NE WHIV STOR(i%) = NEWHIV(i%)
Next i% ‘storing values of AIDS, HIV and Deaths for comparison with small
changes in parameter values, i.e. partial derivatives and calculation of 
chi-square.
N = N * (1 + INCN)
For i% = 1 To nyrs%:
DABYDN(i%) = (NEWAIDS(i%) - NEWAIDSTOR(i%)) / (INCN * NSTOR): Next i% 
N = NSTOR
Betac = Betac * (1 + INCB)
For i% = 1 To nyrs%:
DABYDB(i%) = (NEWAIDS(i%) - NEWAIDSTOR(i%)) / (INCB * BETACSTOR):
Next i%
N = NSTOR
Betac = BETACSTOR
YINIT = YINIT * (1 + INCYO)
For i% = 1 To nyrs%:
DABYDY0(i%) = (NEWAIDS(i%) - NEWAIDSTOR(i%)) / (INCYO * YINITSTOR):
Next i%
N = NSTOR
Betac = BETACSTOR
YINIT = YINITSTOR
r = r * (1 + INCR)
For i% = 1 To nyrs%:
DABYDR(i%) = (NEWAIDS(i%) - NEWAIDSTOR(i%)) / (INCR * RSTOR): Next i%
N = NSTOR 
Betac = BETACSTOR 
YINIT = YINITSTOR 
r = RSTOR
lam = lam * (1 + INCLAM)
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For i% = 1 To nyrs%:
DABYDLAM(i%) = (NEWAIDS(i%) - NEWAIDSTOR(i%)) / (INCLAM *
LAMSTOR)
N = NSTOR 
Betac = BETACSTOR 
YINIT = YINITSTOR 
r = RSTOR 
lam = LAMSTOR
Calculation o f the Information matrix elements using partial derivatives.
111=111+ (DABYDN(I2%) A 2) / NEWAIDSTOR(I2%)
112 = 112 + (DABYDB(I2%) * DABYDN(I2%)) / NEWAIDSTOR(I2%)
113 = 113 + (DABYDY0(12%) * DABYDN(I2%)) / NEWAIDSTOR(I2%)
114 = 114 + (DABYDR(I2%) * DABYDN(I2%)) / NEWAIDSTOR(I2%)
115 = 115 + (DABYDLAM(I2%) * DABYDN(I2%)) / NEWAIDSTOR(I2%) 
121 =  112
122 = 122 + (DABYDB(I2%)A 2) / NEWAIDSTOR(I2%)
123 = 123 + (DABYDY0(12%) * DABYDB(I2%)) / NEWAIDSTOR(I2%)
124 = 124 + (DABYDR(I2%) * DABYDB(I2%)) / NEWAIDSTOR(I2%)
125 = 125 + (DABYDLAM(I2%) * DABYDB(I2%)) / NEWAIDSTOR(I2%)
131 =113
132 = 123
133 = 133 + (DABYDY0(12%) A 2) / NEWAIDSTOR(I2%)
134 = 134 + (DABYDR(I2%) * DAB YD Y 0(12%)) / NEWAIDSTOR(I2%)
135 = 135 + (DABYDLAM(I2%) * DAB YD Y 0(12%)) / NEWAIDSTOR(I2%)
141 = 114
142 = 124
143 = 134
144 = 144 + (DABYDR(I2%)A 2) / NEWAIDSTOR(I2%)
145 = 145 + (DABYDLAM(I2%) * DABYDR(I2%)) / NEWAIDSTOR(I2%)
151 =115
152 = 125
153 = 135
154 = 145
155 = 155 + (DABYDLAM(I2%) A 2) / NEWAIDSTOR(I2%)
Calculation o f elements in vector S.
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DLBYDN = DLBYDN + (0(11%) / NEWAIDSTOR(I2%) - 1) * DABYDN(I2%) 
DLBYDB = DLBYDB + (0(11%) / NEWAIDSTOR(I2%) -1) * DABYDB(I2%) 
DLBYDR = DLBYDR + (0(11%) / NEWAIDSTOR(I2%) - 1) * DABYDR(I2%) 
DLBYDYO = DLBYDYO + (0(11%) / NEWAIDSTOR(I2%) -1) * DAB YD Y 0(12%) 
DLBYDLAM = DLBYDLAM + (0(11%) / NEWAIDSTOR(I2%) -1) *
DABYDLAM(I2%)
MINVERSE performed on excel Sheet 1 before reading in values, also MMult o f inverse 
and S matrix performed on excel Sheet 1 to get correction values.
NCOR = Worksheets(" Sheet 1 ").Cells(2, 15) 
BCOR = Worksheets("Sheetl ").Cells(3, 15) 
YOCOR = Worksheets(" Sheet l").Cells(4, 15) 
RCOR = Worksheets(" Sheet 1 ").Cells(5, 15) 
LAMCOR = Worksheets(" Sheet 1 ").Cells(6 , 15)
N1 = NSTOR + NCOR
BETAC 1 = BETACSTOR + BCOR
Rl = RSTOR + RCOR
YINIT 1 = YINITSTOR + YOCOR
LAM1 = LAMSTOR + LAMCOR
End Sub
‘new suggested value for N 1978 
‘new suggested value for Pc 
‘new suggested value for r 
‘new suggested value for ai9 7 8  
‘new suggested value for X
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CHAPTER 4
THE FINAL FIT OF THE CARDIFF HIV/AIDS 
EPIDEMIC MODEL
The previous chapter brings to light some limitations of implementing a 5-parameter 
MLE process within the fitting of the HIV/AIDS Epidemic model, i.e. the assumption of 
constant parameter values over all time. Also, assessing a large number of parameters at 
once may increase uncertainty in their final estimated value due to the interactions 
between parameters that occur during the estimation process and the fact that less is 
assumed known within the epidemic model. Furthermore, the question of which 5 
parameters to estimate needs to be considered. Some parameters, such as the death rate, 
co, cause complications if introduced into the MLE technique due to the lack of effect a 
change in value of this parameter has on the estimated AIDS Incidence. In addition, the 
death rate in particular can be analysed directly from AIDS data by investigating the ratio 
between the numbers of deaths from AIDS and the total number of people living with 
AIDS, within a time period of a year. However, due to the introduction of treatments, it 
is unrealistic to assume an average constant estimate for the death rate based on all time, 
1979-2002. Consequently, further work on the death rate is undertaken within this 
chapter, including a comparison between values of co estimated within the model and 
extracted directly from observed AIDS data.
Within this chapter, AIDS Incidence is the observed dataset extracted from EuroHIV 
(2003), which the expected AIDS Incidence, generated by the Cardiff HIV/AIDS model, 
is fitted to, subject to alterations in parameter values. Additionally, HIV Incidence 
(extracted from the same dataset) can be incorporated into this fit by measuring a 
combined goodness of fit between observed and expected AIDS, and HIV, Incidence. A 
chi-square value is calculated over all time periods for the fit between AIDS Incidence 
(1979-2002) and HIV Incidence (1995-2002). This total x2  is then minimised to obtain 
the best compromised fit for AIDS and HIV data. In addition, later on in this chapter, the 
involvement of a chi-square value with respect to observed and expected deaths from 
AIDS is considered.
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4.1 Parameter Estimation
The model is split into time eras to overcome the limitation of maximum likelihood 
estimation, i.e. that of constant parameter values over all time. For each time period 
separate MLE’s are calculated, then all time eras are linked together, using smoothing 
techniques, to create a unified time model. The HIV/AIDS Epidemic lends itself to the 
division of time in accordance with the introduction of treatments in 1987 and 1995, as 
well as observed changes in behaviour and attitudes towards the disease. Consequently, 
the Cardiff model has been split into three different time eras: Pre-treatment era (1978- 
1986) - which covers the period from the start o f the epidemic, before any treatments 
were available; Early Treatment era (1987-1994) - relating to the founding of the first 
antiretroviral drug, zidovudine (AZT) in 1987, the start of mono-therapy and the 
commencement of treatments such as prophylaxis in 1988; and Combination Treatment 
era (1995-2002) -  concurrent with the introduction of combination ‘cocktail’ therapies in 
1995 and the instigation of highly active antiretroviral treatments (HAART). Figure 4.1, 
overleaf, demonstrates the separating of these time eras and the order of estimation that is 
employed for the work within this chapter. The four parameters chosen for estimation,
A, ai9 7 g, Pc and r, were chosen due to their difficulty to be evaluated from other resources 
and their significance within the model, in particular with regard to changing behaviours 
and the effect of new treatments being introduced. The entry rate into the High Risk 
Susceptibles, A, and the number of High Risk Infectives at the end of year 1978, ai97 g, 
can both be assumed to uphold a constant value over all time, 1978-2002, and so are 
estimated only once throughout the entire stretch of the model. The infectivity 
parameter, pc, however, is expected to have significantly reduced in value (Winkelstein 
et al. 1988) after public awareness campaigns and media attention were directed towards 
the HIV/AIDS disease in the mid 1980’s. Specifically, in 1985/1986, a government 
operation promoting safe sex (Johnson & Gill 1989; Evans et al. 1993) is believed to 
have changed the attitudes and behaviours of homo/bisexual men in the UK, resulting in 
a reduction in the number of sexual contacts per individual, c, and thus, a fall in the total 
value of pc. Thus, Pc is estimated twice throughout the entire time period, firstly from 
1978-1986 (Pci) and secondly from 1987-2002 (PC2 ), with this second value of pc 
assuming a value smaller than, or equal to, that of the first, i.e. pci > pC2 . Of course, the
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change in behaviour of the homo/bisexual population in the UK did not occur overnight; 
therefore, a smoothing technique has been applied to the change in value from pci to |3c2 
to avoid abrupt amendments in the model. Over the two years surrounding the change in 
parameter value (1987-1988), starting at the beginning of 1987, pci drops a small and 
equal amount each time increment of one week until it reaches its new value of (3c2 two 
years later. That is, a linear weekly decrease in the value of the infectivity rate, pc, 
during the years 1987 and 1988, of:
The treatment effect in the model, r, where r is the product of the incubation period (IP) 
in the calculation of the stage transition rates, yi, is incorporated within the model as 
follows:
where rj is the proportionate increase in length of the incubation period as a result of the 
introduction of new treatments, with respect to stage i of HIV infection;
Yi is the transition rate from stage i to stage i+ 1 , i = 1 , . . . ,  m;
m is the number of stages during HIV infection, i.e. m = 6 ; and
IP is the length of the incubation period of HIV infection prior to treatments.
This treatment effect, r, changes value 3 times throughout the entire time period of the 
epidemic. It starts at a fixed (non-estimated) value of 1, representing the model as it 
would be without a treatment effect; then, in 1987, it is estimated in the MLE process to 
take a value greater than, or equal to, 1 , mimicking an increase in the length of the 
incubation period due to the introduction of early antiretroviral treatments; and then, in 
1995, it is re-estimated to take an even larger value than that in the Early Treatment era, 
with respect to the introduction of combination treatments. In other words, each new 
estimation of r assumes that the IP is increasing in length subject to the two levels of 
treatment introduction, one in 1987 and the next in 1995, i.e. r < rl < r2, where r = 1 in
|/Sfc, -yfifc2|/104
i = 1 ,..., m
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the Pre-treatment era (1978-1986), rl relates to the first estimation of r for the Early 
Treatment era (1987-1994) and r2 represents the second estimation of r for the 
Combination Treatment era (1995-2002). The effect of treatments would not be 
immediate and so, again, a smoothing technique is applied for each transition of value of 
r (from r to r l, and then from rl to r2). A two year smoothing period, from 1987 to 1988, 
is employed for the conversion of r, in the Pre-treatment era, to rl, in the Early Treatment 
era, where the additional linear weekly increments in the value of r, starting at the 
beginning of 1987, are:
|r —rl|/104
For the initiation of combination treatments in 1995, a longer time for the changeover in 
value of r is incorporated within the model due to the fact that the effect of new remedies 
is not just witnessed in the initial impact of highly active antiretroviral therapies but also 
in the changing infective population to one in an earlier stage of HIV infection, implying 
that as time progresses the effect of treatments continues to lengthen the incubation 
period. That is to say, as a result of the introduction of cocktail medications in 1995, a 
larger proportion of the population of HIV infectives remain in the earlier stages of HIV 
infection, whilst those in the later stages of HIV infection gradually progress to AIDS, 
resulting in enhanced effectiveness of the new treatments since more of the population 
have an improved health status to work with. Plus, as new HIV infections occur, 
additional benefits are observed due to drug naivety, where individuals have no treatment 
history thus boasting a lack of resistance to antiretrovirals resulting in greater 
effectiveness of combination treatments. Furthermore, the increase in expertise and 
knowledge when treating individuals with a blend of antiretrovirals permits even more 
substantial results as advanced combinations are being formed and information on drug 
resistance and treatment history is being more efficiently implemented for each 
individual. Consequently, this prolonged effect of new combination medicines is 
represented using a smoothing period of six years. That is, rl increases to its new value, 
r2 , over six years, with each weekly rise in value equated by:
|H -r 2 |/3 1 2
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Moreover, previously it was assumed that each stage within the HIV infective category 
was of equal length, that is, the IP was constant staged (with 6  stages in total). However, 
the introduction of highly active antiretroviral therapies have confirmed this assumption 
to be unrealistic due to the fact that an individual living with stage 1 of HIV infection will 
be expected to react differently to the new treatments than an individual living with stage 
6  of HIV infection. It is likely that an individual in the last stage of progression through 
the course of HIV will have a poorer health status and will consequently not react as well 
to new-found medications when compared to a healthier individual. Also, an individual 
in stage 6  of HIV infection will have lived with the virus for some time, say 
approximately 1 0  years, and have been administered throughout most of this time with 
early treatments such as single dose antiretrovirals (mono-therapy), thus the occurrence 
of complications with drug resistance and toxicities might be apparent, resulting in a less 
reactive response to the new combination therapies. This idea of a delayed impact on 
those in the final stage of HIV infection is incorporated within the parameter estimation 
process by allowing r to take two values at the same time; rj relating to stages 1 to 5 of 
HIV infection and relating to stage 6  of HIV infection, as demonstrated in equation 4.1 
below.
Identical smoothing increments are added to rl for each of the transition paths, rj and r6 . 
However, the smoothing process is employed one year later for r6  than it is for r* to 
reproduce the concept of delayed reaction times to treatments concerning those 
individuals in the last stage of HIV infection, as illustrated in Figure 4.1. Then, once the 
transition from rl to r2  has taken place (that is, from 2 0 0 1  onwards), the stages are 
assumed to revert back to being equal, that is, yi = 7 2  = ... = 7 6  once more, thus the 
incubation period is assumed to return to being constant staged.
Finally, during the estimation of parameters certain constraints need to be enforced in 
order to maintain realism within the model. For instance, neither of the parameters, the 
entry rate into the High Risk Susceptibles, A, or, the number of High Risk Infectives at
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the start of the epidemic, a^g , can take a value of less than zero, as this would suggest 
that individuals are leaving the model before they have entered, or that a negative number 
of people were living with HIV at the end of year 1978. As neither of these 
circumstances is plausible, a non-negativity constraint is placed upon both A and ai9 7 8 . 
The infectivity parameter, pc, is also subject to a non-negativity restriction, in fact, for the 
work within this chapter, it is limited to a value no smaller than 0.5. This is due to the 
assumption that infectivity never drops below this amount, even after the variation in 
behaviours and attitudes that occurred after the mid 1980’s. Reports have suggested, 
however, that Pc could drop to as low as a fifth (Griffiths et al. 2000) after public 
awareness of the virus increased due to advertising campaigns around 1985 (Garfield 
1994). Lastly, the treatment effect, r, is given an upper boundary of 5, since it is deemed 
unrealistic for the effect of treatments to increase the length of the incubation period by 
more than 5 times its original length, suggesting that an individual could potentially live 
with HIV for more than 57 years on average (since, r x IP = 5 x 11.4 = 57 years). The 
complete list of constraints is provided below:
• A, a 1978 > 0, non-negativity,
• pci, Pc2 > 0.5, non-negativity (since both p > 0 and c > 0) plus boundary for 
realism,
• Pci > Pc2 , where Pci is the first estimate of pc and pc2 is the second,
• 1 < rl < r2 < 5, ensuring that as time progresses the value of r is restricted to only 
increase the IP further due to the introduction of treatments, plus an upper 
boundary for realism.
4.2 The Final Fit
Employing maximum likelihood techniques on the parameters, A, ai9 7g, Pc and r, with the 
order of parameter estimation as described in the previous section of this chapter, 
improves the fit between the expected AIDS incidence and the observed AIDS incidence 
data, as attained from the ENAADS dataset (EuroHIV 2003), by suggesting alterations in 
parameter values until the best fit is obtained. The initial conditions and parameter
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values are as listed in Chapter 3, with co = 1 (Snary 2000, Griffiths et al. 2000 and Lowrie 
2000), and all model assumptions remain as previously announced. The goodness of fit 
is measured and the subsequent total x2 value is minimised for AIDS and HIV incidence 
data over the sum of all years; 1979-2002 for the AIDS incidence fit and 1995-2002 for 
the HIV incidence fit. The final estimated parameter values, that created the best fits for 
AIDS and HIV Incidence, are as follows:
A =1665 
&1978 = 405 
Pci = 1.28 
Pc2 = 0.5 
r l = 1.23 
r2 = 4.89
The entry rate into the High Risk Susceptibles, A; the number of HIV positive individuals 
at the beginning of the epidemic, a^g ; and the infectivity parameter from the start of the 
epidemic, prior to a change in behaviour, Pci, all coincide with reported suggested values. 
If we take the entry rate in its simplest form, A = A.N1 9 7 8, and assume that X = pi such that 
the arrival rate equals the exit rate of the susceptible sub-population as it would if the 
HIV/AIDS epidemic was not being considered, then X = pi = 0.003, as obtained from 
population statistics (DH1 2002) for the exit (death) rate from the general population.
This means that the total number of homosexuals in the population at the beginning of the 
epidemic is equal to N 197 8 = AIX = 1665/0.003 = 555,000. For comparison, looking at 
population statistics, the UK has a total male population (aged 15-64) of about 17 million 
(DH1 2002). If we then assume an approximate 2-4% of these men partake in 
homosexual activities (these percentages of homosexual behaviour are based on 
NATSAL surveys undertaken by Wellings et al. 1994 and, more recently, by Erens et al. 
2003, with the results tabulated in section 5.1 of this thesis) then we have a population of 
340,000-680,000 homosexual/bisexual men in the UK. Thus, the estimate of 1665, for 
the entry rate, A, seems to be realistic. In work completed by Snary (2000), the MLE for 
ai9 7 8 was found to be 379, calculated from the yearly AIDS data 1979-1994, and the MLE
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for pc was derived to be 1.257, assuming a constant value over the years 1979-1994. 
Griffiths et a l (2000) set Pc equal to 1, before reducing it when a behavioural change 
occurred in 1985. Thus, the MLE’s obtained during the work in this chapter, based on 
years 1979-2002, have proven to coincide approximately with other work.
During the estimation process, only one of the constraints listed in the previous section 
was put into action; the value of Pc2 reached its lower limit of 0.5. Outside of this, all 
other boundaries that were built in to the model for the estimation procedure were 
adhered to with no need for enforcement. The value of Pc was expected to fall from its 
previous value, and the constraint was placed in order to prevent the new value of Pc to 
drop by too much. In fact, other work by researchers suggests that Pc could drop to a 
value of about 0.4 (Griffiths & Williams 1994); Griffiths et a l (2000) even propose using 
a value of 0 . 2 2  for Pc after the change in behaviour witnessed in the mid 1980’s, so it is 
not surprising that, in the work within this chapter, Pc2 wants to fall to a value below 0.5. 
The value of Pci is supported by the idea that the probability of transmission per contact 
with the virus, p, is approximately 0.1 (Griffiths et a l 2000) and the mean number of 
sexual contacts per homosexual, c, is about 1 0 - 1 2  per year prior to prevention tactics in 
the 1980’s. Dangerfield et a l (2001) explore varying infectivity dependent upon the 
stage of HIV infection; they consider three infective stages within 3 models. Model 1 
assumes a patient moves to a state of advanced HIV disease in the event of therapy 
breakdown; Model 2 assumes a patient moves to a state of late-stage AIDS in the event of 
therapy breakdown; and Model 3 involves separating out patients on HAART according 
to their disease state at the commencement of therapy. Within this work by Dangerfield, 
p is allocated a value of 0.125 for stage 1 of HIV infection in Models 1 and 2 and a value 
of 0.126 in Model 3. The rate of transmission, p, would not be expected to change value 
subject to changes in attitudes or to the introduction of treatments; it is the mean number 
of contacts, c, which is deemed influential throughout this work. With Pc2 = 0.5, we are 
suggesting that the mean number of sexual encounters each year has reduced from about 
12 to 5, due to the impact of government campaigns exposing the virus, how it is 
transmitted and how individuals can prevent transmission.
The increase in value of r from 1 to 1.23, in congruence with the introduction of the first 
antiretroviral drug in 1987, ziduvodine (AZT), and the commencement of other early
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treatments such as prophylaxis against opportunistic infections, relates to an increase in 
the length of the HIV incubation period of 23%. The incubation period (IP) was given an 
initial value of 11.4 years (derived from Snary 2000) for the Pre-treatment era (1979- 
1986). This new value of r (rl) has meant that the HIV IP over the years 1987-1995, in 
the Early Treatment era, is assumed to be 11.4 x 1.23 ~ 14.022 years; meaning an 
individual being treated with early treatments, such as monotherapy, can live with HIV 
more than 2 1/2 years longer than they could before the introduction of treatments. Then, 
in 1995, with the beginning of the Combination Treatment era, the value of r increases to 
4.89 resulting in an increased IP of 11.4 x 4.89 = 55.746 years, postponing the onset of 
AIDS by more than 44 years in comparison to the Pre-treatment era and by a further 41.5 
years in comparison to the Early Treatment era. This implies that an individual 
contracting HIV today can potentially live with HIV infection for 55 years before 
progressing to diagnosis of AIDS. This may seem initially unrealistic, but, in fact, holds 
true to what is being witnessed in clinical research and findings, which suggest the HIV 
incubation period has been lengthened to such an extent that some patients of the virus 
die from non-AIDS causes (Sabin 2002).
These final parameter estimations result in a total minimized x2 value of: 177.3, made up 
of a x2 value of 32.8 (ldp), summed over the years 1979-2002, for the fit between 
observed and expected AIDS incidence and a x2 value of 144.5 (ldp), summed over the 
years 1995-2002, for the fit between observed and expected HIV incidence. Within the 
total AIDS incidence fit, as seen in Figure 4.2, overleaf, separate values for each 
treatment era can be withdrawn as follows: Pre-treatment era (1979-1986) AIDS x2 = 9.5 
(ldp); Early Treatment era (1987-1994) AIDS x2 = 4.8 and Combination Treatment era 
(1995-2002) AIDS x2  = 18.5. It is worthy of note that due to the inclusion of HIV data 
into the fitting process, the original possible overall fit for AIDS incidence is 
compromised somewhat. However, the overall benefits to the model observed when 
including the HIV data, far outweigh this slight cost in AIDS fit, which is still 
outstandingly good. As can be seen from the x2 values, the majority of the ‘bad fit’ for 
the AIDS Incidence data stems from the Combination Treatment era, this could be due to 
a number of reasons, the first being that this time era is coincident with the years for 
which the HIV Incidence fit is also taken into account (1995-2002); the second being that
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Figure 4.2 Fit between Observed and Expected AIDS Incidence
the observed data for the years 1999 onwards are erratic and do not follow a smooth trend 
line, thus resulting in difficulty in matching exact numbers; and thirdly, the last few years 
of observed AIDS data may still be subject to some amount of ambiguity due to under­
reporting and reporting delays.
The fit between observed and expected HIV incidence data is represented in Figure 4.3 
overleaf. This fit is not as close as that of the AIDS Incidence fit partly because HIV 
incidence data is only available for the years 1995-2002 from the ENAADS dataset 
(maintaining consistency with the dataset from which observed AIDS cases were 
extracted). In addition, as with AIDS Incidence, if the HIV Incidence chi-square had 
been minimized independently, without the inclusion of the AIDS Incidence data, then a 
better fit to the eight observed HIV data points would have been witnessed. Thus, the fit 
between observed and expected HIV data is compromised, creating a more accurate and 
realistic overall model of the HIV/AIDS epidemic. Note that HIV data, in general, is 
more uncertain than AIDS data due to the difficulties in ascertaining the date of infection, 
thus it is of greater significance that the model fits the AIDS data than the HIV data. 
Included in Figure 4.3 is the count of new diagnosed cases of HIV, obtained from HPA
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(2005) and by direct contact with the CDSC, which date back to 1985. It is important to 
realize that new HIV diagnoses and HIV incidence are often not consistent with one 
another due to the incongruity between diagnosis of HIV and the point at which HIV 
infection actually occurs mainly resulting from the latent period of HIV, as explained in 
greater detail in section 2.3.1 of this thesis. However, numbers of newly diagnosed HIV 
cases can still be a good approximation to HIV incidence figures; hence, comparisons 
between the expected HIV incidence produced by the model and the observed new 
diagnosed HIV infections attained from HP A, can be of use. Prior to 1985, it is probable 
that a shape, like that seen in the expected HIV incidence curve depicted in Figure 4.3, 
occurs when compared with suggested trends investigated by Snary (2000); Downs & 
Houweling (1997); Day Report (1996); and De Angelis et al. (1998), whom all, in 
general, recommend that HIV incidence numbers peak in 1982/1983 at a level of about 
3500-4500 new HIV cases per year. Post 1983, owing to a government campaign 
promoting safe sex in 1985/1986 (Johnson & Gill 1989; Evans et al. 1993), levels of HIV 
incidence are assumed to have fallen quite rapidly and, in more recent years, have 
maintained their reasonably low, and stable, annual levels of about 1600 cases each year.
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4.2.1 Investigation of the death rate, ©>
Other results can also be extracted from the model, including the expected number of 
deaths from AIDS and the prevalence of HIV/AIDS. These can also be compared with 
observed data counts in order to establish whether the model is fitting the HIV/AIDS 
epidemic realistically. Expected deaths from AIDS, shown in Figure 4.4 overleaf, are 
calculated within the model described by equation 4.2 below, where 5t = 1/52.
i/a i/a
co o+i;z(o .(4.2)
i=1 /=!
Within the initial conditions of the model, the death rate, go was defined to take a value of 
1, based on work by Snary (2000) and Lowrie (2000) and, also, Dangerfield et.al. (2001) 
who suggest a starting mean survival time of 0.9 yr, which corresponds to a mean death 
rate of 1.11 (since mean survival time = 1 / mean death rate). The value of go has not 
been altered or estimated within the model and, consequently, has kept its value as 1 
throughout the fitting process. This may be deemed as unrealistic due to the introduction 
of treatments in 1987 and 1995, which have strong associations with a much reduced 
death rate. Looking at the trajectory of the expected deaths from AIDS numbers with 
co = 1, in Figure 4.4, it is seen that the estimated amounts continually overestimate that 
which is documented by the CDSC to be the actual numbers of deaths from AIDS that 
occur for the years 1985-2002. To improve this fit, as performed for AIDS and HIV 
incidence, observed deaths from AIDS figures, obtained from the CDSC, can be 
employed to investigate a new variable value for go for different time eras throughout the 
epidemic using a goodness of fit measurement for the observed and expected deaths data 
and minimizing the consequent total x2 subject to changes in the value of the death rate, 
co. This process of minimizing the x2 has been performed and the results exemplified in 
Figure 4.4 overleaf. The total x2 value for the fit of deaths from AIDS data reduced from 
817 (when co was fixed at a value of 1 over the entire time period, 1979-2002) to nearly a 
sixth of the amount, 138 (rounded to nearest integer). The improvement in fit was 
created by go initializing at a fixed value of 1 for the Pre-treatment era (1979-1986), 
reducing to a value of 0.6 in the Early Treatment era (1987-1994) and then dropping,
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Figure 4.4 Comparison between observed and expected deaths from AIDS cases
even further, to a value of 0.09 in the Combination Treatment era (1995-2002). As 
previously, smoothing techniques are employed for each change in value of co; a 
smoothing period of 2 years was utilized, (i.e. smoothing periods over the years 1987- 
1988 for the first change in value and 1995-1996 for the second) with the weekly 
decrease in value of co calculated to be:
The first reduction in the value of co, due to the introduction of AZT in 1988, coincides 
with work by Dangerfield et al. (2001) whom assume a change in mean survival from 0.9 
yr to 1.8 yr, equivalently reducing the mean death rate from 1.11 to 0.55. Referring to 
the AIDS/HIV Quarterly Surveillance Tables (HPA 2005), the yearly number of AIDS 
diagnoses and deaths, for all exposure categories, can be found dating back to 1989, as 
well as a cumulative total for the years up to and including 1988. From this, AIDS 
prevalence can be calculated and consequently an average death rate for all years prior to 
1988 and individual death rates for each year 1989-2002 can be produced. In order to
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compare the estimated value of co, as produced within the Cardiff model, with that 
calculated from available AIDS data, Table 4.1 below has been created. The shaded cells 
refer to the years during which the smoothing process for a change in the estimated value 
of co occurs. The value for the death rate labeled within these cells is the value co will 
take by the end of that year, i.e. co reduces from a value of 1 to 0.6 over the years 1987- 
1988 via a linear weekly incremental process, thus by the end of year 1988 co has reached 
its value of 0.6. Note that, during the years 1989-1994, the death rates produced by the 
model are almost twice those extracted from data, this discrepancy can be partly 
explained due to the difference in point of application; the death rates computed from the 
data are calculated by date (or year) of death whereas those created by the model are 
specific to individuals living with AIDS, thus are not expected to be as large in value.
For additional support refer back to Table 2.2, in section 2.4.7 of this thesis, which details 
median UK AIDS survival times for year of diagnosis, over the years 1982-1994.
Table 4.1 Comparison of the value for the death rate, co
Year Death Rate calculated from 
observed AIDS data (3.d.p.)
Death Rate estimated from 
Cardiff HIV/AIDS Model
1988 or earlier 0.591 I o Os
1989 0.355 0.6
1990 0.345 0.6
1991 0.357 0.6
1992 0.347 0.6
1993 0.379 0.6
1994 0.386 0.6
1995 0.383 ' * 0.345
1996 0.348 -----► 0.09
1997 0.193 0.09
1998 0.131 0.09
1999 0.113 0.09
2 0 0 0 0.106 0.09
2 0 0 1 0.099 0.09
2 0 0 2 0.099 0.09
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4.2.2 HIV Prevalence investigation
Figure 4.5 illustrates the fit for HIV/AIDS Prevalence, as produced by the model with co 
variable. Data on observed HIV/AIDS prevalence only dates back to 1996, stemming 
from a variety of sources: PHLS (2002b) provided diagnosed figures for years 1996-1998 
and 2000; CDSC (2000) and DH (2000) provided the 1999 prevalence figure; DH (2002) 
and CDSC (2002) provided data for 2001 and 2002. In addition to these diagnosed 
prevalence figures, it is expected that a number of HIV positive individuals are unaware 
of their status; for the years 1999-2002, total prevalence estimates can be obtained from 
DH (2000) and CDSC (2000) for 1999; PHLS (2002b) for 2000; and DH (2002) and 
CDSC (2002) for 2001 and 2002. These total prevalence estimates (diagnosed and 
undiagnosed), as obtained from the sources listed above for the years 1999-2002, assume 
the following percentages of homosexuals are unaware of their serostatus: 25%; 19%; 
23% and 24% respectively. Figure 4.5 also shows the expected HIV/AIDS Prevalence as 
produced by the model for each year 1996-2002. This is the sum of the prevalence at 
time t in the four infective sub-populations, as defined in equation (4.3).
HTV Prevalence = Y(t) + V(t) + A(t) + Z(t) ... (4.3)
Comparison between observed and expected prevalence is difficult due to the few 
observed statistics available and their inconsistency in origin. However, as an example of 
a possible good fit the percentage of homo/bisexual men unaware of their infection status 
is fixed at a decreasing linear amount each year, starting at 49% unaware in 1996 and 
reducing to 28% unaware by 2002 (falling by 3.5% each year). The reduction in the 
proportions of individuals unaware of their serostatus each year can be argued partly due 
to the improvements in surveillance and testing over time, but also as a result of the 
introduction of treatments; the fear of testing and diagnosis of HIV may have diminished 
due to an increase in confidence of the new treatments available. A proportion of the 
population as large as 49% being unaware of their infection in 1996 can not be validated 
by published literature on the topic; conversely, there is no evidence against this estimate 
of undiagnosed cases.
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Figure 4.5 Comparison between observed and expected HIV Prevalence
The fit between expected and observed HIV prevalence proposed in Figure 4.5 is subject 
to debatable assumptions and inconsistent data sources and so is deemed to be 
questionable. Nevertheless, the apparent fit serves the purpose of acknowledging that the 
expected HIV prevalence, obtained via the model equations, is not too dissimilar from the 
true HIV prevalence that may exist.
4.2.3 The Information Matrix
As an integral part of the MLE process, the information matrix, as defined and discussed
in Chapter 3, is formulated within the iterative procedure 6n+x = 6n + I XS. This
information matrix is reproduced inside an Excel Spreadsheet, where it is inverted and 
read back into the VB script for the deduction of parameter correction values to create 
new and improved estimates, i.e. the multiplication of I' 1 with the matrix containing 
partial derivatives of the log-likelihood function by each parameter to be estimated, S. At 
this point in the program the information matrix and its inverse can be investigated, 
noting that I'1 = V where V is the variance-covariance matrix, in order to calculate the 
standard error (S.E.), as well as forming subsequent confidence intervals (C.I.’s), for each
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parameter estimate, &, and determining the correlation coefficients, within the correlation 
matrix & which measure the extent by which two parameters within the model co-vary. 
Since the work within this Chapter splits the total time period, 1979-2002, into three 
separate time eras, each with their own MLE process, there are three information 
matrices to consider: the first is with respect to the Pre-treatment era (1979-1986), 
denoted Ip; the second is relevant to the Early Treatment era (1987-1994), denoted Ie;and 
the third is respective of the Combination Treatment era (1995-2002), denoted Ic. These 
three MLE processes are then linked together to form an overall model of the HIV/AIDS 
epidemic over the year span 1979-2002, allowing some parameters to change value 
between time eras and others to hold a constant value over two, or all three, of the time 
eras, as illustrated in Figure 4.1 earlier on in the Chapter. The three information matrices, 
relating to each time era, are shown below (with figures rounded to 4.s.f.):
A fie i a\91%
A "255.4 33210 105 '
fie, 33210 4318000 13650
ai97S _ 105 13650 43.13 _
A Pc2 a\91% #•1
A '  2640 826000 976.5 287700 '
pc2 826000 267900000 303500 95650000
—e
f l 1978 976.5 303500 368.4 105300
#•1 287700 95650000 105300 34730000
A Pc2 a\91% r2
A '  3142 990800 1028 304800
pc2 990800 321900000 320500 101300000
a\91i 1028 320500 378.9 107000
r2 304800 101300000 107000 35310000
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The respective inverted information matrices, that are the variance-covariance matrices 
for each time era, are then as shown below (to 4.s.f.), using the same sub-script notation 
as previously. From these matrices, the first point to note is the significant difference 
between the variances seen in the Pre-treatment era against those seen in either of the 
Early Treatment era or Combination Treatment era. When calculating the standard error 
(S.E.) for each parameter (to 4.s.f.), those within the Pre-treatment era are found to be 
13.16 for the entry rate, A; 0.1381 for the infectivity rate, Pci; and 13.15 for the number 
of HIV positive individuals at the start of the epidemic, ai9 7g. The S.E.’s relating to A 
and ai9 7 8 are comparatively much larger than the S.E.’s calculated for the other two eras. 
This is due to the fact that the model has only reached the year 1986 in its computations, 
at which point the information matrix is extracted for investigation. This means that the 
model has only had 8 years of data to obtain estimates for A, 0c i and a^g . Since both A 
and a^ g  are eventually being estimated over all three time eras, the larger standard errors 
witnessed in the Pre-treatment era are not of concern, particularly when noting the S.E.’s 
seen for the same parameters within the later Treatment eras.
— p  — p
c = v,
/:■ = v
A PC1 f l 1978
A '-173.3 1.795 —146.1"
ftcx 1.795 0.01908 1.67
^1978 -146.1 1.67 - 172.8_
A fic2 f l 1978 rl
A 0.3404 -0.002222 -0.1101 0.003634
fic2 -0.002222 0.00001581 0.0003591 -0.00002623
f l 1978 -0.1101 0.0003591 0.155 -0.0005466
rl _ 0.003634 -0.00002623 --0.0005466 0.00004382
A fic2 ®1978 r2
A 0.04994 -0.000161 — 0.05534 0.0001983
PC 2 -0.000161 0.0000005543 0.0001695 -0.0000007141
® 1978 -0.05534 0.0001695 0.08191 -0.0002567
r2 0.0001983 -0.0000007141 -0.0002567 0.000001143
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Looking at the variance-covariance matrix relative to the Early Treatment era, Ve, the 
standard errors for A, PC2 , ai9 7 8 and rl are calculated to be 0.5834; 0.003976; 0.3937; and 
0.00662 respectively, as shown in Table 4.2b overleaf. These are much better results for 
A and ai9 7 8 , with significantly less variability than seen for the Pre-treatment era, for 
which the standard errors are displayed in Table 4.2a. Consequently, the parameter 
values estimated within the year range 1987-1994 are considered to be more reliable.
The standard error (S.E.) together with the parameter estimate (A = 1665; Pci =1.28; 
pC2 = 0.5; ai9 7 8 = 405; and rl = 1.23) can be employed to create a confidence interval 
(C.I.) for each MLE, for 95% confidence; these are listed in Tables 4.2a and 4.2b on the 
next page, with all figures to 4.s.f.. The same information is provided for the 
Combination Treatment era as for the Early Treatment era and the Pre-treatment era, as 
seen in Table 4.2c; for this time period the standard errors for each parameter estimate are 
even smaller than observed in the Early Treatment era, being calculated to 4.s.f. to be 
0.2235 for A; 0.0007445 for PC2 ; 0.2862 for ai978; and 0.001069 for r2. In fact, referring 
back to the variance-covariance matrix for this time range, Vc, it is apparent that many of 
the variances and co-variances are approximately zero; specifically, only the variances of 
A and a 1 9 7 8, together with their co-variance, are greater than zero when rounded to 3.d.p. 
All of the standard errors in either the Early Treatment era or the Combination Treatment 
era are appreciably small in terms of their respective maximum likelihood estimates, as is 
confirmed looking at the extremely narrow ranges in the respective confidence intervals 
for each parameter estimate as listed in Tables 4.2b and 4.2c overleaf. In order to help 
explain the reasoning behind the tight scope of the C.I.’s witnessed overleaf, it is 
important to note that the confidence limits listed in Tables 4.2a, 4.2b and 4.2c are 
subject to changing parameter values affecting the minimization of the chi-square. That 
is to say that any alteration in parameter values outside of the range stated by the C.I.’s 
will result in an increased x2 value, calculated from AIDS incidence, HIV incidence and 
deaths from AIDS data. Thus, in order to maintain such a low chi-square value, and 
consequent good fit between expected and observed AIDS, HIV and deaths data, the 
parameters are confined within their respective exceptionally narrow limits.
As a final point, the determinant for each of the variance-covariance matrices can be 
calculated. Interestingly, all three computed determinants result in near zero values, with
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T a b le  4 ,2 a  Investigation of the Information Matrix extracted at end of Pre-
Treatment era, in 1986.
PARAMETER MLE S.E. C.I.
A 1665 13.16 [1639, 1691]
pci 1.28 0.1381 [1.004, 1.556]
A1978 405 13.15 [378.7, 431.3]
T a b le  4 ,2 b  Investigation of the Information Matrix extracted at end of Early
Treatment era, in 1994.
PARAMETER MLE S.E. C.I.
A 1665 0.5834 [1664, 1666]
Pc2 0.5 0.003976 [0.492, 0.508]
a i9 7 8 405 0.3937 [404.2, 405.8]
rl 1.23 0.00662 [1.217, 1.243]
T a b le  4 ,2 c  Investigation of the Information Matrix extracted at end of 
Combination Treatment era, in 2002.
PARAMETER MLE S.E. C.I.
A 1665 0.2235 [1665, 1665]
pc2 0.5 0.0007445 [0.4985, 0.5015]
&1978 405 0.2862 [404.4,405.6]
r2 4.89 0.001069 [4.888,4.892]
the determinant for Vp taking the largest value of 0.001988 (4.s.f.). The reason for these 
low determinants, however, is due to the extremely small values within the respective 
matrices, as opposed to the matrices being singular.
For each of the time eras a correlation matrix, p, can be determined based on the 
respective variance-covariance matrix, V. Again, the same subscript notation as used 
previously is applied to the correlation matrices shown overleaf which dictate the
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correlation coefficients to 4.s.f. These correlation matrices are derived by dividing each 
variance-covariance coefficient within the matrix V by the product of the two relevant 
standard deviations, i.e. entry Vy, relating to the element in the i* row and j* column of 
matrix V, is divided by the product of standard errors, as calculated previously, for the ith 
and j th parameter, hence all of the diagonal elements within the correlation matrix return a 
value of 1. From these matrices, relations between pairs of parameter estimates for each 
time era can be deduced and discussed. To begin with, the only coefficients reasonably 
close to zero (where a zero value coefficient shows independence between parameters) 
relate to the number of people living with HIV at the start of the epidemic, ai9 7 8 , in the 
Early Treatment era. This parameter produces a correlation value of 0.229 for its 
relationship with PC2 ; -0.210 for its relationship with r l; and -0.479 for its relationship 
with A, all rounded to 3.d.p. A positive correlation coefficient means that the two 
associated parameters are positively allied, that is, if one increases then the other wants to 
increase also. For the Pre-treatment era the correlation between ai9 7 8  and 0c 1 is valued at
0.920 (3.d.p.), this demonstrates a strong correspondence between the two parameters 
with its closeness to 1 suggesting a nearly linear association with positive gradient.
A fie, f l 1978
A - 1 0.987 -0.844"
fie, 0.987 - 1 0.920
a\91i -0 .844 0.920 - 1
A fic2 ^1978 r l
A 1 -0 .958 — 0.479 0.941 '
fic, -0.958 1 0.229 -0.996
a\91% -0 .479 0.229 1 - 0 . 2 1 0
rl _ 0.941 -0 .996 - 0 . 2 1 0  1
A fic2 a\91% r l
A 1 -0 .967 -0.865 0.830 "
fic2 -0 .967 1 0.796 -0.897
a\91% -0 .865 0.796 1 -0 .839
r l 0.830 -0.897 -0.839 1
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The connection between these two parameters has dropped to almost a quarter of its 
previous amount by the Early Treatment era (with correlation coefficient equal to 
approximately 0.229 between ai9 7 8  and pC2 for the years 1987-1994) in accordance with 
the change in value of the infectivity rate, reducing from 1.28 to 0.5; the increased length 
of time since the start of the epidemic when ai9 7g played its most vital role; and the 
introduction of a fourth parameter into the estimation process, r l . The coefficient 
between a 1978 and rl seen in the Early Treatment era of -0.210 (3.d.p.), and that witnessed 
between a 1973 and A of -0.479 (3.d.p.) for the same time period, demonstrate negative 
correlation between the two parameters in each set, i.e. as one increases the other wishes 
to decrease in value. By the Combination Treatment era this negative correspondence 
between a 1978 and r2, and that between ai9 7g and A, has strengthened to -0.839 (3.d.p.) 
and -0.865 (3.d.p.) respectively, suggesting a nearly linear association between the two 
parameters in either pair with negative gradient. In addition, the relationship between 
a 1978 and PC2 in the Combination Treatment era has strengthened to take on a correlation 
coefficient of 0.796 (3.d.p.). All other elements, within the correlation matrices on the 
previous page, take on values close to ± 1 , demonstrating the almost complete 
dependence the parameters have on one another. Of all the possible pairings of 
parameters, the sets that have strong negative correspondence (close to -1 ) include:
[A, PC2 ]; [A, ai9 7g]; [pc, r]; and [ai9 7 8 , r], whilst those pairings that have strong positive 
associations (close to +1) only include: [pc, a 1 9 7 3]; [A, Pci]; and [A, r]. These 
relationships between the parameters being estimated seem sensible in terms of the 
compensatory effects on the fit between observed and expected AIDS data. For instance, 
if the entry rate, A, or the length of the incubation period of HIV, r, increases then, in 
order to compensate, the infectivity rate, pc, or the number of infected individuals at the 
start of the epidemic, a 1 9 7 8 , would need to decrease in value to keep the same numbers of 
new AIDS cases. Equally, if the length of the incubation period of HIV, r, increased then 
the entry rate would also need to increase, or if the infectivity rate, Pc, rose then the 
number of infected individuals at the start of the epidemic, ai9 7 g, would need to rise as 
well in order to keep the same fit for AIDS incidence.
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4.3 Extrapolations
Now that a good-fitting, realistic, model has been formulated, it can be used to project the 
short-term future of the HIV/AIDS epidemic, with the assumption that all parameter 
values and conditions remain constant. Predicting HIV incidence, AIDS incidence and 
deaths from AIDS up until the year 2008 (with © variable), as seen in Figure 4.6 overleaf, 
shows that levels of incidence are maintaining the stability witnessed in the last few years 
of the modelled epidemic. This means that, assuming no changes, approximately 1680 
people will become infected with HIV each year whilst AIDS incidence and deaths from 
AIDS figures will remain at 200 new cases each year from now until the final year 
extrapolated, 2008. This may initially seem like a positive trend creating a hopeful 
insight of the epidemic to come. However, when investigated deeper there are further 
predictions that may be cause for concern. Figure 4.7 on the next page shows the 
prevalence of individuals within the sub-populations, X(t), Y(t), V(t), A(t) and Z(t), 
extrapolated to the year 2008. Whilst the number of individuals susceptible to 
HIV/AIDS, X(t), is relatively constant at just under 5000 susceptibles present each year, 
for the later years of the epidemic, and both High Risk and Low Risk AIDS prevalences, 
A(t) and Z(t) respectively, are maintaining low counts over the years leading up to 2008, 
the number of people living with HIV is increasing exponentially year on year. 
Coincident with the introduction of combination therapies in 1995, prevalence, in both 
High Risk and Low Risk HIV Infective categories, Y(t) and V(t) respectively, is rising to 
levels that may be deemed unsustainable in the near future, increasing to amounts never 
reached before. This is not surprising since treatments such as HAART have reportedly 
postponed the onset of AIDS, and/or death, to such an extent that it is now believed that 
virions in the blood can be virtually cleared, given that treatments are initiated early 
enough with the correct knowledge and expertise applied (Gulick et a l 1997; Hammer et 
al 1997). Also, as seen in Figure 4.6, HIV incidence levels are constant, so more and 
more people are gathering in the infective stage of the epidemic. It can also be noted 
from Figure 4.7 that the prevalence of Low Risk Infectives actually overtakes that of the 
High Risk Infectives in 2002, due to the constant transition of individuals from High Risk 
to Low Risk behaviour.
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Figure 4.6 HIV Incidence, AIDS Incidence and deaths from AIDS extrapolated up 
to 2008
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Figure 4.7 Sub-populations extrapolated up to 2008
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Exploring the individual stages of both High and Low Risk HIV infection, as shown 
overleaf in Figures 4.8a and 4.8b, extrapolating up until the year 2008, it can be seen that 
the increasing prevalence in both risk behaviour groups is due mostly to the earlier stages 
of HIV infection increasing exponentially from 1995 onwards. This is not surprising due 
to the concept that the infective population shifts to one in an earlier stage of HIV 
infection in accordance with the introduction of highly active antiretroviral drugs. In 
particular, it is the prevalence of individuals within stage 1 of High Risk HIV infection 
that is the most prominent in its steep inclination, accounting for 6,742 (58%) of the total 
11,677 High Risk Infections prevalent in 2008. The prevalence in stage 2 of High Risk 
HIV infection is also on the increase, but not as significantly as that for stage 1, moreover 
the prevalence in stage 3 is rising slightly, but even less notably than that for stage 2. The 
prevalence within the other stages of High Risk Infection, stages 4, 5 and 6 , seems to be 
diminishing over time, as expected, reaching a combined level of 1058 individuals 
prevalent by 2008, only 9% of the total High Risk prevalence for this year. The Low 
Risk Infective stage prevalence figures, in Figure 4.8b, illustrate the explanations behind 
the exponential increase witnessed in the total Low Risk Infective prevalence. None of 
the 6  stages are reducing in prevalence, in addition to the fact that prevalence in stages 1 , 
2 and 3 of Low Risk Infection is increasing dramatically due to the introduction of 
antiretroviral combination therapy. By 2008, the number of HIV positive people 
partaking in Low Risk activities, living in any of stages 2 to 6  of HIV infection, has 
overtaken the amounts seen in the respective High Risk sub-population. The only 
exception of this is seen in the first stage of HIV infection where just over a third (3,551) 
of the number of homosexuals living with stage 1 of HIV are classified as Low Risk, 
whilst the majority (6,742) are still participating in High Risk sexual activities. This is 
possibly due to the notion that individuals this early on in the progression of HIV may not 
be aware of their serostatus yet and consequently have not changed behaviour, in addition 
to the fact that, even if aware of their infection, they are still reasonably healthy with 
fewer symptoms of disease and suffering less adverse effects and complications from 
drug regimens, thus may be prone to riskier and more frequent sexual behaviour.
As a consequence of the greater prevalence numbers of HIV, future estimates of HIV 
incidence might be set to increase since there are more people living with HIV in the
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Figure 4.8a Stage prevalence within the High Risk Infective category, extrapolated
up until 2008.
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Figure 4.8b Stage prevalence within the Low Risk Infective category, extrapolated 
up until 2008.
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population to infect other people. Furthermore, treatments are improving the health 
status of people living with HIV and, consequently, infectives may be more sexually 
active than before, increasing the risks of further transmission of the virus (per 
individual) into the susceptible population. These behaviours may result in an increase in 
HIV incidence in the future, which would then return an even greater rise in HIV 
prevalence in years to come. Concerns exist as to whether increased levels of HIV 
prevalence, such as suggested in the near future, are sustainable in the long-term. Many 
researchers believe that methods of intervention, such as prevention and awareness 
campaigns, need to be stepped up to meet the levels of success of new treatments in order 
to ensure the continuation of the beneficial treatment results seen so far. The cost of 
treatment for every individual living with HIV in the UK may become unaffordable if 
high prevalence levels persist and, consequently, treatment uptake may diminish if 
prevalence levels continue to rise, resulting in a rapid incline in AIDS incidence and 
deaths from AIDS to unprecedented amounts.
4.4 Cost Discussion
Gazzard & Johnson (2003) support the notion that an increase in new cases of HIV 
combined with a longer expected lifespan for each infected individual results in the mean 
number of people living with HIV/AIDS rising; estimates obtained from the House of 
Commons Health Committee in 2003 predict an increase of 47% between 2000 and 2005 
over all exposure categories (House of Commons 2003). Dr Paul Lister, Network Lead 
Clinician of South West London HIV & GUM Clinical Services Network, states that 
South West London Clinics witnessed a rise of greater than 75% in the number of HIV 
infectives under care between 1996 and 2000. In support of this, Royal Liverpool and 
Broadgreen University Hospitals reported that during 2001-02 the GUM department had 
observed a continued increase in HIV prevalence (House of Commons 2003). 
Troublingly, in response to this increased number of people living with HIV, there has 
been no improvement in the amount of funding for HIV care and management, although 
funding did endeavour to meet the escalation of drug costs. In fact, concern as to the 
effects of under-funding is provided from Homerton University NHS Trust in Hackney
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which testifies that some patients are now being refused access to HIV treatments and 
services on account of increased disease prevalence and demand.
In 2000, the average lifetime treatment cost for a HIV positive individual, which implies 
both spending on drugs and use of hospital resources (inpatient and outpatient), was 
evaluated to be in the range of £135,000 to £181,000 (DH 2001b). As maintained by the 
National Association of NHS Providers of AIDS Care and Treatment (PACT), the annual 
cost of managing a single patient with HIV in the UK is £15,000 (House of Commons 
2003). The overall expenditure on HIV treatment and care in the UK, in 2002-03, was 
estimated to be £345 million, with the prospect of additional diagnoses costing a further 
£30 million (House of Commons 2003). Assessment of cumulative lifetime treatment 
costs by 2007, estimated by The Medical Foundation for AIDS and Sexual Health 
(MEDFASH), suggested that expenses will be greater than £5 billion for individuals 
known to be living with HIV. The cost/benefit of preventing a single case of HIV was 
estimated by MEDFESH to be approximately £0.5 million which agrees with the HPA 
who stated, in 2004, that each HIV infection prevented saves between £500,000 and £1 
million (HPA 2004). MEDFASH then go on to conclude that averting half the annual 
number of existing new infections of HIV would bestow a cost/benefit of £1 billion 
(House of Commons 2003).
The House of Commons Health Committee reports that £165 million was appointed for 
treatment and care of HIV in 2001-02. In contrast to this seemingly large amount of 
money, present estimates are that suppliers of HIV services are under-funded each year 
by around £3,000-5,000 per patient. As the HIV incubation period is lengthened, and 
people are living with HIV for longer, the per-patient rate escalates. Additionally, as new 
increasingly expensive drugs are introduced, such rises in costs are likely to be steeper. 
Consequently, the financial burden caused by the HIV/AIDS epidemic on the NHS is 
increasing; HIV drug therapy is the largest burden on the allocation of funds for treatment 
and care. Continuous money shortages in HIV services, as well as the ever increasing 
price and choice of antiretroviral drugs, results not only in clinicians struggling to advise 
on apposite therapies, but also in necessary funds being redirected from other sexual 
health services (House of Commons 2003). The cost of antiretroviral regimens and the 
impact that this has on health finances has been a popular area of debate for many years
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(Beck et al. 1994a, 1994b, 1996 and Beck & Mandalia 2003); recently, a 
pharmacoeconomic study suggested that the increase in expenditure on drugs experienced 
due to the introduction of HAART, has been compensated by the changing proportions of 
people using either inpatient or outpatient services (Beck & Mandalia 2003). Then again, 
the same article demonstrated that because the usage of new drugs and regimens are 
increasing (salvage therapy, for instance), drug costs may rise even further (Beck & 
Mandalia 2003, Youle 2001).
Increasing costs of HIV treatment and care in the UK are problematic for the NHS, which 
has limited resources available. Furthermore, ring-fenced funding for HIV treatment 
from the rest of a health authority’s budget ended in 2 0 0 2  and changes to the 
commissioning of HIV services were seen (All-Party Parliamentary Group on AIDS 
2003, House of Commons 2003). The House of Commons Health Committee (2003) 
explains that Primary Care Trusts (PCTs) are now obliged to budget services for HIV 
positive individuals via mainstream allocations. The concern of many researchers in the 
field is the detrimental effect on HIV/AIDS service provision that the conclusion of ring- 
fenced funding will bring, even with assurances from the Department that investments in 
HIV treatment and prevention will be monitored (House of Commons 2003). Budget 
increases have been pledged to the NHS from 2002 to 2007, however, the sum of money 
that will be accessible for HIV services at this time is unsure, particularly as HIV 
treatment and care competes directly for funding with other services, possibly not being 
viewed compassionately as a result of the ongoing stigma linked with the disease (All- 
Party Parliamentary Group on AIDS 2003).
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CHAPTER 5
WHAT-IF SCENARIOS
Within Chapter 4, the final Cardiff model was produced with parameter values either 
derived from previous literature, population statistics or maximum likelihood estimation. 
Within this chapter, the composed model is employed in order to predict the path of the 
HIV/AIDS epidemic over the near future given the occurrence of specific potential 
situations. For instance, the number of homo/bisexual men in the UK population could 
change or the behaviour of individuals might be modified as a result of future possible 
prevention campaigns. The most probable scenarios that may arise can be deduced by 
researching modem literature on the HIV/AIDS epidemic; looking at trends in other STI’s; 
examining HIV/AIDS specific organizational web-sites and publications; surveying 
government policies and priorities towards HIV/AIDS, with specific regard to the 
availability of funding; and investigating changes in population statistics. The four most 
likely modifications that may be witnessed in the near future are: A change in the number 
of homosexuals living in the UK (either increasing or decreasing); an increase or a decrease 
in risky sexual behaviour; the introduction of a preventive vaccine; or the introduction of a 
therapeutic vaccine. Each of these situations is considered individually within this chapter 
to see the effect that alterations in the value of the relevant parameters will have on the 
epidemic’s future path. All other parameters are assumed to maintain their previous values, 
as defined in Chapters 3 and 4. Forecasts will be made up until the year 2012, under the 
assumption that each change in the epidemic occurs in 2005, with a two year smoothing 
period from 2005 to 2007, giving a five year projection from 2007 to 2012, with the new 
constant parameter values in place.
The model derived in Chapter 4 was based upon AIDS incidence data relating to the year 
span 1979-2002, with base year 1978. Figures 5.1a, 5.1b and 5.1c show the extrapolated 
trajectories of the model up until the year 2 0 1 2 , assuming no change in parameter values.
It is worth noting that the epidemic’s course, seen in these Figures up until 2002, will not 
be affected by any future change in parameter values, thus, in order to illustrate only the 
time era when the epidemics path is influenced by changing parameter values, each ‘what- 
i f  scenario is displayed in Figure form relating to the 10 years 2002-2012 only.
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Figure 5.1a Cardiff Model trajectories for prevalence in sub-populations, 1978-2012.
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Figure 5.1b Trajectories for HIV/AIDS incidence and deaths from AIDS, 1978-2012.
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Figure 5.1c Cardiff Model trajectory for total HIV/AIDS prevalence, 1978-2012.
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5.1 Change in the Entry Rate
Assessments on changing sexual behaviour in Britain are detailed on the Avert.org website 
(AVERT 2005b). The fact sheet provided within this web-page investigates how many gay 
and lesbian people live in the UK and how this sub-population of individuals is changing 
its proportion within the total UK population. Wellings et a l (1994) undertook a National 
Survey of Sexual Attitudes and Lifestyles (NATSAL) observing a cross section of almost 
19,000 individuals throughout Britain in order to examine their perceptions on sexual 
encounters, including homosexual relationships, between 1989 and 1990. A second 
NATSAL study was repeated between 1999 and 2001 (Erens et al. 2003) with a subject 
group of just over 11,000 people. Table 5.1 overleaf compares the results of both studies, 
illustrating how same sex sexual behaviour in the British male population is shifting. In the 
2000 NATSAL study, a larger proportion of men admitted to having had a homosexual 
experience than they did in the 1990 study, increasing from 5.3% in 1990 to 8.4% in 2000. 
This trend could reflect an increase in homosexual behaviour between 1990 and 2000 
amongst men in Britain and/or that more homo/bisexual men were prepared to report their 
sexual activities in 2000 than they were in 1990. Table 5.2 introduces the concept of age 
into changing sexual behaviour among men in Britain. The differences in reported male 
sexual activities by age group are less obvious than those seen in Table 5.1 (without 
considering age), with the average proportion of men participating in homosexual sexual 
activities for 2000 being the same as it was in 1990 (4.3%). What one can construe from 
the male data seen in Table 5.2, is that homosexual encounters occur far more often for 
individuals older than 18 years of age; 5.6% of young men aged between 18-19 years and 
6.3% of those aged between 20-24 years are both higher proportions than the total 16-24 
year old average of 4.3%. Under reporting is likely to occur during surveys such as the 
NATSAL studies, possibly due to ongoing prejudice against the gay community in the UK. 
Thus, the data represented in Tables 5.1 and 5.2 is considered to be an underestimation of 
the true proportions of homosexual activity amongst men in Britain.
It is possible that one of the main reasons for the apparent increase in the male homosexual 
population in Britain is down to status acceptance amongst the UK inhabitants. More 
homo/bisexual men feel able to confront their sexuality, possibly as a result of two major 
changes which have taken place in the UK (and other parts of Europe and the United States
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NATSAL I 
(%) 1990
NATSAL II 
(%) 2 0 0 0
Ever had a sexual experience, not necessarily 
including genital contact, with a partner of the same 
sex?
5.3 8.4
Ever had sex with a same sex partner, including 
genital contact? 3.7 6.3
Have you had a same sex partner in the last five 
years? 1.4 2.6
Table 5.1 Findings of NATSAL surveys among men in Britain.
NATSAL I NATSAL II (%) 2000
(%) 1990 16-
17yrs
18-
19yrs
2 0 -
24yrs
Average, 
16-24 yrs
Ever had a sexual experience 
with a same sex partner? 4.3 1.2 5.6 6.3 4.3
Ever had sexual 
intercourse/genital contact with 
a same sex partner?
2.4 1.2 2.3 4.2 2.6
Table 5.2 Findings of NATSAL surveys among 16-24 year old men in Britain.
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of America) over recent years, these are (AVERT 2005b):
• More frequent imagery of gay and lesbian people (e.g. popular gay musicians and 
gay characters in mainstream television shows)
• More gay and lesbian strives for equality which attracts public, political and legal 
attention (e.g. the demand for parenting and marital rights).
Within this section the focus is on a change in the entry rate to the epidemic model due to 
the idea that the homosexual population in the UK has either grown or reduced in size, as 
discussed in the previous literature. These same concepts can be applied to changing 
sexual behaviour of homosexual men, however may not be directly linked to greater or 
lesser risk-taking. The notion of more or fewer homo/bisexual men partaking in high risk 
sexual activities is considered in the next section, specifically looking at the effect of a 
change in the infectivity rate, Pc. In order to model the possibility of an increasing (or 
decreasing) homosexual population in the UK, the entry rate into the High Risk Susceptible 
category, A, can be enlarged or reduced accordingly. The change in value of the entry rate 
occurs in 2005, assuming the homo/bisexual population increases or decreases at this time, 
and takes two years of weekly linear increments before reaching its final value of either 
±10% on its original value, by 2007. More specifically, A will take the value of 1665 up 
until 2005 (since this is the value it was estimated to be in Chapter 4, using MLE) at which 
point it will begin its transformation over two years, 2005-2006, to form its new value of 
1665 ± (0.1 x 1665) = 1498.5 or 1831.5, by 2007. The two year transition represents the 
idea that changes in the population do not occur within a single time increment of 1 week, 
but more likely as a steady progression over time, thus avoiding abrupt changes in 
parameter values and smoothing out ‘kinks’. The weekly increment is taken as a linear 
amount, as in Chapter 4, and is calculated for this particular change in parameter value as 
follows:
l A ^ - A j / 1 0 4
Figures 5.2a, 5.2b and 5.2c, incorporated over the next few pages, show the effect on the 
epidemics path when altering the entry rate into the High Risk Susceptibles in this way.
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Figure 5,2a Sub-populations within the Cardiff model with the Entry Rate, A, varying 
from 2005, reaching ±10% by 2007.
Note that up until 2005 all scenarios follow the same path due to the fact that, as yet, there 
have been no modifications performed within the model. It is post 2005 that the effect of 
changing the value of the entry rate, A, by ±10%, or not at all, can be observed.
From Figure 5.2a, it is noticeable that a change in the entry rate from 2005 onwards, of 
±10%, specifically affects the susceptible and infective sub-populations, X(t), Y(t) and 
V(t). However, extrapolating up until the year 2012, there is no apparent effect on the 
AIDS case sub-populations, A(t) or Z(t). This is because different sub-populations within 
the model have different reaction times to a change in parameter value; in particular, a 
change in entry rate will affect the High Risk Susceptible sub-population first and the 
AIDS case sub-populations last. The fact that A(t) or Z(t) do not change prior to 2012 is 
dependent on the length of the HIV stages within Y(t) and V(t); if projected over a longer 
period of time A(t) would change, however, it is not wise to extrapolate beyond 2012 for 
reliability of predictions. Figure 5.2a shows this difference in reaction times, with the 
prevalence of High Risk Susceptibles, X(t), and the prevalence of High Risk Infectives, 
Y(t), reacting in 2006, slightly before the prevalence of Low Risk Infectives ,V(t), which
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does not change until 2010. When the prevalence of ADDS cases eventually shifts from 
their original paths, post 2 0 1 2 , it is expected to be a much more subtle effect than that seen 
on the prevalence of previous sub-populations, due to the diffusion of change that occurs as 
individuals progress through the model en route to the AIDS stage. Looking at Figure 5.2a, 
this dispersion of effect, that a change in entry rate has incurred on the model, is apparent; 
as an individual moves from the High Risk Susceptible category to the High Risk Infective 
category and then, possibly, to the Low Risk Infective category, the effect that a change in 
entry rate has on each sub-population decreases. In 2005, the number of high risk people 
susceptible to HIV, X(t), was estimated to be 4801; this is the same for all scenarios with 
regards to altering the entry rate. Without a change in entry rate and assuming all other 
parameters maintain their constant values as previously stated, the prevalence of High Risk 
Susceptibles is predicted to be 4617 by 2012. This suggests a steady, perhaps slightly 
falling, trend in the number of people participating in high risk activities who are 
susceptible to HIV/AIDS. In comparison to this, the number of High Risk Susceptibles, 
with a change in entry rate, by 2012, is either greater than (if A increased by 10%) or less 
than (if A decreased by 10%) the 4617 prevalence by nearly 500 homosexuals (this is a 
change in prevalence of X(t) of just over 10%). This rise, or fall, in the number of 
Susceptibles has had a consequent effect on the number of High Risk Infectives, Y(t), 
which by 2012 has either increased (if A increased by 10%) or decreased (if A decreased 
by 10%) by approximately 400 people (roughly ± 3%) on its predicted original value of 
12,104 people when no change in entry rate is considered. Furthermore, this change in 
prevalence of High Risk Infectives, Y(t), has affected the prevalence of Low Risk 
Infectives, V(t), which by 2012 is about ± 90 individuals (± 0.55%) on its original 
prediction (assuming no change in entry rate occurs) of 16,308 people.
Figure 5.2b shows the trajectories of HIV incidence, AIDS incidence and deaths from 
AIDS, over the years 2002-2012, considering a change in the entry rate of either ±10%, or 
not at all, in 2005. Similar to Figure 5.2a, AIDS incidence and deaths from AIDS numbers 
do not seem to be affected by a change in entry rate, prior to 2012. This can be explained 
by the delayed and reduced effect that a change in entry rate has on these later stages within 
the model, as with the prevalence of AIDS cases, A(t) and Z(t). HIV incidence, however, 
has significantly altered its course due to a change in entry rate value. The variation begins
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Figure 5.2b HIV, AIDS and deaths cases with the Entry Rate, A, varying from 2005, 
reaching ±10% by 2007.
almost immediately, in 2006, with HIV incidence rising if the entry rate increases by 10% 
in 2005, and falling if the entry rate decreases by 10%. In 2005, the annual number of 
homosexuals predicted to contract HIV is 1678. Assuming no change in entry rate, the 
number of new infections each year is projected to maintain a reasonably stable level, up 
until 2012. In comparison to this, if a 10% rise in entry rate takes place in 2005, then for 
each year after this point (2006 through to 2012) an increase in the annual number of new 
infections is predicted to occur. Similarly, if a 10% fall in entry rate takes place in 2005, 
then HIV incidence is expected to reduce each year. Table 5.3, overleaf, illustrates this 
difference in projected HIV incidence for each year, in terms of the number of HIV 
infections gained or lost subject to a change in entry rate, in addition to the implication in 
terms of costs saved or spent which is provided using knowledge that the cost/benefit per 
single case of HIV infection prevented is estimated to be in the range of £0.5 million to £1 
million (HPA 2004). The table shows that 523 individuals less than the 13,418 predicted to 
contract HIV in the years 2005 to 2012, will become infected with the virus if the entry rate 
reduces by 10% in 2005-2006, equivalent to a reduction in HIV incidence of 3.9%. In
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PROJECTED HIV 
INCIDENCE
CHANGE IN HIV 
INCIDENCE
RANGE OF 
COST/BENEFIT 
(£M)
YEAR
No 
change 
in A
Decrease 
in A by 
10%
Increase 
in A by 
10%
Decrease 
in A by 
10%
Increase 
in A by 
10%
Decrease 
in A by 
10%
Increase 
in A by 
10%
2005 1678 1678 1678 - 0
(-0 % )
0
(0% )
0 0
2006 1680 1676 1683 -4
(-0 .2 % )
3
(0 .2 % )
2 -
4
-1 .5 -
-3
2007 1680 1658 1702 - 2 2
(-1 .3 % )
2 2
(1 .3 % )
1 1 -
2 2
-1 1 -
- 2 2
2008 1680 1626 1732 -54
(-3 .2 % )
52
(3 .1 % )
2 7 -
54
-2 6 -
-52
2009 1678 1596 1758 -82
(-4 .9 % )
80
(4 .8 % )
4 1 -
82
-4 0 -
-80
2010 1676 1572 1779 -104
(-6 .2 % )
103
(6 .1 % )
5 2 -
104
-51.5 — 
-103
2011 1674 1552 1794 - 1 2 2
(-7 .3 % )
1 2 0
(7 .2 % )
6 1 -
1 2 2
-6 0 -
- 1 2 0
2012 1672 1537 1806 -135
(-8 .1 % )
134
(8 % )
67 .5 -
135
-6 7 -
-134
TOTAL 13418 12895 13932 -523
(-3.9%)
514
(3.8%)
261.5-
523
-257-
-514
T a b le  5 .3  Projected HIV incidence and consequent cost implications, resultant from a 
change in entry rate, for the years 2005 -  2012.
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Figure 5.2c HIV/AIDS Prevalence with the Entry Rate, A, varying from 2005, 
reaching ±10% by 2007.
terms of the financial costs avoided as a result of these 523 people not contracting HIV, a 
potential £261.5 - £523 million could be saved in 8 years. Correspondingly, however, if 
the entry rate increases by 10%, then an additional 514 infections are predicted to occur 
over the years 2005 - 2012, equating costs of £257 - £514 million.
Projected HIV/AIDS prevalence is illustrated in Figure 5.2c, with or without a change in 
entry rate in 2005. A significant change in prevalence is not witnessed until 2007, when, as 
expected, an increase in the entry rate results in HIV/AIDS prevalence enlarging to 
amounts greater than it would have reached otherwise, and, similarly, a decrease in the 
entry rate results in HIV/AIDS prevalence shrinking below its otherwise expected 
trajectory. By 2012, dependent upon whether the entry rate has risen; not changed; or 
fallen, extrapolated HIV/AIDS prevalence reaches values of 31,099; 30,617; or 30,126, 
respectively. This means that an increase in entry rate by 10% in 2005 results in the 
number of people living with HIV/AIDS rising by nearly 500 people (1.57%) by the year 
2012. Similarly, a decrease in entry rate by 10% in 2005 results in the number of people 
living with HIV/AIDS falling by nearly 500 (1.6%) by the year 2012.
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5.2 Change in Behaviour and Attitudes
The suggestion of trends is one of increasing risky sexual behaviour resulting in a rise in 
the number of new diagnoses of HIV infection. Dukers et al. (2001) demonstrate this trend 
by showing that after the introduction of combination treatments such as HAART, 
unprotected sex became more common and incidence of STI’s, such as gonorrhea, 
increased among HIV negative and positive men. Interestingly, among HIV infected men, 
once HIV-1 RNA became detectable and CD4 cell counts increased with the use of 
HAART, risky sexual behaviour with casual partners increased. In fact, even if an 
individual was not receiving HAART, unprotected sex with casual partners increased if 
they had high HIV-1 RNA levels (above 105 copies/ml). Glass et al. (2004) confirm that it 
is imperative to understand the mechanisms behind this trend of worsening behaviour.
Some of the potential determinants of sexual conduct, which might help explain a change 
in behaviour, are highlighted by Donovan & Ross (2000) and are listed below:
• Psychosocial factors (procreation/desire/curiosity etc.),
• Evolutionary factors (selective advantage/disadvantage),
• History & Culture (perception of peer behaviour),
• Individual developmental and physiological factors (neurological/hormonal 
factors),
• Intoxicants (alcohol/drugs),
• Particular situation and opportunity,
• Education and knowledge of partners’ (real or potential) infection status.
HIV optimism, as a consequence of new HIV drug therapies such as HAART, has been 
theorised as one possible explanation behind the recent incline in high-risk sexual 
behaviour. In 2002, Elford et al. examined the effect of HIV optimism on sexual behaviour 
among London Gay men between 1998 and 2001 and found that the percentage of men 
declaring high-risk unprotected anal intercourse (UAI) increased from 15.3% to 38.8% for 
HIV-positive men; from 6 .8 % to 12.1% for HIV-negative men; and from 2.1% to 7.7% for 
men who had not been tested before. Of these participants, less than one in three claimed 
to be optimistic about new HIV therapies. Elford et al. (2002) concluded that there was no
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significant difference in the rate of increase of high-risk sexual behaviour, between 1998 
and 2001, for gay men in London, whether optimistic or not. A further aspect of HIV 
optimism, in addition to new drug therapies, is the availability of post exposure prevention 
(PEP), which, too, needs to be considered as a contributable factor to escalating levels of 
risk behaviour among homosexuals. However, Waldo et al. (2000) conclude that, among 
gay men in San Francisco, there is little evidence to suggest that the availability of PEP for 
sexual exposures might be linked to increased sexual risk taking. Perceived viral load, but 
not actual load, is another possible factor related with increasing unprotected sex with 
stable partners of negative (or unknown) HIV status (Stolte et al. 2004), as well as seeking 
sex on the internet being associated with recent increasing STD incidences and high-risk 
sexual behaviour among gay men, both HIV positive and negative, in London (Elford et al. 
2001). In addition to these associations with increasing risky behaviour, HIV testing, in 
particular the voluntary confidential HIV test (VCT), remains strongly related to sub­
populations at high risk (McGarrigle et al. 2005). In a survey produced by Leaity et al.
(2 0 0 0 ), no significant dissimilarities were discovered in the frequency of unprotected 
penetrative sex (UPS) between repeat and first-time testers, except for gay men with a 
history of three or more previous HIV tests, who reported raised levels of risky behaviour. 
Furthermore, an increase in self-testing methods (serving populations who either do not 
have access to, or do not use, facility-based standard VCT services) could additionally 
encourage high-risk behaviour in these sub-populations (Spielberg et al. 2004).
On a more positive side, Leaity et al. (2000) suggest that, repeat HIV testing enables: the 
foundation of seroconcordance with a regular partner (i.e. identical HIV status), thus 
forming an important role in terms of risk reduction; the opportunity to provide HIV test 
counselling to address high-risk behaviour issues and reinforce personal risk-reduction 
approaches; and strategies to reduce undiagnosed prevalent HIV infection (McGarrigle et 
al. 2005). HIV counselling and testing has been shown to improve sexual behaviour 
among people who are HIV positive (Weinhardt et al. 1999 and CDC 2000), whilst for 
HIV negative people, the results on the benefits of counselling are a little more varied. 
Counselling methods need to be modernized in order to maximize effectiveness in reducing 
high-risk sexual behaviour and, consequently, prevention of increasing numbers of new 
infections. As well as counselling, HIV testing can provide the opportunity to encourage
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gay men to participate in negotiated safety (NS). NS refers to a HIV risk reduction strategy 
(Kippax et al. 1993 and 1997) based on two main ethics (Elford et a l 1999):
1. An acknowledgment to only have unprotected anal intercourse (UAI) with their 
regular partner and not with casual partners,
2. Verification that both men in a (regular) relationship are HIV seroconcordant.
Davidovich et al. (2000) investigated the concept that steady relationships provide a 
situation that permits sexual risk-taking, finding that elevated rates of risky UAI were 
coincident with steady partners, even after correcting for NS. Elford et al. (1999) surveyed 
gay men in London gyms, revealing that most homo/bisexual men have adopted the first 
notion of NS (as listed above), but not the second. As a result, greater than 1 in 10 men 
testified to participating in high-risk UAI with their main partner. Thus, Elford et al.
(1999) conclude that HIV prevention strategies should continue to promote NS for gay men 
in a relationship. This notion is supported by most researchers, including: Dukers et al.
(2 0 0 1 ) who confirm the need for readdressing prevention programmes to the requirements 
of HIV infected homosexuals, as well as promoting safe sex prevention messages among 
uninfected men; and Stolte et al. (2004) whom also reinforce the call for pioneering 
prevention activities.
According to a study released on May 13th 2003, by the Global HIV Prevention Working 
Group, HIV/AIDS prevention programmes are reaching fewer than 1 in 5 people at risk of 
HIV infection worldwide (McCarthy 2003). McCarthy (2003) goes on to say that 29-45 
million of HIV incidences predicted between 2003 and 2010 could be avoided if key 
prevention strategies are initiated. For instance: activities that control sexually transmitted 
infections; voluntary counselling and testing; encouragement of harm reduction 
programmes; and promotion of delaying sexual activity, reducing the number of sexual 
partners, and using condoms. Whenever a fully researched behavioural intervention is put 
in place, assuming substantial funding is available, HIV incidence and/or prevalence 
decline (Donovan & Ross 2000); studies by Kegeles et al. (1999), Meda et al. (1999) and 
Celentano et al. (1998) are just a few examples of successful prevention programmes in 
action. For details of specific interventions and preventions that are currently
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recommended for widespread distribution, refer to the CDC’s Division of HIV/AIDS 
Prevention which has produced a Compendium of HIV Prevention Interventions with 
Evidence of Effectiveness (CDC 1999b); most of these, however, are resource exhaustive 
and complex to adapt to the real world (Rietmeijer 2003).
Building on the above information, four ‘what-if scenarios are modelled within this 
section, based upon changing sexual behaviours within the homo/bisexual population in the 
UK, altering the value of the infectivity rate, (3c. More specifically, it is the mean number 
of sexual partners, c, that is expected to be influenced by changing behaviours, rather than 
the rate of transmission of HIV per contact, p. In Chapter 4, pc was estimated, using 
maximum likelihood techniques, to take a value of 1.28 over the years 1978-1986 and a 
value of 0.5 thereafter (with a two year linear smoothing process from 1987-1988). Within 
this chapter, a further change in behaviour is modelled, assuming occurrence in 2005, with 
two year linear smoothing. As at 2005, the value of the infectivity parameter, pc, will 
begin to either increase by 10%; stay the same value as it was previously (0.5); decrease by 
10%; or reduce to a value of zero. These changes in value of pc model the following 
situations respectively: increased risky sexual behaviour as a result of HIV optimism or 
perceived viral load, for instance; non-changing sexual behaviour; decreased risky sexual 
behaviour due to a possible intervention of prevention programmes; or an end to all risky 
sexual behaviour attributable to a highly successful prevention strategy being implemented. 
Since Pc = 0.5 prior to these ‘what-if scenarios taking place in 2005, the resultant change 
in value of Pc will either be: +0.05; 0; -0.05; or -0.5, respectively. These changes in value 
will occur over two years of linear smoothing (2005-2006) adhering to the weekly 
incremental technique as used in Chapter 4 and in the previous section of this Chapter. For 
this specific case, the weekly increments are as follows:
I P c*  —/fc J /1 0 4
Thus, Pc results in a new constant value from 2007 onwards of either: 0.55; 0.5; 0.45; or 0, 
respectively. Figures 5.3a, 5.3b and 5.3c, illustrated within the following pages, show the 
resultant trajectories for each ‘what-if scenario regarding a change in behaviour. The 
prevalence within each sub-population, as seen in Figure 5.3a overleaf, shows many of the
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Figure 5.3a Sub-populations within the Cardiff model with the Infectivity Rate, pc, 
varying from 2005, reaching ±10%, or 0, by 2007.
same reactions to a change in infectivity rate, as they did in Figure 5.2a to a change in entry 
rate. Only the High Risk Susceptible sub-population, X(t), and the Infective (High Risk 
and Low Risk) sub-populations, Y(t) and V(t) respectively, appear to be affected prior to, 
and including, the year 2012. Both the High Risk and Low Risk AIDS case sub­
populations, A(t) and Z(t) respectively, do not alter from their original path, which they 
would follow given no change in parameter values. This lack of effect on AIDS prevalence 
could be resultant of two main contributing factors: firstly, a change in infectivity rate in 
2005 might affect the AIDS prevalence estimates (high risk and low risk), but not prior to 
2012; and secondly, the amount of effect that a change in value of the infectivity rate 
causes is concentrated on the sub-populations closest to it, i.e. High Risk Susceptibles and 
Infectives, with the effect becoming increasingly less the further away a population is from 
the respective parameter, with Low Risk Infectives showing a lesser effect than either High 
Risk Susceptibles or High Risk Infectives, and AIDS cases (High Risk and Low Risk) 
displaying an even slighter effect than Low Risk Infectives. Figure 5.3a illustrates that 
these two principles hold true in terms of the sub-populations affected by a change in
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behaviour, i.e. the effect on Low Risk Infective prevalence, V(t), is delayed and is less 
significant when compared to the effect on High Risk Susceptibles, X(t), and High Risk 
Infectives, Y(t). Looking at all three affected prevalence trajectories (X(t), Y(t) and V(t)), 
the most dramatic effect, not surprisingly, is caused when the infectivity rate is reduced to a 
value of zero. By 2012, the number of High Risk Susceptibles, given no change in the 
value of pc, would be approximately 4617, yet when considering the ‘what-if scenario of a 
highly successful prevention programme being enforced in 2005, resulting in no new 
infections of HIV by 2007, the number of High Risk Susceptibles prevalent reaches 14,585. 
Of even more interest is the number of High Risk homosexuals living with HIV by 2012; 
without a change in behaviour high risk HIV prevalence would have reached 12,104 
people, however, with pc reduced to zero from 2007 onwards, the prevalence significantly 
drops down to less than half that number, that is, by 2012 only 5133 high risk individuals 
would be expected to be living with HIV infection. Furthermore, of the four ‘what-if 
scenarios modelled in this section, only the case where HIV incidence is equivalently 
stopped (that is, Pc drops to zero) reduces the exponential increase that would otherwise 
occur in the Low Risk Infective category; improving the value of the infectivity rate 
noticeably diminishes the incline of low risk HIV prevalence, as seen by the reduction in 
value of pc by 10% in Figure 5.3a, however, it is not until pc is dropped to zero that this 
prevalence stops increasing altogether and even starts to fall by 2012. The suggestion here 
is that new infections of HIV need to be permanently stopped in order to bring the 
HIV/AIDS epidemic under restraint and prevent further escalating prevalence figures. 
When considering a slight increase or decrease in value of Pc, of 10%, caused by either an 
increase in risky sexual behaviours or a decrease in risky sexual behaviours respectively, 
the trajectories of prevalence in the High Risk Susceptible sub-population, High Risk 
Infective sub-population and Low Risk Infective sub-population are affected as one might 
expect. An increase in high risk behaviour of homosexual men results in a decrease in the 
number of high risk susceptibles present in 2012 (4116 people compared to 4617) and an 
increase in the number of homosexual men living with HIV in 2012, for both high risk and 
low risk sub-populations, (12,418 compared to 12,104 and 16,446 compared to 16,308, 
respectively) when evaluated against the prevalence in these sub-populations if no change 
in behaviour occurs. Similarly, a decrease in high risk behaviour of homosexual men
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results in an increase in the number of high risk susceptibles present in 2012 (5205 people 
compared to 4617) and a decrease in the number of homosexual men living with HIV in 
2012, for both high risk and low risk sub-populations, (11,724 compared to 12,104 and 
16,155 compared to 16,308, respectively) when contrasted to the prevalence in these sub­
populations if there was no change in behaviour.
The effect that a change in behaviour has on HIV incidence is seen in Figure 5.3b. Similar 
to the work performed in the previous section, referring to a change in value of the entry 
rate, when the value of the infectivity rate is altered projected AIDS incidence and deaths 
from AIDS estimates are not affected prior to 2012. When Pc begins its transition, in 2005, 
to take on a value of zero, by 2007, HIV incidence immediately drops to zero due to the 
very nature of the infectivity rate parameter. When pc takes on a slightly larger or smaller 
value, of ±10%, the number of new HIV infections reacts by either jumping to a peak of 
1797 new infections in 2008, or falling to a trough of 1552 new infections in 2008, 
respectively, compared to 1680 new infections predicted given no change in behaviour. 
After the extreme count of new cases of HIV in either case, the path of HIV incidence 
gradually begins to curve back to the steady level witnessed if no change in infectivity rate 
occurs. The point where all three trajectories rejoin is not seen prior to the year 2012, but 
the trends of both scenarios (a slight increase in risky behaviour and a slight decrease in 
risky behaviour) suggest that all paths will eventually converge back to the one original 
path, or at least, each scenario will ultimately result in a similar number of HIV incidences 
once the initial impact of the change in value of the infectivity rate has occurred and 
recovery from this impact has taken place. The annual number of new HIV infections with 
regards to each scenario (+10%, no change or -10%) in 2012 are 1707, 1672 or 1617 new 
incidences of HIV, respectively. This trend for HIV incidence to revert back to 
approximately 1675 new HIV infections each year, despite a change in behaviour, is cause 
for concern as well as being beneficial. Considering an uptake in high risk behaviour, for 
such reasons as HIV optimism, perceived viral load or reinforcement through testing 
methods (i.e. repeated negative test results adversely encouraging high-risk individuals to 
maintain, or increase, their risky sexual behaviour), the tendency of HIV incidence 
numbers to maintain their stability is one of a positive nature. However, when considering 
the intervention of prevention programmes having an incomplete effect on HIV
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Figure 5.3b HIV incidence, AIDS incidence and deaths cases with the Infectivity Rate, 
pc, varying from 2005, reaching ±10%, or 0, by 2007.
incidence figures, that is, prevention strategies not being entirely successful and new HIV 
infections still occurring as a consequence, the movement of HIV incidence figures back to 
the steady levels that would have been seen without any such intervention questions the 
effectiveness of prevention tactics when not well-defined or sufficiently funded. On the 
contrary, when a prevention strategy is 100% successful, as modelled by the scenario 
where Pc reaches a permanent value of 0 from 2007 onwards, there is no such apparent 
recovery of HIV incidence. This, however, may be deemed as unrealistic, thus the scenario 
where a number of semi-successful prevention programmes being put into action is 
considered, as demonstrated in Table 5.4 overleaf, with the results imposed onto Figure 
5.3b(2). This idea has been implemented by assuming that every two years, another 
prevention programme, with resultant 10% reduction in the infectivity rate, pc, is 
introduced. It is also assumed that each prevention strategy takes two years to fully 
instigate, hence a two year linear smoothing process is employed for each change in value 
of Pc. As seen in Figure 5.3b(2), the continuous intervention of prevention programmes
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Year Change in pc Value of pc
2004 0 0.5
2005-2006
-10%
\
0.
f
45
2007-2008
-10%
\fiCou “ A J / 1 0 4
0.; •05
2009-2010
-10%
\PcM - /* U /1 0 4
0.3645
2 0 1 1 - 2 0 1 2
-10%
1 /* W - / f c J /1 0 4
0.3? :805
Table 5.4 Changing pc subject to continuous semi-effective prevention programmes.
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Figure 5.3b(2) HIV incidence with the Infectivity Rate, pc, varying from 2005,
reaching ± 1 0 %, 0 , or with continuous semi-effective prevention methods.
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PROJECTED HIV INCIDENCE 
R A N G E  O F  C O S T /B E N E F I T  (£ M )
YEAR
No change 
in pc
Decrease in 
pc by 100%
Decrease in 
pc by 10%
Continual 
Decrease in 
pc by 10%
Increase in 
pc by 10%
2005 1678 1678
0
1678
0
1678
0
1678
0
2006 1680 1253 
2 1 3 .5  - 4 2 7
1638
2 1 - 4 2
1638
2 1 - 4 2
1721 
-20.5 - -41
2007 1680 429 
6 2 5 .5  - 1 2 5 1
1569 
5 5 .5  - 111
1569
5 5 .5 - 1 1 1
1788 
-54 - -104
2008 1680 0
8 4 0  - 1 6 8 0
1552 
6 4  - 1 2 8
1513 
8 3 .5  - 1 6 7
1797 
- 5 8 .5 - - 1 1 7
2009 1678 0
8 3 9  - 1 6 7 8
1574 
5 2  - 1 0 4
1467 
1 0 5 .5  - 211
1767 
-4 4 .5  - -8 9
2010 1676 0
8 3 8  - 1 6 7 6
1591 
4 2 .5  -  8 5
1427 
1 2 4 .5  - 2 4 9
1743 
-3 3 .5  - -6 7
2011 1674 0
8 3 7 - 1 6 7 4
1605 
3 4 .5  - 6 9
1391 
1 4 1 .5  - 2 8 3
1723 
-2 4 .5  - -4 9
2012 1672 0
8 3 6  - 1 6 7 2
1617
2 7 . 5 - 5 5
1359 
1 5 6 .5  - 3 1 3
1707 
- 1 7 .5 - - 3 5
TOTAL 13418 3360
5 0 2 9 - 1 0 0 5 8
12824
2 9 7 - 5 9 4
12042
6 8 8 - 1 3 7 6
13924 
- 2 5 3 - - 5 0 6
T a b le  5.5 Projected HIV incidence and consequent cost implications, resultant from a 
change in infectivity rate, for the years 2005 -  2012.
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inhibit the HIV incidence curve from returning to its previous elevated levels, 
demonstrating that even semi-effective prevention strategies can have a significant effect 
on the number of new HIV infections occurring when considered within a larger 
intervention programme, i.e. a multi-staged prevention programme consisting of numerous 
prevention activities. However, the concern still remains that if the continual prevention 
strategy were to end, or be interrupted for some reason, HIV incidence levels would begin 
to rise again. Table 5.5, on the previous page, illustrates the effect on extrapolated HIV 
incidence over the years 2005 to 2012, resultant from a change in the infectivity rate. Also 
within Table 5.5, a summary of the potential costs in relation to the differing number of 
new HIV cases each year is provided, formulated by multiplying each single case of HIV 
infection prevented by its relevant cost/benefit, estimated to be in the range of £0.5 million 
to £1 million (HPA 2004). Over the time period 2005-2012, a total of 13,418 new HIV 
infections are predicted, if  no change in behaviour occurs; if a slight decrease or increase in 
risky behaviour takes place (i.e. pc decreases or increases by 1 0 % respectively) then this 
total number of new infections either falls to 12,824 (-4.4%) or rises to 13,924 (+3.8%). 
The financial costs associated with such changes in behaviour equate to a potential £297 - 
£594 million saved in 8  years if behaviour becomes less risky (that is, assuming the 
scenario of a prevention programme being enforced which not only stops the trends of 
increasing risk taking but also reduces the present amount of high-risk sexual activities by 
10%) or £253 - £506 million spent, that may be saved if the increase in high-risk sexual 
behaviour is stopped. Even further sums of money could possibly be conserved if a series 
of prevention programmes are introduced, reducing risk taking by 1 0 % every two years. 
For this scenario, extrapolations suggest a total ranging between £ 6 8 8  and £1,376 million 
saved, over the seven years 2005-2012. Furthermore, if new HIV infections are stopped 
altogether by 2007, then an incredible £5,029 - £10,058 million could potentially be saved. 
However, these amounts are calculated with no consideration for the costs involved in 
implementing such a prevention programme. Consequently, they represent gross, not net, 
benefit incurred and are thus greatly over estimated.
As suggested by the investigation so far into the effect a change in behaviour has on 
projected populations, when looking at total HIV/AIDS prevalence figures, as seen in 
Figure 5.3c, overleaf, each scenario follows its expected altered course: an increase in
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Figure 5.3c HIV/AIDS Prevalence with the Infectivity Rate, pc, varying from 2005,
reaching ±1 0 %, 0 , or with continuous semi-effective prevention methods.
high-risk behaviour results in higher HIV/AIDS prevalence (31,068 people estimated to be 
living with HIV/AIDS by 2012); a slight decrease in risky behaviour results in HIV/AIDS 
prevalence increasing at a slower rate (30,083 people estimated to be living with 
HIV/AIDS by 2012); and an end to all high-risk sexual behaviour amongst homo/bisexual 
men results in HIV/AIDS prevalence dropping dramatically down to an estimated 21,416 
homosexual men living with HIV/AIDS by 2012, compared to 30,617 individuals if there is 
no change in behaviour. When the scenario of continuous prevention methods 
implemented every 2 years is considered, each resulting in a reduction in the value of Pc by 
10%, total HIV/AIDS prevalence stops increasing at the same speed as it would otherwise. 
In fact, the curve of the prevalence path for this scenario of continuous intervention 
distinctly gives the impression that each prevention activity that is employed slows the rate 
of incline of the total HIV/AIDS prevalence further and further, suggesting that beyond 
2012, prevalence figures can be restrained and possibly even reduced with the utilization of 
semi-effective, but numerous, prevention strategies.
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5.3 Introduction of a Vaccine
Since 1987, the National Institute of Allergy and Infectious Diseases (NIAID) has 
conducted a total of 79 HIV vaccine clinical trials, registering more than 12,000 volunteers 
and testing over 52 distinct vaccine candidates; more vaccines than ever before are being 
tested today, with the number of trial locations expanding globally (NIAID 2005a). 
However, despite numerous HIV/AIDS vaccines existing in clinical trials, there are none, 
as yet, that are permitted for practical use (AIDSinfo 2005). Thus, at present, there is no 
available cure for HIV/AIDS; while new combination therapies have considerably reduced 
AIDS-related morbidity, the current treatments available are multifarious, expensive, can 
produce adverse side effects and are commonly associated with drug resistance (NIAID 
2005a). The most promising option for concluding, or at least restraining, the HIV/AIDS 
epidemic is through the manufacture of reasonably priced, non-harmful and effective 
vaccines which educate the immune system to identify and, consequently, protect itself 
against viruses such as HIV (NIAID 2005a). Vaccines, such as these, are known as 
preventive vaccines and are targeted at HIV-negative individuals with the aim of 
preventing HIV infection (AIDSinfo 2005). Other types of HIV vaccines are also being 
tested, and may be advantageous for HIV-positive individuals by postponing the 
establishment of AIDS or by decelerating the progression of HIV (NIAID 2005a); these 
types of vaccine are known as therapeutic vaccines and their objective is to improve the 
immune system (AIDSinfo 2005).
It is widely believed, by scientists and researchers alike, that a successful vaccine is 
achievable. In fact, main objectives throughout the world are to restrain, or even end, the 
HIV/AIDS epidemic by developing an effective vaccine to protect individuals against 
contraction of HIV, against illness once infected with HIV, or to decrease viral load post 
infection with the virus (NIAID 2005b). However, designing such a vaccine will inevitably 
be problematic: it will necessitate numerous trials, each trial drawing closer to an effective 
vaccine; vaccines for other communicable diseases are prone to be more effective than an 
early HIV vaccine candidate; and a HIV vaccine is doubtful to be valuable against all HIV 
strains (CDC 2001). The ideal vaccine would be 100% effective against HIV infection, 
inexpensive, easy to store and administer, capable of protecting against all strains of HIV 
and accessible to defend every person from infection (NIAID 2005a, 2005b). Even if a
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vaccine only partially protects the total target population, it could still significantly affect 
transmission rates of HIV and help manage the HIV/AIDS epidemic (NIAID 2005a). In 
2004, the National Institute of Allergy and Infectious Diseases listed some types of 
experimental vaccine presently under investigation, these included (NIAID 2004):
((
• Component (or Subunit) vaccine: a structural piece of HIV, such as the outer 
surface components ... or a regulatory protein, produced by genetic engineering
• Live vector vaccine: a live bacterium or virus such as vaccinia (used in the 
smallpox vaccine) modified so it can not cause disease but can transport into the 
body a gene or genes that makes one or more HIV proteins
• Vaccine combination: for example, use of a recombinant vector vaccine to induce 
cellular immune responses followed by booster shots of a component vaccine to 
stimulate antibody production, referred to as a prime-boost strategy
• Peptide vaccine: chemically synthesized pieces of HIV proteins (peptides) known 
to stimulate HIV-specific immunity
• Virus-like particle vaccine (pseudovirion vaccine): a non-infectious HIV look-alike 
that has one or more, but not all, HIV proteins
• DNA vaccine: direct injection of genes coding for HIV proteins
• Whole-killed virus vaccine: HIV that has been inactivated by chemicals, 
irradiation, or other means so it is not infectious
• Live-attenuated virus vaccine: live HIV from which one or more disease-promoting 
genes of the virus have been deleted. Due to safety considerations, live-attenuated 
HIV vaccines have not been tested in humans. “
NIAID are founding the Center for HIV/AIDS Vaccine Immunology (CHAVI), in 2005, in 
order to hasten the forthcoming development of a safe and effective HIV vaccine. This is 
in response to optimism for more hopeful vaccine candidates to go under development in 
the near future; standardized lab assays around the world; greater capacities for clinical trial
• • • • bprogrammes; and better resourced animal facilities (NIAID 2005 ).
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In view of the above literature appraisal on current vaccine capabilities and the optimistic 
progression to the development of a future HIV vaccine, this section considers two case 
scenarios: the introduction of a preventive vaccine and the introduction of a therapeutic 
vaccine. For both scenarios, a new parameter is invented which represents the coverage of 
a 1 0 0 % effective vaccine within its respective population, that is, the proportion of the 
population that the vaccine is administered to, after a period of initiation for that vaccine 
(i.e. a smoothing process lasting two years, as performed previously). These new 
parameters, denoted vacp and vact, symbolizing the coverage of the preventive vaccine and 
therapeutic vaccine respectively, are initially given a value of 0  at the start of the epidemic 
(1978), i.e. 0% of the population is vaccinated. In 2005, vacp and vact will begin to 
increase from this value of zero, over a linear smoothing period of two years, to eventually 
take on their final proportion of coverage, from 2007 onwards, of either: 50%; 70%; or 
90%, of the population vaccinated (i.e. vacp = vact = 0.5, 0.7 or 0.9 respectively).
5.3.1 The Introduction of a Preventive Vaccine
As mentioned above, in order to represent the introduction of a preventive vaccine, vacp is 
established within the model corresponding to coverage of the vaccine in the population. 
The vaccine within this scenario is assumed to be 100% safe and effective, thus, when an 
individual is administered with the preventive vaccine, they are assumed to no longer be 
susceptible to the HIV virus. The nature of a preventive vaccine is that it is administered to 
non-infectives in an attempt to prevent contraction of HIV, hence, within this scenario it is 
the transition from the High Risk Susceptible sub-population, X(t), to the High Risk 
Infective sub-population, Y(t), that is relevant for the incorporation of the new parameter, 
vacp. Previously, the parameter associated with this movement between compartments, 
within the Cardiff Model, was a, the rate at which High Risk Susceptibles become infected, 
which was calculated as follows:
a = P c . m+m
X (t) + Y(t) + A(t)
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To incorporate vacp within this transition from the X(t) category to the Y(t) category, a  is 
multiplied by (1 - vacp) to get the new rate at which Susceptibles become infected of:
a ( l - v a c )  = ( \- v a c ) p c -
X (t) + Y(t) + A(t)
Three situations are modelled allowing for different final coverage levels of the vaccine, 
these are 50%, 70% or 90% vaccine coverage (i.e. 50%, 70% or 90% of the High-Risk 
Susceptible population will be treated with the preventive vaccine by 2007). For each case, 
vacp goes through a smoothing period, from 2005 to 2007, where it increases from its 
original value of 0 (0% coverage) to its new value of 0.5, 0.7 or 0.9 respectively. The 
linear smoothing process is the same as used previously and incorporates the following 
linear weekly increments:
vacD -v a cPnew Pold /104
Figure 5.4a shows the sub-population prevalences, where, as noticed in prior ‘what-if 
scenarios, both of the AIDS case prevalence paths (High Risk and Low Risk) are not 
affected by a change in parameter value this early on in the stages of the epidemic. As with 
a change in value of the entry rate and a change in value of the infectivity rate, the 
introduction of a preventive vaccine, affecting the incidence of HIV from the High Risk 
Susceptible category, is not directly linked to the AIDS case sub-populations and, hence, 
any effect that may be witnessed in either the High Risk or Low Risk AIDS case 
categories, A(t) or Z(t) respectively, will happen later and lesser than for the other sub­
populations. This trend is witnessed in the prevalence of the High Risk Susceptibles, X(t), 
and the High-Risk Infectives, Y(t), which react much quicker, changing course 
immediately in 2005, to the introduction of a preventive vaccine than the prevalence of 
Low Risk Infectives, V(t), which does not change its path until 2007. Also, the amount by 
which each prevalence changes is worthy of note; for the High Risk Susceptibles the 
prevalence for each scenario, 0%; 50%; 70%; and 90%, by 2012, is 4617; 8594 (an 
increase of 8 6 %); 10,883 (an increase of 136%); and 13,360 (an increase of 189%),
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Figure 5.4a Sub-populations within the Cardiff model with coverage of Preventive 
Vaccine, vacp, introduced in 2005, reaching 50%, 70% or 90% by 2007.
respectively, and for the High Risk Infectives the prevalence for each scenario is 12,104; 
9395 (a decrease of 22%); 7766 (a decrease of 36%); and 5999 (a decrease of 50%) high 
risk people living with HIV by 2012, respectively. This implies that given the introduction 
of an 100% safe and effective preventive vaccine in 2005, even without full coverage, the 
HIV/AIDS epidemic is significantly altered: with only 50% coverage the number of high 
risk individuals living with HIV is reduced by more than a fifth by 2012; with 70% 
coverage, less than two-thirds of the original number of high risk individuals are expected 
to be living with HIV by 2012; and with 90% coverage, more than half of the high risk 
individuals expected to be living with HIV in 2012, if no vaccine is introduced, are now 
expected to be HIV negative. For all three measures of vaccine coverage, the prevalence of 
Low Risk Infectives, V(t), is reduced: 50% coverage relates to 15,367 low risk individuals 
living with HIV in 2012, compared to 16,308 without the introduction of a vaccine, 
approximately 1000 people less; 70% coverage corresponds to 14,876 low risk people 
living with HIV, roughly 1500 less; and 90% coverage refers to 14,347 HIV-positive
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homosexuals participating in low risk sexual activities, which is about 2 0 0 0  fewer people 
living with HIV than there would be otherwise, by 2012. The trajectory for each mapping 
of the Low Risk Infective prevalence suggest that the greater the proportion of the 
susceptible population vaccinated, the more likely it is that the HIV/AIDS epidemic can be 
restrained; for increasing coverage, the Low Risk Infective population reduces its growth 
more and more. Most significantly, if 90% of the population were vaccinated by 2007, 
then the prevalence of low risk infections would be almost stabilized by 2 0 1 2 ; projecting 
beyond this point in time could even predict a reduction in low risk infective prevalence. 
AIDS incidence and deaths from AIDS, as displayed in Figure 5.4b overleaf, are not 
affected by the introduction of a preventive vaccine and continue their steady paths of 
about 200 new cases each, annually. The most influenced trajectory seen in Figure 5.4b is 
that of the HIV incidence, for which levels dramatically fall in value on initiation of a 
preventive vaccine into the High Risk Susceptible population, irrespective of which 
coverage percentage the vaccine is modelled to encompass. The greater the coverage, the 
steeper the decline in HIV incidence; by 2008, 50% coverage accomplishes levels lower 
than 1000 infections annually, 70% coverage incurs a fall in HIV incidence to below 600 
individuals annually, and 90% coverage attains readings nearly as low as 200 new HIV 
infections occurring annually. However, it is noteworthy that despite these impressive 
declines in HIV incidence, post 2008 each path slowly begins to escalate again. Between 
2008 and 2012, HIV incidence has increased from 945 to 1107 for 50% coverage, from 587 
to 676 for 70% coverage, and from 206 to 210 for 90% coverage. This could either suggest 
that HIV incidence will, eventually, return to its previous high levels, despite the 
introduction of a 100% effective vaccine, or that HIV incidence levels will stabilize at a 
new quantity, dependent upon the proportion of the population vaccinated. Inspecting the 
curves for each scenario of coverage, in Figure 5.4b, one could speculate that for 50% 
coverage HIV incidence will settle at about 1200 new infections annually, for 70% 
coverage HIV incidence will converge to about 700 new infections annually, and for 90% 
coverage HIV incidence will maintain its levels of about 200 new infections annually. 
Another noticeable trend, when looking at Figure 5.4b, is that the greater the coverage, the 
less the HIV incidence increases post 2008. In fact, for 90% coverage, it could be argued 
that HIV incidence has already stabilized at new levels of 200 new infections each year.
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Figure 5.4b HIV, AIDS and deaths cases with coverage of Preventive Vaccine, vacp, 
introduced in 2005, reaching 50%, 70% or 90% by 2007.
Table 5.6, on the following page, illustrates the effect on extrapolated HIV incidence over 
the years 2005 to 2012, resultant from the introduction of a preventive vaccine. Also 
within Table 5.6, a summary of the potential costs in relation to the differing number of 
new HIV cases each year is provided, as in the previous sections of this Chapter. The total 
extrapolated number of new HIV infections occurring between the years 2005-2012 differs 
depending on the percentage of the population treated with the preventive vaccine. With 
0% vaccinated, HIV incidence over the 7 years totals 13,418 new infections, this 
diminishes rapidly with the introduction of a vaccine, returning total HIV incidences of 
9402 (-29.9%), 7094 (-47.1%) and 4588 (-65.8%), for 50%, 70% and 90% coverage rates, 
respectively. The associated financial costs equate to a potential £2,008 - £4,016 million 
saved in 7 years if 50% of the population are vaccinated; £3,162 - £6,324 million saved if 
70% of the population are vaccinated; and £4,415 - £8,830 million saved if 90% of the 
population are vaccinated. As for the costs involved with implementing prevention 
programmes however, the cost/benefits here do not take into account the expenses involved 
in producing and distributing such a vaccine, thus, over estimate the true savings.
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PROJECTED HIV INCIDENCE 
R A N G E  O F  C O S T /B E N E F I T  (£ M )
YEAR
0% of the 
population 
vaccinated
50% of the 
population 
vaccinated
70% of the 
population 
vaccinated
90% of the 
population 
vaccinated
2005 1678 1678
0
1678
0
1678
0
2006 1680 1469
1 0 5 .5 - 2 1 1
1383 
1 4 8 .5  - 2 9 7
1297 
1 9 1 . 5 - 3 8 3
2007 1680 1092 
2 9 4  - 5 8 8
835 
4 2 2 .5  - 8 4 5
567
5 5 6 . 5 - 1 1 1 3
2008 1680 945 
3 6 7 .5  - 735
587 
5 4 6 .5  - 1 0 9 3
206
7 3 7 - 1 4 7 4
2009 1678 997 
3 4 0 .5  - 681
623 
5 2 7 .5  - 1 0 5 5
2 1 2  
733  - 1 4 6 6
2010 1676 1039 
3 1 8 .5  - 6 3 7
648 
5 2 4  - 1 0 2 8
203
7 3 6 .5 - 1 4 7 3
2011 1674 1075 
2 9 9 .5  - 5 9 9
664 
5 0 5  - 1 0 1 0
215 
7 2 9 .5  - 1 4 5 9
2012 1672 1107 
2 8 2 .5  -  5 6 5
676 
4 9 8  -  9 9 6
2 1 0  
731 - 1 4 6 2
TOTAL 13418 9402 
2 0 0 8  -  4 0 1 6
7094
3 1 6 2 - 6 3 2 4
4588
4 4 1 5 - 8 8 3 0
T a b le  5 ,6  Projected HIV incidence and consequent cost implications, resultant from 
the introduction of a preventive vaccine, for the years 2005 -  2012.
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Figure 5.4c HIV/AIDS Prevalence with coverage of Preventive Vaccine, vacp, 
introduced in 2005, reaching 50%, 70% or 90% by 2007.
Figure 5.4c shows total HIV/AIDS prevalence for each scenario regarding the 
establishment of a preventive vaccine, i.e. for each coverage level of 0%, 50%, 70% and 
90%. Almost immediately after the introduction of a preventive vaccine, in 2005, the 
HIV/AIDS prevalence curve changes its path dramatically for each coverage level, 
dropping radically away from its otherwise linear increase if a vaccine is not introduced. 
The greater the coverage the greater the effect on HIV/AIDS prevalence, although even 
50% coverage brings the HIV/AIDS prevalence, predicted for 2012, down to 27,000 from 
30,600. For both 70% and 90% coverage, not only has the growth of 
HIV/AIDS prevalence been restrained, the introduction of a 100% effective preventive 
vaccine at these levels has caused a severe decline in HIV/AIDS prevalence from 2006 
onwards; 70% coverage reaching prevalence levels of less than 25,000 by 2012, and 90% 
coverage reaching amounts as low as an estimated 22,600 people living with HIV/AIDS in 
2012 .
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5.3.2 The Introduction of a Therapeutic Vaccine
Similar to the introduction of a preventive vaccine, a new parameter, vact, is introduced 
into the Cardiff model representing the coverage of the vaccine, i.e. 50%, 70% or 90% of 
the target population being administered with the therapeutic vaccine. The fundamental 
dissimilarity between a preventive vaccine and a therapeutic vaccine is that the former is 
administered to HIV-negative individuals, in order to prevent infection with HIV, and the 
latter is administered to HIV-positive people, with the aim of halting further progression of 
HIV, thus preventing the onset of AIDS. Furthermore, a therapeutic vaccine might also be 
able to improve an individual’s health status. Consequently, vact is not incorporated into 
the model at the same point as vacp i.e. when High Risk Susceptibles become infected with 
HIV and enter the High Risk Infective category via the associated parameter, a. Instead, 
vact will be concerned with the transition rates from stage i to stage i+ 1 , i = 1 , ..., 6  with 
stage 7 relating to AIDS. These transition rates are denoted by yi and are calculated within 
the model as follows:
where m = 6  is the number of stages in the HIV infective category, IP is the incubation 
period of HIV, which is assumed to be 11.4 years (derived from work by Snary 2000), and 
r is a measure of treatment effect on the incubation period. Chapter 4 investigates the 
parameter r in much detail, estimating its value for different time eras within the model in 
addition to allocating various smoothing methods employing longer transitions of change in 
parameter value as well as unequal transition rates. The value of r by 2002, with equal 
transition rates back in force, was estimated to be 4.89, thus yj ~ 0.108, i = 1, ..., 6 .
With the notion that the therapeutic vaccine being introduced is 100% safe and effective, 
the yi are assumed to reduce to a value of zero for those that the vaccine is administered to, 
reflecting no more progression through the stages of HIV once an individual has been 
vaccinated. The new transition rates to allow for the introduction of a therapeutic vaccine 
are thus calculated as follows:
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vact initiates at a value of zero (representing 0 % of the infective population vaccinated with 
the therapeutic vaccine) at the start of the epidemic and increases in 2005, over two years 
of smoothing, to take on its new value of either: 0.5; 0.7; or 0.9, by 2007. For this case, 
the linear weekly increments added to vact over the 2 years, 2005-2006, are:
As well as preventing further progression of HIV, the introduction of a therapeutic vaccine 
could also improve the health status of an HIV-positive individual. The concept of 
improving health can be modelled by evaluating backward movements through the stages 
of HIV disease progression, i.e. an increase in CD4 cell count. Thus, we introduce the 
parameter yt,i to represent the backward transition rates from stage i to stage i-1 , where i =
2, ..., 6 , assuming all transition rates are equal i.e. Yb2 = Yb3 = ■ • • = Yb6 - As for the forward 
transition rates, Yi, the supposition is of ‘1 -step’ directional movements only, that is to say 
an individual can progress to the next consecutive stage of HIV disease, or digress back to 
the previous stage of HIV disease, but can not ‘jump’ or ‘skip’ stages. It is assumed that, 
since a therapeutic vaccine is not a cure for HIV, once an individual is infected with HIV 
there is no full recovery back to the susceptible category, thus there is no backward 
transition from stage 1 of infection to stage 0 (where stage 0 represents the High Risk 
Susceptible sub-population). Also, once an individual has progressed to AIDS there is no 
reversion to being HIV only, hence no backward transition from stage 7 to stage 6 . These 
backward transition rates create additional paths within the model, thus the differential- 
difference equations need to be revised to incorporate the new movements (equations 
(5.1a)-(5.1e) overleaf). Note that the backward transition rates (representing improvements 
in health) are only applicable to those people whom have been vaccinated with the 
therapeutic vaccine. Thus, Ybi is multiplied by the proportion of vaccine coverage within 
the infective population, vact, as seen in the differential-difference equations (5.1a)-(5.1e). 
Since, prior to 2005, no therapeutic vaccine is assumed to exist (i.e. vact is designated a 
value of zero up until this point in time), the vactYbi terms, seen in equations (5.1b) and 
(5. Id), equate to zero previous to 2005, resulting in the set of original differential- 
difference equations, without considering the introduction of a therapeutic vaccine.
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X(t + S ) = X(t) + [A -  ^ X (t)  -  aX(l)]S
Y(t + S ) = Y Y ,(t + a )
(=1
Yl(t + a) = Yl(t) + [aX(t) + vac,yb2Y2(t)-(y , +v 2 + /i2 )!;(()]<*
Y!(t + a ) = Yl(t) + \yl_lYl_,(t) + vac,yb(M)YM(t)-(vac,rbl + y, + n 2 +v2)Yl(t)\fi
i = 2 ,...,m -\
Y Jt+ a> = Y jt)+ \y^, Ym_{ (t) -  (vac, rbm +ym + fh +*/2 )r»(0 ]«
A(t + a) = A(l) + \y„bY„ (/) + ymgVm(t)-(<o+v3 )A(tj]fi
m
v (t+ a )= '£ y ,( t+ a )
1=1
(< + <*) = v, (!) + [v2 y; (<) + vac, yb2 V2 (0 -  O', + / / 2 )F, (/)]<*
^  (< + 5) = K( ( 0  + (<) + v2 1  ^( 0  + vac, K(tl (t) -  (vac,yb, +yl +M2Wl (<)}*
/ = 2, . . . , /w-l
V J > + & )  =  Vm (0  + [jv , Fm_, (/) + v2 (/) -  (vac,y,„ +ym +  fi2)Vm(t)\fi 
Z(t + a)=Z(t) + \ym(\-b)Ym(t) + ym(l-g )V m(t) + v2A(t)-m Z(()^
...(5.16)
...(5.1c)
..(5.M)
...(5.1e)
Additionally, the backward transition rates, y^, can be set to zero before 2005 to illustrate 
the notion that there is no vaccine before this time, hence no improvements in health are 
present, however, vact is already designated this role, therefore altering the value of ybi, 
from zero to its new value, is inconsequential. Once the vaccine is instigated in 2005 and 
vact begins its increase from 0 to 0.5, 0.7 or 0.9, by 2007, the backward transition rates, ybi, 
are introduced into the calculation of the differential-difference equations as the vactybi
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terms begin to take on positive values. Three situations of improving health, for those 
individuals administered with the vaccine after 2005, are modelled within this section: 
firstly, the case where ybi = 0  is considered, representing no improvements in health with 
the treatment of a therapeutic vaccine, however progression of HIV disease is halted; 
secondly, ybi = 0.5 is modelled, reflecting a backward movement at a rate of 0.5 (signifying 
an average of 2 years per stage before moving back to a previous stage of HIV infection), 
plus the conclusion of further HIV disease progression; and finally, the case where ybi = 1 
is contemplated, demonstrating a backward movement at a rate of 1 (implying an average 
time of 1 year spent in each stage of HIV before improving to the previous stage), as well 
as no further forward movements through the HIV stages. Each scenario of improving 
health (ybi = 0, 0.5 or 1) is examined for each of the coverage levels that the therapeutic 
vaccine reaches (vact = 0, 0.5, 0.7 or 0.9), with the model projections up until the year 2012 
illustrated in Figures 5.5a(l), 5.5a(2) and 5.5a(3), with regards to the number of people 
living in each sub-population of the HIV/AIDS epidemic; Figures 5.5b(l), 5.5b(2) and 
5.5b(3), relating to the number of new HIV and AIDS cases as well as deaths from AIDS; 
and Figures 5.5c(l), 5.5c(2) and 5.5c(3), with respect to total HIV/AIDS prevalence.
Firstly, looking at the effect the introduction of a 100% safe and effective therapeutic 
vaccine has on the sub-populations within the model, assuming only a prevention in disease 
progression is resultant, with no improvements in health (illustrated in Figure 5.5a(l)), the 
two most affected sub-populations are the Low Risk Infectives, V(t), and the Low Risk 
AIDS cases, Z(t). The prevalence of High Risk Susceptibles, X(t), is not affected since it is 
assumed that the therapeutic vaccine is not a cure for HIV, thus, once an individual is 
infected with HIV they have the virus for life i.e. there is no possible return back to 
susceptible status. For the High Risk Infective sub-population, Y(t), there is no change in 
course since the rate at which High Risk Infectives, in the last stage of HIV, progress to 
AIDS, y6 , is insignificant in comparison to the rate at which High Risk Infectives, from all 
stages of HIV, become low risk, V2 . Similarly, the High Risk AIDS cases, A(t), are not 
affected due to the fact that combination therapies have already reduced High Risk AIDS 
prevalence down to zero with the reduction in the transition rate, y6 , together with the 
concept that there are fewer people in stage 6  of HIV infection for this transition rate to be 
applicable to, as the majority of infectives, by 2005, remain in the earlier stages of the
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Figure 5.5a(l) Sub-populations with Therapeutic Vaccine, vact, and ybi = 0.
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Figure 5.5a(2) Sub-populations with Therapeutic Vaccine, vact, and ybi = 0.5.
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Figure 5.5a(3) Sub-populations with Therapeutic Vaccine, vact, and ybi = 1.
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disease due to the success of ‘cocktail’ antiretroviral drug therapies. Investigating the sub­
populations that are affected, the Low Risk Infective prevalence swells with the 
introduction of a therapeutic vaccine due to the notion that the same numbers of people are 
becoming low risk (moving from the High Risk Infective stages) and, once low risk, no 
further movements are possible, except for exiting the model from causes other than AIDS 
at a rate of jij = 0.03. Escalating Low Risk Infective prevalence is witnessed prior to the 
introduction of a therapeutic vaccine since more individuals are entering the Low Risk 
Infective category than are leaving (i.e. V2Yi(t) > /*2Vi(t) + y6V6(t), i = 1 ,..., 6 ); with the 
introduction of the vaccine, in 2005, resulting in no further forward movements (yi = 0, 
i = 1 ,..., 6 ), the inequality of new low risk HIV infection and exits from this category is 
exaggerated, thus, even further increases in Low Risk Infective prevalence are witnessed. 
On the other hand, Low Risk AIDS cases, Z(t), decrease with the introduction of a vaccine 
in 2005 since the onset of AIDS is stopped and there are no High Risk AIDS cases to 
transfer into the Low Risk AIDS category, via rate V3 .
Comparing Figure 5.5a(l), which assumes no improvements in health, with Figures 5.5a(2) 
and 5.5a(3), which assume backward transition rates throughout the HIV stages of ybi = 0.5 
and 1 , respectively, the only difference in effect on the sub-populations that is apparent is 
in the Low Risk Infective sub-population, V(t), and the Low Risk AIDS case sub­
population, Z(t). For 50% and 70% vaccine coverage levels, the prevalence for each of 
these sub-populations converges to that of the 90% vaccine coverage level i.e. with 
improvements in health for lower vaccine coverage levels (50% and 70%), Low Risk 
Infectives increase faster and to larger numbers than without improvements in health, 
similarly, Low Risk AIDS cases decrease quicker and to lesser numbers than with no 
recovery in health. Moreover, the faster that health improves (represented by ybi taking on 
larger values) the quicker the convergence of the 50% and 70% vaccine coverage scenarios 
to the 90% vaccine coverage sub-population prevalence paths. When looking at the 90% 
vaccine coverage level, no significant change is apparent in any sub-population prevalence, 
when comparing improving health with no change in health status, due to the fact that 
virtually maximum effect, in terms of sub-population prevalence, is already being 
witnessed.
Figure 5.5b(l), overleaf, shows HIV incidence, AIDS incidence and deaths from AIDS for
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the years 2 0 0 2 - 2 0 1 2  with the introduction of a therapeutic vaccine that prevents further 
progression of the virus once administered, but does not improve an individual’s health.
No matter how many infectives (50%, 70% or 90%) the new therapeutic vaccine is 
administered to, the number of new cases of HIV infection is not affected; it is only AIDS 
incidence and deaths from AIDS that change course. This is due to the fact that a 
therapeutic vaccine is provided for the infective populations to aid individuals living with 
HIV/AIDS, thus the susceptible category or, more specifically, the rate at which HIV is 
contracted, is not influenced. AIDS incidence falls to new steady levels of about 90 new 
cases for 50% vaccine coverage; 50 new cases for 70% vaccine coverage; and 10 new cases 
for 90% vaccine coverage, by 2012, compared to the alternate annual AIDS incidence of 
approximately 200 new cases of AIDS, for no vaccine coverage. This resultant change in 
AIDS incidence is not unexpected due to the very nature of the new therapeutic vaccine 
preventing the onset of AIDS. Consequently, the more infectives vaccinated, the fewer 
people that progress to AIDS, hence AIDS incidence reduces further for higher coverage 
levels of the vaccine. Comparing AIDS incidence for all scenarios of improving health, i.e. 
Ybi = 0, 0.5 or 1, the greater the rate of improvement in health, the quicker AIDS incidence 
falls to new lower levels. For the case where ybi = 1, as seen in Figure 5.5b(3), AIDS 
incidence reduces to zero by 2012 for all coverage levels considered (50%, 70% and 90%). 
Accordingly, deaths from AIDS also fall with the introduction of a therapeutic vaccine, 
since fewer individuals are living with AIDS, hence, less people are present to die from the 
disease. Note that the death rate from AIDS, co, maintains its estimated value of 0.09 
throughout the extrapolated years, 2 0 0 2 -2 0 1 2 , and has not changed value as a result of the 
introduction of a therapeutic vaccine due to the assumption that once an individual 
contracts AIDS, their immune system is too weak for a therapeutic vaccine to be effective. 
Similar to the effect on AIDS incidence, the greater the rate of improvement in health, ybi, 
the quicker the number of people dying from AIDS declines. However, for 90% coverage 
the number of deaths from AIDS is not significantly affected by any suggested 
improvements in health since nearly complete maximum affect is already being observed. 
Thus, as the rate for improving health increases the trajectory of deaths from AIDS for both 
50% and 70% vaccine coverage levels converge to that for 90% vaccine coverage. It 
would be expected in future years for deaths from AIDS to eventually reduce to zero if
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Figure 5.5b(l) HIV, AIDS and deaths with Therapeutic Vaccine, vact, and Ybi = 0.
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Figure 5.5b(2) HIV, AIDS and deaths with Therapeutic Vaccine, vact, and Ybi= 0.5.
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Figure 5.5b(3) HIV, AIDS and deaths with Therapeutic Vaccine, vact, and Ym = 1.
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AIDS incidence maintains a count of zero; looking at Figure 5.5b(3), taking the scenario 
where = 1 and vact= 0.9, if all conditions and parameters stay constant, then the steady 
linear decline apparent in the number of deaths from AIDS could potentially reach zero by 
2020 (based on the approximation that over the four years, 2008-2012, when AIDS 
incidence is zero, deaths from AIDS have dropped by roughly a third).
Finally, Figures 5.5c(l), 5.5c(2) and 5.5c(3) overleaf show total HIV/AIDS prevalence 
extrapolated up until the year 2 0 1 2  for all scenarios regarding the introduction of a 
therapeutic vaccine (i.e. different coverage levels of the vaccine and different 
improvements in health as a result of the vaccine). The effect seen in the HIV/AIDS 
prevalence projection is minimal; the introduction of a therapeutic vaccine, for all cases 
considered, marginally increases HIV/AIDS prevalence, however, allowing for different 
coverage levels and health improvements does not seem to affect the proportion of change. 
This is due to the notion that the introduction of a therapeutic vaccine does not remove 
individuals from the HIV/AIDS category, but simply dictates the movements between 
stages within the overall HIV/AIDS population. Referring back to Figures 5.5a(l), 5.5a(2) 
and 5.5a(3), the increase in Low Risk Infective prevalence, V(t), is approximately 
cancelled out by the resultant decrease in Low Risk AIDS prevalence, Z(t). The slight 
increase that is witnessed in the total HIV/AIDS prevalence, seen in all of Figures 5.5c(l), 
5.5c(2) and 5.5c(3), is consequent to the decrease in deaths from AIDS observed in Figures 
5.5b(l), 5.5b(2) and 5.5b(3). Fewer deaths from AIDS imply more people living with 
HIV/AIDS, i.e. greater HIV/AIDS prevalence. The lack of effect that a reduction in deaths 
has had on the total HIV/AIDS prevalence is due to the small resultant influence that the 
introduction of a therapeutic vaccine has had on deaths from AIDS numbers. This is due to 
the fact that the number of deaths was already very low, prior to the introduction of a 
potential therapeutic vaccine, as a result of the large impact highly effective antiretroviral 
drug combinations have previously had on the epidemic, reducing morbidity dramatically.
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Figure 5.5c(l) HIV/AIDS prevalence with Therapeutic Vaccine, vact, and ybi = 0.
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Figure 5.5c(2) HIV/AIDS prevalence with Therapeutic Vaccine, vact, and ybj = 0.5.
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Figure 5.5c(3) HIV/AIDS prevalence with Therapeutic Vaccine, vact, and ybi = 1
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5.4 Summary of Potential Cost/Benefits
A brief comparison between the what-if scenarios investigated previously within this 
chapter is provided in Table 5.7 overleaf, in terms of the potential costs saved or spent per 
HIV infection avoided. Note that the scenario allowing for the introduction of a therapeutic 
vaccine is not considered in terms of costs at any point within this chapter due to the lack 
of influence such a development has on the rate of HIV incidence or prevalence (resultant 
from the already highly effective drug treatments and therapies available). In addition to 
this, complications arise since the cost/benefit of between £0.5 and £1 million per HIV 
infection prevented, used within this comparison, does not allow for individuals initiating 
therapy but not needing it to continue due to the initiation of a therapeutic vaccine. 
Furthermore, the point at which the vaccine is prescribed during the progression of HIV 
needs to be taken into account as well as the possibility that individuals still require the use 
of hospital resources (inpatient and outpatient) and counselling facilities, despite 
medication with the new vaccine. In terms of financial costs, it may be the case that 
expenditure on the development and administration of a new therapeutic vaccine is equal to 
or even greater than that spent presently on antiretroviral drugs. However, monetary 
figures alone can not be used to measure the overall potential benefit of such an innovation; 
other more difficult to quantify measures need to be considered, such as improvements in 
quality of life; greater resource availability at hospitals and clinics; and more free time for 
clinicians and patients alike. It is important to remember this concept of non-monetary 
value when looking at Table 5.7, as well as considering the costs behind implementing the 
various interventions. A change in the entry rate, for instance, is subject to natural 
variations that may occur within the UK population and should not be associated with any 
subsequent cost, similarly, a greater infectivity rate, caused by an increased amount of high 
risk sexual behaviour among the homosexual population, should not be linked with a cost 
of occurrence. However, a change in the infectivity rate for the better is assumed to result 
from decreasing high-risk sexual attitudes and behaviours most likely due to the launch of 
prevention programmes and awareness campaigns, which will cost money to instigate. In 
particular, it should be assumed that the 1 0 0 % and continuously effective prevention 
programmes, considered within this Chapter, will cost more than the 10% effective 
intervention. The greatest cost associated with the occurrence of any of the scenarios
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SCENARIO
TOTAL HIV INCIDENCE 
2005-2012
COST/BENEFIT (£M) 
2005-2012
Change in Entry Rate 
+10%
13932 -257--514
Change in Entry Rate 
-10%
12895 261.5-523
Change in Infectivity Rate 
+10%
13924 -253 - -506
Change in Infectivity Rate 
-10%
12824 297 -  594
Change in Infectivity Rate 
-10% continuously
12042 688-1376
Change in Infectivity Rate 
-100%
3360 5029-10058
Preventive Vaccine with 
50% coverage
9402 2008-4016
Preventive Vaccine with 
70% coverage
7064 3162-6324
Preventive Vaccine with 
90% coverage
4588 4415-8830
T a b le  5.7 Cost/Benefit comparisons for ‘what-iP scenarios over the years 2005-2012.
discussed is expected to be related to the introduction of a preventive vaccine, its invention, 
distribution and administration. Moreover, the greater the coverage of the preventive 
vaccine the greater the costs are expected to be. However, for this work, since no 
information on expenses associated with the occurrence of any such ‘what-if scenario is 
available, further investigation into the net cost/benefits is halted and focus is brought back 
to the gross cost/benefits seen in Table 5.7, above. That is, the total amount of money that 
could potentially be saved if prevention programmes are introduced, or a preventive
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vaccine invented, without accounting for the price of implementing either form of 
intervention. For comparison, with no intervention a total of 13,418 new HIV infections 
are predicted to occur during the years 2005-2012. The best case scenario, from Table 5.7, 
is the situation where a 1 0 0 % effective prevention programme is put into place, completely 
halting all new infections of HIV from 2007 onwards. This reduces total HIV incidence 
over the years 2005-2012 down to 3,360 (a reduction of about 75%) and could potentially 
save £5,029 - £10,058 million. However, the idea of preventing all possible new HIV 
infections completely can be deemed as an unrealistic success. Second best is the scenario 
where a preventive vaccine is introduced; for all three coverage levels (50%, 70% and 
90%) the total number of new HIV cases over the years 2005-2012 has dropped 
dramatically to 9,402 (-30%), 7,064 (-47%) and 4,588 (-6 6 %), respectively, resulting in 
possible costs saved of between £2,008 - £8,830 million, dependent on the coverage level. 
As mentioned previously, this scenario may be viewed as the most expensive to implement, 
however, these expenses may be outweighed by the substantial costs saved as a result. 
Failing the introduction of a preventive vaccine, the next best scenario, and possibly the 
most realistic of all the scenarios considered, is that of the intervention of continuous 
prevention programmes which can moderate total HIV incidence, during the years 2005- 
2012, down to 12,042 (-10%) and save costs amounting to a prospective £ 6 8 8  - £1,376 
million.
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CHAPTER 6 
SUGGESTIONS FOR FUTURE WORK AND 
SUMMARY
6.1 Suggestions for Future Work
The main outcome of the HIV/AIDS epidemic model created within this thesis is the 
excellent fit produced between observed and expected HIV incidence, AIDS incidence 
and deaths from AIDS data, providing a basis for more in-depth investigation into 
specific sub-topics. For instance, clinical stages of HIV infection, normally defined by a 
measure of CD4 count, can be mapped onto the 6  mathematical stages of HIV infection 
incorporated into this model, which are assumed to be of equal length. This develops a 
specified version of the model capable of helping policy makers, clinicians and health 
officials make better, more informed decisions due to the ability to measure, or estimate: 
costs of treatments; treatment uptake; treatment effectiveness (possibly linked to 
adherence); cost-effectiveness of prevention programmes; and the development of drug 
resistance. For reference, Rauner & Brandeau (2000) discuss key issues of AIDS policy 
modelling.
The datasets used as the source of observed AIDS incidence, HIV incidence (ENAADS) 
and deaths from AIDS (CDSC) throughout this thesis are based on homosexual men in 
the UK. In order to investigate other transmission modes within the UK, the same 
datasets can be employed as the foundation of observed figures. In particular, 
heterosexual transmission has overtaken homosexual transmission over recent years, in 
terms of new HIV incidences, and will potentially be the future main mode of HIV 
transmission within the UK. The Cardiff HIV/AIDS Model produced within this thesis 
can be utilised to model the heterosexual population within the UK simply by 
implementing the observed data for heterosexual infections (ENAADS and CDSC) and 
re-estimating the entry rate into the High Risk Susceptibles; the infectivity rate (or, the 
mean number of sexual contacts per individual); the number of heterosexuals living with
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HIV/AIDS at the start of the epidemic; and the effect of treatments on the length of the 
incubation period. All other parameters and model assumptions could be presumed to 
remain as originally designated when modelling the homosexual population. Other 
geographical regions can also be modelled by applying the relevant observed data for 
those regions and re-estimating the parameters (A, pc, a 1 9 7 8 and r), however, care needs to 
be taken when doing so due to the concept that a number of parameter values within the 
model are based on UK population statistics, research or epidemiological studies, i.e. the 
exit rate, p, from the model from causes other than AIDS; the rate, v, at which an 
individual changes behaviour from high to low risk; and the death rate, co, may all take on 
different values for other regions within Europe or elsewhere in the world.
Many more adaptations and extensions can be investigated within the Cardiff HIV/AIDS 
Epidemic Model due to its flexibility. Further ideas can mostly be based upon the main 
assumptions employed in the creation of the model within this thesis, as explored in the 
following sections of this chapter.
6.1.1 Further work involving the Entry Rate
The first assumption within the Cardiff Model to examine is the entry rate, A, into the 
model. Throughout this work it has been assumed that entry into the model is via the 
High Risk Suscepible category only. Extended work could look at the possibilities of 
entry into both the High Risk and Low Risk Susceptible categories. Furthermore, a 
proportion of entry, say q, into either risk group can be set, see Figure 6 .1.
Y(t) V(t)
Exit
Figure 6.1 Entry rate into both High Risk and Low Risk Susceptible categories.
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Note that if q = 1 the model is the same as proposed throughout this thesis, with all 
individuals entering the model via the High Risk Susceptible category, at an entry rate of 
A. The proportion of entry split between high and low risk behaviour sub-populations, q, 
can be investigated in more detail, allowing q to take various values between the range 
0 < q < l .  This new consideration for the entry rate would specifically affect the 
differential-difference equations associated with the sub-populations X(t) and W(t). The 
modified formulae for these sub-populations are shown in equations (6 .1 a) and (6 .1 b) 
below.
The adapted equations, as seen above, would replace the original equations in the Cardiff 
HIV/AIDS model and, consequently, the differential-difference equations within the VB 
script, relating to the High Risk and Low Risk Susceptibles, would require 
reprogramming. Then, the MLE techniques can be reproduced for this modified model 
involving the new concept of insertion of the entry rate, with q and A being estimated.
In addition to this broadened exploration of the point of entry into the model, is the 
investigation of the assumption that the entry rate, A, is estimated as a single independent 
parameter, with N 1978 fixed. The entry rate is subsequently constant over time as a result 
of this assumption and consequent estimation process. However, A could be represented 
as a time-dependant variable by imposing the concept that A is proportional to time; for 
instance, the entry rate could be considered to be proportional to the number of AIDS 
cases, A(t) + Z(t); to HIV/AIDS prevalence, Y(t) + V(t) + A(t) + Z(t); to the number of 
High Risk individuals in the population, X(t) + Y(t) + A(t); or even to the total population 
in the model at time t, X(t) + W(t) + Y(t) + V(t) + A(t) + Z(t). In this way, the entry rate 
would vary over time subject to changing prevalence in the respective sub-populations. 
Within the model, this would mean the introduction of a proportional parameter, say p 
(which could take the form of X, the arrival rate), within the estimation process such that 
A = p x (sum of appropriate sub-populations with respect to t). Consequently, A would 
be removed from the estimation process and calculated as shown above.
X(t + a) = X{t) + [qA -  (m + v 1 )Y(0 -  oX(t)]fit 
Wit + a) = W(t) + [(1 -  q)A + vxX(t) -
...(6 .1a)
. . . (6 .16)
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6.1.2 Further work involving the Infectivity Rate
Another consideration for future work involves the infectiousness of HIV/AIDS, P, which 
is assumed to be constant throughout this thesis. Studies by Anderson (1988); Blythe & 
Anderson (1989b); Roberts & Dangerfield (1990b); Dangerfield & Roberts (1994); 
Jacquez et al. (1994); Garnett & Anderson (1996); and Dangerfield (1999), however, 
employ the notion of greater infectiousness in the earlier stages of the HIV infection, 
which decreases before rising again just prior to progression to AIDS. This concept of 
variable infectiousness can be introduced into the model by defining a different 
infectivity rate for each stage of HIV infection. When doing so, since the infectivity rate, 
pc, takes into consideration the rate of transmission per contact (infectiousness of 
HIV/AIDS), p, as well as the mean number of sexual contacts per individual, c, the 
change in behaviour noticeable, relative to different levels of perceived viral load, also 
needs to be considered. That is, the healthier an individual believes he is, the riskier his 
sexual behaviour tends to be, i.e. c might be expected to be greater in the earlier and 
middle stages of HIV infection. Thus, an exaggerated greater infectivity rate at the start 
of HIV disease progression could be investigated, with falling infectivity as the disease 
develops, perhaps with a slight rise just before the onset of AIDS in accordance with the 
literature references listed above, although this rise in infectiousness might be cancelled 
out by a decrease in sexual activity associated with poor health. Another consideration 
with respect to the infectivity rate, pc, is the assumption of constant value over time for 
the Pre-treatment era, 1979-1986, and for the Early Treatment and Combination 
Treatment eras, 1987-2002, post smoothing. Investigation could be made into the effect 
of a time-dependant pc profile on the fit to the ENAADS AIDS incidence data. Since 
HIV incidence is problematic to estimate, due to a long incubation period and lack of 
acute symptoms prior to severe immunosuppression, and, even though numbers of 
diagnosed infections are deemed more accurate records, diagnosis may take place years 
after initial contraction with HIV, other sexually transmitted disease (STD) data is the 
best option for monitoring levels of high risk behaviour. Thus, a time-dependent Pc term 
can be created which enlists the profile of the incidence of a STD with a short incubation 
period. Snary (2000) inspects this suggestion within her PhD thesis and employs rectal 
gonorrhoea data in order to directly obtain a time-dependent profile for parameter Pc.
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Equation (6.2) below is the initial, simple, formula utilised for the work undertaken by 
Snary (2000), before considering other more complicated formats for the make-up of a 
time-dependant infectivity rate.
pc. =  Lx/fc ...(6 .2 )
1 RG
Where 0ct is the value of the parameter pc at time t,
RGt is the number of rectal gonorrhoea cases in year t,
RG is the mean number of rectal gonorrhoea cases over the years 1979-1994 and, 
Pc is the mean value of the infectivity parameter for the same period 1979-1994.
Within this extension, the mean value of the infectivity parameter, Pc, can still be 
estimated using maximum likelihood techniques, as performed previously.
6.1.3 Further work involving changing behaviours
The Cardiff Model within this thesis assumes a change in behaviour from High Risk to 
Low Risk at the rate of Vi for the Susceptible category, V2 for the Infective categories and 
V3 for the AIDS case category. However, the assumption is that an individual will not, 
once converted to their respective Low Risk category, return back to their previous High 
Risk category. That is to say that so far within this work, the transition between risk 
groups has been one-way in direction. Further work could contemplate a two-way 
movement between respective behaviour sub-populations, as illustrated in Figure 6.2 
overleaf. The idea that an individual may revert back to their previous high risk 
behaviour is supported by data from other STD’s, such as rectal gonorrhoea, that suggest 
a significant increase in UK reported cases due to such factors as complacency; HIV 
optimism as a result of new combination drug therapies; and a reduction in media 
coverage and publicity. As shown in Figure 6.2, the parameters Vbi, Vb2 and Vb3 can be 
introduced into the model to represent the rates at which individuals revert from the Low 
Risk categories back to the respective High Risk categories. This would result in the
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X(t)
Vb2
V(t)Y(t)
A(t) Z(t)
Deaths 
from AIDS
Exit
Exit
Exit
F igure 6,2 Two-way directional movements between High Risk and Low Risk sub­
populations.
alteration o f differential-difference equations in order to include the aforementioned 
backward transitions, from Low Risk to High Risk. The Cardiff HIV/AIDS model would 
need re-evaluating with the adapted equations, as shown overleaf in equations (6.3a)- 
(6.3f), replacing those already programmed into the VB script. Once the modified model 
is set-up, the new backward transition rates of behaviour change need to be assessed and 
quantified to permit the program to perform the formulation of the model and subsequent 
estimation o f the specified parameter values using maximum likelihood techniques.
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X(t + a) = X(t) + [a -  (u, + v, )X(t) -  aX(t) + vM W(t)]a 
w(t+a)=w(t)+[v,x(t)-(H +vbl)w(t)]a
Y(t+a)=^Yfi+a)
f=i
Y<(t + a) = Yl(t) + [aaX(t) + (1 -  a)aW(t) + vb2 V, (t) -  (h + v2 + iu2)^(/)]«
Yl(t + a) = m  + \r , ^ l(t) + yb2V,(t)-(r, +ft2 +v2Wi(t)\a i=2,...,m
A(t + <*) = A(t) + \ymbYm(t) + y„gVm(t) + vaZ(t)-(co+v,)A(t)\a
m
f (<+<*>=£/(/+<*)
J=1
v, (t+a)=v, (t)+ [v2j; (t) -  O', + + vM )F, (;)]<*
Vi(l+a) = Vl (t) + (O + v2Yi(t)-(ri +Mi +vK)V,(t)]S i = 2,...,m
...(6.3a) 
...(6.3b)
■ ...(6.3c)
,(6.3rf)
,..(6.3e)
Z(/ + 5 ) = Z «)+ \y„(\-b)YJt) + ym(\-g )V m(t) + v2 A(t) ~ ( m + )Z«)]« ...(6.3/)
6.1.4 Further work involving treatment uptake considerations
Another area for deliberation is the conjecture that treatment uptake is assumed equal for 
all stages of HIV infection in the formation of the Cardiff model within this work; the 
parameter r applies to all stages of HIV infection at the same rate, with the exception of 
stage 6  when highly effective combination treatments are introduced since a slower and 
dulled reaction to the new therapies is expected for this sub-population of people with a 
weaker immune system and possible development of drug resistance. The model can be 
re-evaluated to look at the concept of when best to initiate treatment. For instance,
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Longini assumes the initiation of treatment once CD4 levels drop to below 500 cells/pi 
(that is, treatment uptake commences from stage 3 onwards) in line with US guidelines, 
whilst current UK guidelines suggest that treatment should be initiated once CD4 count 
falls below 350 cells/pl (BHIVA 1999), which is concurrent with stage 4 of HIV
estimation of the parameter r, relevant only to those beyond a certain point in HIV 
disease progression. For example, if  the scenario where treatment is initiated for 
individuals with a CD4 cell count less than 500 cells/pi is employed, then the transition 
rates would be calculated as follows:
This concept of treatment initiation and uptake can easily be introduced into the Cardiff 
HIV/AIDS model simply by restating the initial calculation of the transition rates within 
the model, to that shown above, and then re-performing maximum likelihood estimation 
on all relevant parameters, not just on r, since changing the foundation of the model may 
also affect the rest of the parameters subject to estimation. Note that the formulation of 
the transition rates could be kept the same as it was previously within the model but with 
the added constraint that if i = 1 or 2 , then r = 1 .
6.1.5 Further work involving the Incubation Period
Finally, and perhaps most importantly, we consider the assumption placed on the 
incubation period; that a patient follows a ‘1 -step’ forward-movement-only transition 
path through the 6  stages of HIV infection, with the added notions that an individual can 
only enter the infective category via stage 1 and can not advance to AIDS unless in the 
final stage of disease progression. This section considers a variety of different concepts 
involving numerous possible transition paths through the incubation period and how 
these assorted paths can be introduced into the Cardiff HIV/AIDS model. A combination 
of ‘1 -step’ or ‘multi-step’ models are explored, with either forward movement only or
infection onwards within Longini’s classification of stages. This would imply a re-
i = 1 ,2 .
i = 3,... ,6 .
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with the additional inclusion of backward transition through the HIV stages of infection. 
Figure 6.3 a represents this interpretation of the incubation period as it has been 
implemented throughout this thesis, where each numbered box represents that specific 
stage of HIV infection.
Y u
Y3,4
Y 4 ,5r
Y6,7
AIDS
Figure 6.3a Incubation Period with ‘1-step’ forward movements only
For this exploration into different transition routes through the incubation period, it is 
important to set up a clear and understandable notation. Thus, yy will represent the 
transition rate from stage i to stage j, where i j  = 1,2, 7 with stage 7 equivalent to
AIDS. Hence, throughout the work within this thesis, yy could also be denoted as yy+i- 
Extending from the original ‘ 1-step’ forward movement transition, as seen in Figure 6.3a, 
‘1-step’ backward transition can be incorporated into the incubation period, as well as ‘2- 
step’ forward and backward movements. These ‘2-step’ actions allow an individual to 
‘skip’ or ‘jump’ a stage of HIV infection and progress to the next-but-one stage of HIV 
infection, thus broadening the model to allow for fast progressors of HIV disease, whose 
health deteriorates severely in a short period of time, or the impact of highly effective
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treatments on an individual’s CD4 count. For both the incorporation of ‘1-step’ and ‘2- 
step’ backward progression through HIV infective stages, the assumption that once AIDS 
is contracted an individual can not then return to being HIV only holds. Thus, as seen in 
Figure 6.3b, there is no backward transition from the AIDS stage (that is, stage 7) to any 
of the HIV infective stages. In addition to these new 1- and 2- step, forward and 
backward, movements, Figure 6.3b illustrates the possible transition from the later stages 
of HIV infection to jump straight to AIDS, that is, the model illustrated in Figure 6.3b 
enables individuals to leap directly to the AIDS stage from any of the HIV stages 3, 4, 5 
or 6.
Y u Y uJ FY2,i 73,1
72,4
y^ t 73,2
74,2
73,7
74,7
73,5
74,6  
75,7
T ^ r 74,3
K i f  f 7 5 ,4
7s,6|  f  7 6 , 5
75,3 
76,4
76,7|
AIDS
Figure 6.3b Incubation Period with ‘1-step’, ‘2-step’ and ‘multi-step to AIDS’ 
forward and backward movements
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Equations (6 .4a)-(6 .4e) demonstrate the relevant alterations that would need to be made 
to the infective differential-difference sub-population equations, Y(t) and V(t), as well as 
the AIDS case sub-population equations, A(t) and Z(t), and the formulation of AIDS 
incidence, if  a ll o f  the transitional routes illustrated in Figure 6.3b were incorporated.
m
Y(t) = Y JY,(‘ ) where
1=1
Y, (t + 8t) = 7 ,  ( / )  +  [aaX(t) + y2J 2 ( t)  +  y„Y, (t)
- ( r ,,2 +  7 ,,3 +Mi +v2)Y,(t)]dt 
Y2(t + St) = Y2 ( t)  + [rU2Yt ( 0  +  y x lY,(t) +  y ^ Y J t)
~ (72,1 +  72,3 +  72,4 +  Ml +  Vl)Yl t t W
Y, «  + # )  = Y, (/) + [y,_2J , . 2 ( 0  + 7,-1., Y,-, (0 + 7 /+w ^ +i (0 + 7,4 UYM (0
-  (7 ,4-2  +  7,4-1 +  7,.,4, +  7 , ,,+2 +  7,,7 +  Hi +  V2 )Y, (.Olfl '' ’ (6A“)
i = 3,...,iw — 2
K (t + St) = Yt ( I)  + [y,_2JY,_2 ( / )  +  ( 0  +  ( / )
-  (7 ,4-2 + 7 ,4 - ,  +7,4+1 +  7,,7 +  Ml + * /2 )^ (0 ]< S
i = m - 1
Y, (» +  <*) =  7  ( O  +  [7 ,-2 ,,7 ,-2  (0 +  7 , -u 7 ,- i  (0
- ( 7 ,4 - 2  + 7 ,4 - ,  + 7 ,,7  + ^ 2  + v 2)7 ;(0 ]< S
i - m
m
V(t) = ^  Vi ( t)  where
i=i
F, ( /  +  <*) =  ^  ( O  +  [(1 -  a)aX(t) +  v2 7, ( / )  +  / 2)1F2 ( 0  +  y3AV3 (t)
- (rh2 + rU3 + MiWii*)]®
V2(t + a )  = V2 ( / )  +  [yU2V\ (0 +  V2Y1 (t) +  y3aV3(t) +  yAt2VA( /)
_  (^2,1 Y2,3 Y2,4 Ml )^1 ( 0 ] ^
f;. (* + # )  =  f ;  ( o  +  [ z  i - 2 , i ^ i - 2  ( 0  +  r w / w  ( 0 + ^  ( 0  + r ^ A i  ( 0  + / I+2Z +2 (0  
-  0 v 2 + Yui- 1  + z 1,1+1 + rw+2 + zi,7 + /*2 (0]<$ i ■ (6.46)
i = 3,...,m - 2
v, (t + a) = v, (t) + [r,-247,-2 (0 + 7,-,.,7,-, (0 + ^  (0 + 7,4,47,+, (0
- ( 7 ,4-2 + 7 ,4 - ,  + 7 ,4+1 + 7 ,,7  +A«,)7((0]«
/ = /W -  1
7, (< +  « )  =  K, ( O  +  [ 7 ,-247,-2 (0 +  7,-,.,7,-, (0 +  v j t (t)
- ( 7 ,4-2 + 7 ,4 - ,  + 7 , ,7 +M i)V,(tW
i = m
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#(?V A (0  + r-,,lV5 (0 + r4,7K4 W + r3,7^(0)
-  (v3 + ju3 + co)A{t)\dt • • • (6.4c)
Z ( < +  < S )  =  Z ( / ) + [ ( 1  -  ( 7 )  +  y51 r 5 ( 7) + y 4 7 y 4 ( ( ) + r „  r 3 ( r ) ) +
0 -g)(r6jV6(0+r„vs(t)+y4,7K4( t)+y,.7F3(0 )
+ v3 A(t) -  (/i3 + <y)Z (t)]St • • • (6.4 d)
AIDS Incidence  =  y61 inco+fn©
. * = i i = i
52 52
Z n w + Z ^ of=i /=i
+ 4^,7
52 52
Z n c o + i x ©
.z=l 1=1
, J 2, 52
y  1,1 Znco+Z^ o
i= l !=1
.(6.4c)
The full se t o f  modified differential-difference equations are as seen in equations (6.4a)- 
(6.4e); th e  o th er sub-population equations are not affected by changes made within the 
incubation period, i.e. X(t), W(t), HIV incidence and HIV/AIDS prevalence are all 
calculated a s  previously.
All o f the aforementioned possible movements within a staged incubation period are 
illustrated in  Figure 6.3b and allowed for in the amendments of the differential-difference 
equations (6.4a)-(6.4e). Of course, in the development of future work, not all of these 
possible p a th s  o f  progression through the incubation period of HIV need to be considered 
sim ultaneously, in fact, more in depth investigation, and consequent understanding, can 
occur i f  e a c h  scenario is considered individually. For instance, the investigation into 
backward transition rates alone is a multifaceted process with numerous possibilities 
requiring a  large amount of research and analysis on a number of different scenarios. In 
order to s tu d y  the individual aspects included within Figure 6.3b and equations (6.4a)- 
(6.4e) separately , the irrelevant transition rates need not be considered, and thus can be 
set to zero to  give the interpretation required. For example, to focus on ‘1-step’ forward
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or backward movements only, the model for the incubation period as seen in Figure 6.3b 
is employed with 7 *4 + 2  = 0, i = 1, .. .,5; 7 1 ,7  = 0, i = 3, 4; and 7 1 + 2 4  = 0, i = 1, . . 4 .  Thus, 
the model illustrated in Figure 6.3c below is utilised, with the paths highlighted in blue 
being the active routes, with associated transition rates, and the dashed paths being 
inactive, corresponding to the transition rates that have been set to zero.
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Figure 6.3c Incubation Period with 41-step’ forward and backward movements only
Accordingly, equations (6.4a)-(6.4e) are utilised within the formation of the Cardiff 
HIV/AIDS model with the relevant transition rates set to zero (as listed above).
Any situation of transition through the incubation period can be examined in this manner, 
by considering the model equations (6.4a)-(6.4e) to represent the parent model encasing 
all other sub-models and possible paths through the HIV incubation period.
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6.2 Summary
The Cardiff HIV/AIDS Epidemic Model implemented throughout this thesis has proven 
to be  a flexible and invaluable tool, demonstrating the potential and adaptability of a 
deterministic compartmental transmission model. The versatility of the model has 
allowed: the introduction of stages within the incubation period of HIV; the splitting of 
tim e into periods relating to the introduction of treatments (i.e. Pre-treatment era 1979- 
1986; Early Treatment era 1987-1994; and Combination Treatment era 1995-2002); the 
value o f parameters in the model to change subject to maximum likelihood estimation 
techniques, respecting separate time eras; the introduction of a new parameter signifying 
the effect o f  treatment on the length of the HIV incubation period; the modelling of future 
projections subject to varying ‘what-if scenarios; and the incorporation of even further 
developed treatments such as the introduction of a vaccine.
Summarising, the concept, objective and consequent result for each of the modifications 
nam ed above imposed onto the basic Cardiff Model as seen in Figure 2.3, a staged 
incubation period where the stages are defined by an immunological marker, CD4 count, 
has provided a realistic interpretation of the incubation period as well as a reliable 
estimate for its variable length. The division of the total year span 1979-2002, subject to 
the introduction of treatments, has engaged a more realistic perspective on the changing 
HIV/AIDS epidemic over time and has subsequently permitted the incorporation of 
numerous linked MLE processes in the determination of altering parameter values, as 
illustrated in Figure 4.1. In particular, splitting time into periods has encouraged 
investigation into changing behaviours and attitudes as reflected within the re-estimation 
o f  the infectivity parameter, Pc, from 1987 onwards. Also, in order to represent a longer 
survival time as a result of improving therapies and treatments, the parameter r was 
introduced which was evaluated in some detail for each time era, taking on a value of 1 in 
the Pre-treatment era and being re-estimated for both the Early treatment and 
Combination Treatment eras. Furthermore, this parameter is directly proportional to the 
length o f the incubation period, and during its second transition, from the Early 
Treatment era to the Combination Treatment era, the value of the parameter r took on a 
m ultifaceted smoothing process to reflect the complex and continuous effect of new 
combination drug therapies on the incubation period and, consequently, the transition
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rates between the HIV infective stages. Overall, the result has been highly successful, 
with an excellent fit between observed and expected AIDS incidence, HIV incidence and 
deaths from AIDS being created. Thus, a reliable, realistic and accurate model of the 
HIV/AIDS Epidemic has been formed and instigated to predict the path of the epidemic 
over future years, as explored in Chapter 4, highlighting concern for the escalating 
prevalence of HIV infection. Also, various what-if scenarios have been modelled using 
the Cardiff HIV/AIDS model; for instance, scenarios of changing future sexual 
behaviours or the introduction of a potential new preventive or therapeutic vaccine have 
been investigated, as detailed in Chapter 5.
In conclusion, the work presented within this thesis has achieved the initial objectives set 
i.e. an excellent fitting model of the HIV/AIDS epidemic has been created, allowing 
confidence in projecting short-term forecasts modelling various ‘what-if scenarios. An 
important finding drawn from the model extrapolations is the rapidly growing prevalence 
of HIV infections. This worrying observation needs to brought to the attention of 
government officials and relevant decision-makers in order for corrective initiatives to be 
implemented, thus reducing the currently unsustainable prevalence of HIV in the UK 
male homosexual population.
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